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Abstract
Currently most cell-based methodologies in microfluidic systems utilize 
homogeneous or heterogeneous cell populations. However, these systems do 
not present an accurate representation of in vivo dynamics. A microfluidic 
based experimental methodology has been developed that offers a biomimetic 
microenvironment in which pseudo in vivo tissue studies can be carried out 
under in vitro conditions. Using this innovative technique, which utilizes the 
inherent advantages of microfluidic technology, liver and cancer tissue have 
been kept in a viable and functional state for over seven days. Biochemical 
assays, histological examination, confocal imaging, epi-fluorescent microscopy 
were all performed to assess the viability of the tissue before and after 
interrogation by several apoptosis inducing and chemotherapeutic agents. Liver 
tissue samples were also disaggregated in situ on-chip into individual primary 
cells, using a collagenase digestion procedure, enabling further cell analysis to 
be carried out off-line. Cancer tissue was probed with chemotherapeutic drugs 
for the analysis of apoptotic biomarkers such as cytochrome c, nucleosomes 
and DMA that were found to be representative of previous published clinical 
results. It is anticipated that this methodology will have a wide impact on 
biological and clinical research in fields such as cancer prognosis and 
treatment, drug development and toxicity, as well as enabling better 
fundamental research into tissue/cell processes.
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1. Introduction
'In the field of observation, fortune favours the prepared mind'
Louis Pasteur 1822-1895
The biological applications of microfluidic technology are expanding 
rapidly, with recent uses including cell culture, DNA sequencing, and cytokine 
separation and detection.(1) Microfluidics utilises micron-scale geometric 
shapes and channels for manipulating pico- to nanolitre volumes of fluid with a 
high degree of spatial and temporal precision and accuracy.(2) The general 
benefits of microfluidics are portability, disposability, and short analysis times in 
relation to conventional testing, lower reagent and sample consumption with 
associated reduction in costs. The biological benefits are the ability to replicate 
the in vivo environment, which are lost when using traditional macroscopic 
vessels, such as laminar flow; mass transport driven by diffusion rather than 
turbulence; and constant removal of waste products whilst maintaining cell-to- 
cell interactions via paracrine and autocrine signalling molecules. The ability to 
replicate the in vivo dynamics of biological tissue is revolutionary and when 
applied to tumour biology, provides a unique platform to explore the tumour 
microenvironment. This technology will permit a better understanding of key 
biological mechanisms operating within pathological and normal tissues as well 
as providing a gateway to novel point of care devices. Key parameters needed 
to achieve this will be discussed in later sections, the first of which is the 
science of microfluidics.
/./ Microfluidics
Since the first paper was published in 1977 culturing cells within a 
microchannel,(3) there has been a growing interest to apply such methodology 
to cell biology in order to address the difficulties of simulating in vivo 
environments in vitro. Current avenues of research in cell biology using 
microfluidics include; cell culture, cell physiology, extracellular signalling, 
toxicology, cell separation, cell sorting and manipulation and cell patterning.
Microfluidics is the science of manipulating minute volumes of fluid (1CT9 to 
1CT18 litres) in small channels (10~5 to 10"4 metres).(4) The sizes of macro 
compared with micro are shown in Figure 1. The major benefits of microfluidic 
technology to cell culture are laminar flows and diffusion-based phenomena, 
both of which will be discussed in later sections.
Micro devices Typical Man made devices
metre
10-1* jo-l* ifl-" ifl-'O 10-8 10"* 10-4 W1 10° 102 
I Diameter of Proton I H- Atom Diameter I Human Hair I Man
Figure 1. Macroscopic verses microscopic. [Adapted from (5)]
1.1.1 Laminar Flow
Fluid flow characteristics in micro devices differ significantly from 
macroscopic devices (Figure 2), in that the flow is laminar whereas in 
macrochannels turbulent flow predominates. Laminar flow occurs when a fluid
flows in parallel layers with very little or no disruption between the layers and
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mixing is diffusion dependant. It is characterised by low (< 2000) Reynolds 
numbers (Re). Reynolds numbers, named after Osborne Reynolds (1842- 
1912), are the measure of the ratio of inertial forces (vsp) to viscous forces (fj/L) 
and are dimensionless.(6)
Turbulent
Laminar
Figure 2. Flow characteristics in channels. Turbulent flow is characterised by Reynolds numbers 
greater than 4000. Laminar flow is characterised by Reynolds numbers less than 2000 is the 
principle flow in microfluidic devices.
The Re of a flow can be calculated with the formula:
Re ='•
P Equation 1
where p (kg/m3) is the fluid density, u is the fluid viscosity, Dh (m) is the 
hydraulic diameter and V (ms~ 1 ) is the characteristic velocity.
Laminar flows are dominated by viscous forces and are characterised by 
smooth, constant fluid motion. Turbulent flow, which are characterised by high 
Reynolds numbers (>4000) are dominated by inertial forces, which can produce 
random eddies, vortices and other flow fluctuations. Transitional flow, which is 
mixture of laminar and turbulent flow, occurs between 2100-4000 Re. Turbulent
flow occurs in the middle of the flow and laminar flow near the channel walls in 
transitional flow profiles.
Fluid flow within in vivo vascular capillaries and tissues is known to have 
Re <100 and therefore is laminar in nature.(7) Furthermore, gradients in shear 
stress within blood vessels, caused by turbulent flow, have a strong correlation 
with the genesis of atherosclerosis with endothelial cells migration and motility 
increased by twofold when subjected to disturbed flow.(8) This contrasted with a 
uniform laminar flow field, where the cells showed no migration and continued 
to rearrange their position within the model of the vessel wall. In addition, cell 
division increased in the vicinity of turbulent flow whereas cell loss increased 
both upstream and downstream in regions where the shear stress gradient 
decreased. Stenotic atherosclerotic plaques are associated with laminar blood 
flow and high wall shear stress upstream of the stenosis and low shear stress 
and turbulent flow downstream.(9) It has been shown that plaque growth 
continues downstream of the plaque and ruptures upstream. Within areas of 
turbulent flow within blood vessels there has also been shown an upregulation 
of cell adhesion molecules, which are not present in laminar flow conditions.
The work of Takayama, as shown in Figure 3, has demonstrated the 
power of multiple laminar flows in which bovine capillary cells (BCE) were 
adhered in a microfluidic channel. Three laminar flows were then used, one 
containing Trypsin/tetraacetic acid (EDTA) and the other two had only media. 
The cells in the Trypsin/EDTA showed removal of cells and disruption of the 
membrane, while cells in the other two streams were unaffected therefore
demonstrating how two different treatments can occur on one cell sample at the 
same time.(10)
Trypsin/EDTA 
Media
Media
Direction of Flow
Figure 3. The use of multiple laminar flows to pattern cells. Localised patterned detachment of 
bovine capillary cells (BCE) by treatment with trypsin/tetraacetic acid (EDTA) with the 
schematic on the left and the photomicrograph on the right. (I1>
Perfusion culture microdevices, in which media flows over adhered cells, 
have been designed to provide microenvironments suitable for the culture of 
several mammalian cell types including HepG2/C3A cell lines,(12) oral cancer-
2.(13), NIH 3T3 fibroblasts,(14) rat hepatocytes co-cultured with 3T3-J2 
fibroblasts,(15) human carcinoma cells (Hel_a),(16) and embryonic hepatocytes 
and kidney cells.(17) Media flow is necessary for cell culture as a means to 
deliver fresh nutrient and oxygen supplies, to remove waste, and importantly, to 
deliver material gradients to affect a range of cell responses as shown in Figure
3. Microfluidics replicates in vivo laminar flow characteristics, as shown in the 
previous examples, and allows for greater approximation of the in vivo 
microenvironment for experimentation and analysis.(11)
1.2 Transport Mechanisms
There are two main transport mechanisms in microfluidics, directed 
transport and statistical transport.(18) Directed transport is controlled by exerted 
pressure on the fluid and results in bulk flow of the fluid either by mechanical 
means with pumps called pressure driven flow, or electrically by voltage called 
electro-osmotic flow (EOF).(19) Statistical transport is an entropy-driven 
transport and only occurs if, after directed transport, the molecules within the 
fluid are more disordered than before. (20) An example of statistical transport is 
diffusion. In microfluidic systems, a combination of the two transport 
mechanisms can occur. When directed transport meets a gradient, whether it is 
temperature or concentration, diffusion (statistical transport) occurs.
1.2.1 Pressure Driven Flow
Pressure driven flow has been employed in many microfluidic applications. 
The reason for this is due to the relative ease and flexibility of operation, 
insensitivity to surface contamination and no alteration to ionic strength or pH of 
the fluid. Pumping or drawing of liquids with syringes or peristaltic pumps, 
achieves hydrodynamic flow in a microfluidic device. The form of the flow is a 
parabolic shape. This is due to the flow being uniaxial along the principal axis of 
the channel with the speed of the flow varying over the cross-section of the 
channel as shown in Figure 4. The rectangular-shaped channel generates 
additional complexity in the distribution of analytes and indicators because of 
the parabolic velocity gradient across one or both cross-sectional 
dimensions.(21)
6
Figure 4. Schematic of pressure driven flow. [From (21)]
Predictions of fluid flow using conventional macroscopic continuum 
models are embodied in the Navier-Stokes equation
Equation 2
Dv is the change in velocity (m/s), Dt is the change in time (s), p is the pressure 
(Pa), p is the fluid density (kg/m3),/is the body force vector (per unit volume), T
is a tensor that represents the surface forces applied on a fluid particle (Pa) and 
V is the del operator.
Using these equations, fluid flow in macroscopic channels can accurately 
be predicted. Within microscopic channels, these equations are not as effective 
due to the differing conditions found at the channel surface.
Continuum models, such as described above, assume there is zero 
velocity at the channel walls as shown in Figure 5. The macroscopic model 
does not take individual particles into account but rather treats them as a
uniform collective, where matter is assumed to be continuous and indefinitely 
divisible.(22) However, fluid in microchannels can be only a few particles wide, 
depending on the size of the particle and channel, and interactions between the 
channel wall and particles distort the flow profile.(23)
NWall XB
' Fluid uelocity no-slip boundary il^Hltf Fluid uelocity slip boundary
Figure 5. Fluid flow at the microscale (A) A continuum model of fluid velocity treats particles 
uniformly and assumes that particles travelling near a channel wall have zero velocity, or no 
slip. (B) A particle-based model can more accurately simulate micrometer-size channels 
because it allows particles near the wall to exhibit slip and not slow to zero velocity.(24)
This is especially true when the fluid is hydrophilic and the walls hydrophobic 
and vice versa. Therefore, particle-based models based on a class of 
computational fluid dynamics (CFD) methods for fluid simulation are being 
investigated. These new models are based on the Lattice Boltzmann Algorithm:
Equation 3
where f is the particle distribution function, ei is the discrete set of velocities 
(m/s) and 0 is the collision operator.
The lattice Boltzmann algorithm(25) is derived from the Boltzmann 
equation, an equation for the evolution of the particle-velocity distribution, by 
discretizing the velocity space using a finite set of velocity vectors. New models 
including the Direct Simulation Monte Carlo (DSMC) method are now being
used to simulate the fluid mechanics in microchannels.(5, 26-28) The DSMC
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method models fluid flow using simulated molecules that represent a large 
number of actual molecules in a probable simulations to solve the Boltzmann 
equation. Molecules are directed through simulated physical space to model 
flow characteristics. Intermolecular collisions and molecule-surface collisions 
are determined using probabilistic, phenomenological predictions.(29) This is a 
new developing model has been used for gas dynamics within 
microchannels.(30)
1.2.2 Electrokinetic Flow
The current work discussed within this thesis has relied principally on 
pressure driven flow however, there are now many cell-based microfluidic 
systems that use electrokinetic flow. Electrokinetics refers to the union between 
electric currents and fluid flow containing electrolytes as shown in Figure 6. 
Electrokinetics includes electrophoresis, electrokinesis, dielectrophoresis, 
electro-osmosis and electroporation.(31) In general terms, electrokinetics 
describes the conversion of electrical energy into kinetic energy and vice versa.
5T
©
B ©-
Figure 6. Basic electrokinetic effects. A Electroosmotic flow (EOF) v, planar velocity profile, B 
Capillary Electrophoresis (CE) F, force, C Dielectrophoresis (DEP) [From (32)]
EOF occurs when the solid substrate of the microchannel such as glass, silicon, 
and polymeric materials acquires a surface charge (zeta potential) when in 
contact with an electrolyte.(33) The immobile surface charge in turn attracts a
cloud of free ions of the opposite sign creating a thin (1-10 nm under typical 
conditions) Debye layer of mobile charges next to the surface.
The thickness of this electric double layer (EDL) is determined by a 
balance between the intensity of thermal (Brownian) fluctuations and the 
strength of the electrostatic attraction to the substrate. In the presence of an 
external electric field, which is acting in a tangential (parallel) direction to the 
double layer (capillary wall), the fluid in this charged Debye layer acquires a 
momentum, which is then transmitted to adjacent layers of fluid through the 
effect of viscosity. If the fluid phase is mobile, it causes the fluid to flow 
(electroosmosis, sometimes also called electroendosmosis).(34)
The electro-migration of a particle under an electrical field is called 
electrophoresis. A charged particle moves towards the electrode of opposite 
electrical polarity under the uniform or homogeneous external electric field. This 
movement is due to Coulombic force, generated by the interaction between the 
net charge on the particle and the applied electric field.(35) Capillary 
electrophoresis (CE) is one of the major separation tools used for bio-analysis, 
based on difference in mobility of analytes in electric field.(36) In such systems 
a physical matrix or gel (gel capillary electrophoresis) is often used to impair 
migration of charged species (such as DNA and certain proteins) to enhance 
the separation process. Dielectrophoresis (DEP) arises from the interaction 
between a dielectric particle within a medium and a non-uniform electric 
field.(37) A dielectric particle and the suspending medium become polarized 
when they are subjected to an electric field. Due to the polarization, electric
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charge separation occurs within the dielectric particle as well as in the liquid 
side of the solid-liquid interface, giving rise to a dipole moment as shown in 
Figure 6.(38) When a charged dielectric particle moves through a region with 
non-uniform electric field inside a microchannel, the electrokinetic motion of this 
particle is the combination effect of EOF, electrophoresis and DEP. (35)
An important advantage of electrokinetic flow over hydrodynamic flow is 
that it provides a uniform velocity profile, except close to the microchannel wall, 
when a consistent distribution of charge is applied to walls.(39) In practical 
terms, microfluidic devices that utilize electrokinetic flow are generally more 
reliable and less likely to breakdown as the need for moving parts (pumps) is 
removed. (21)
1.2.3 Diffusion
Diffusion occurs when there is a concentration gradient within a fluid. The 
control of diffusion-based processes is achieved by utilizing small length scales 
and/or short distances. Molecules diffuse from areas of higher concentration to 
areas of lower concentration due to their intrinsic kinetic energy, which can be 
mathematically modelled using Fick's first law of diffusion:
dc j — _jfj _
dx Equation 4
where J (amount of substance length"2 time"1 ) is the flux of molecule, D is the 
diffusion coefficient (length2 time"1 ); C (amount of substance length"3) is the 
concentration, and x (length) is the position.
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Transverse diffusion of solutes in pressure-driven flow of two or more 
miscible or immiscible liquids has been of interest in chemical field. In 
microfluidic devices, simply T sensors achieve separation of solutes, as shown 
in Figure 7. T sensors contain two inputs and one output allowing the two flows 
to come in contact side by side. By adjusting the volumetric flow rates of the two 
input streams, hydrodynamic spreading and narrowing can be controlled. 
Typical measurements are achieved by fluorescent detection along the optical 
axis.
| | slowly -diffusing
analyte 
p*| quickly diffusing
analyte 
  Interdiffusion
region
Figure 7. Gradient generation using microfluidics. (A) A schematic representation of a T-sensor 
with two inputs. Diffusion can be seen between the two laminar flows along the microfluidic 
channel.(40)
The rate of diffusion between the contacting surfaces at the microscale is very 
quick (ms"1 ) depending on the size of the molecule and the distances needed to 
cross fluid volumes. As the size parameters shrink to microscale, the surface 
area-to-volume (SAV) ratio also increases. In their review 'Microenvironment 
design considerations for cellular scale studies' Walker et al(41) give the 
example of a 35 mm tissue dish with 1 ml of medium having a SAV ratio of 11 
cm"1 . A microchannel with the dimensions of 50 ^m x 50 M,ITI x 3 mm (H x W x
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L), a volume of 75 nl and a SAV ratio of 800 cm"1 . Ratios of this magnitude are 
advantageous for cell culture due to increased efficiency in mass transport via 
diffusion to and from cells. An increase in SAV ratio limits turbulence and 
therefore eddies and vortexes, which affects the in vitro cell microenvironment. 
High SAV ratio also limits regional variations in glucose, oxygen and H+ as large 
media volumes are decreased, which can affect an individual cell's behaviour 
such as cell signalling. There is no limitation to diffusion-reaction kinetics such 
as decreased substrate delivery and metabolite removal from proliferating cells 
therefore allowing the cells to exhibit more natural behaviour.(42) The driving 
force of mass transport in microfluidic devices is diffusion the same as in vivo 
microenvironments. The types of diffusion, which occur in vivo, are osmosis and 
facilitated diffusion.
Figure 8. A microfluidic cell culture array containing 100 cell culture chambers and a 
demonstration of gradient generation using red, yellow and blue dyes.(16)
Microfluidics has become a clearly understood technology by many 
chemists, engineers and physicists. The new frontier actively researched in the 
last two decades has been in the field of cell biology. Microfluidic devices with 
the additional features of miniaturized culturing vessels and highly controllability 
for operation and on-line monitoring/sensing are becoming increasingly of
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interest in cell culturing and cell interrogation techniques. Cell culture has been 
the cornerstone of many areas of biology in the last and present century. By 
the application of microfluidics to cell and explant culture models it is hoped that 
a new methodologies which can create biomimetic microenvironments in which 
pseudo in vivo studies can be carried out under in vitro conditions.
1.3 Cell culture
Cells used in in vitro models are obtained from either primary tissue 
samples or from established immortal cell lines. Cells are grown in suspension 
or in monolayers within flasks of differing sizes. These cells are set in culture 
flasks from which aliquots are taken and used for analysis. The main 
advantage to cell culturing is the ability to possess a single well-defined cell 
type with the ability to work in controlled conditions that allows the manipulation 
of an individual cell phenotype. Cell culture also provides access to large 
number of different cells with identical phenotypes in days. Culturing offers an 
alternative to large-scale animal testing and can be used as initial model 
systems for the discovery of physiological principles which can later be verified 
or tested on a relatively smaller number of animals.(43)
The disadvantages of cell culture are biological relevance, the cell will 
exhibit behaviour that is not representative of the cell dynamics found in vivo, 
and the genotype and phenotype will also alter as an artifact of culturing 
methodology, as will be discussed.
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1.3.1 History of cell culture
The concept of maintaining animal cells in vitro was first deliberated in the 
19th Century, demonstrated at the turn of the 20th Century and becoming routine 
from the 1950s as shown in Table 1. Ross Harrison (1870-1959) published the 
first study on cell culture when he described the in vitro growth of frog neurons 
in 1907. (44)
Table 1. The initial years of cell ami tissue culture - an abridged hislon
1902 Leo Loeb places embryonic epithelial tissue in agar and coagulated serum and then inserts them in 
____an adult animal. Not strictly cell culture.___ __
1907 Ross Harrison publishes experiments showing frog embryo nerve fibre growth in vitro
1912 Carrel and Burrows cultures connective tissue for extended periods and shows heart muscle tissue 
contractility over two or three months
1948 Katherine Sanford et al. clone L cells for the first time
1952 George Gey et al establishes the first human cell line - HeLa from a cervical carcinoma
1954 Abercrombie and Heaysman begin quantitative cell culture experimentation when they observe 
contact inhibition between fibroblasts
1955 Harry Eagle and others develop defined media and describe attachment factors and feeder layers
1961 Hayflick and Moorhead describe the finite lifespan of normal human diploid cells
1962 Buonassisi el al publish describe methods for maintaining differentiated tumour cells
1968 David Yaffe studied the differentiation of normal myoblasts in vitro
[Adapted from (45)]
Explants of neural tissue from frog embryos were sealed into a chamber 
containing coagulable frog lymph that subsequently generated neuron axons. 
This simple experiment began the technique of cell culture, probably the most 
important and widely used tool in biological sciences.(46)
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The early days of cell culture were dominated by the work of Alexis Carrel 
(1873-1944) who continued Harrison's work to improve the method of cell 
cultivation by culturing the tissues of the chick embryos in plasma.(47) The 
complexity of Carrel's methods coupled with the lack of antibiotics delayed 
significant progress until the late 1940s.
In 1961, Leonard Hayflick and Paul Moorhead published their seminal 
work(48) that contradicted Carrel's assertion that diploid cells had infinite 
potential to replicate and that cells entered a stage of replicative senescence 
where cells stopped dividing and is discussed in Section 1.3.4. Further major 
developments in cell culturing methodology were the use of proteolytic enzymes 
such as trypsin to remove continuously growing cells from culture vessels. By 
the 1970s, specialized media were being developed for the growth of numerous 
different cell lines. The defined mixture of supplemental components required 
for a variety of cell lines come from methods described in this era.(45)
In the 1980s cell culture became an important technology in the 
establishment of molecular biology.(49-51) Cell culturing remains vitally 
important when studying pathological states, tissue engineering and 
manufacturing pharmaceutical products such as monoclonal antibodies, 
hormones and enzymes.(52-54)
1.3.2 Primary culture
Primary cell culture can be derived from any source of tissue. Tissue can 
be acquired from normal or tumour, somatic or embryonic tissue and from
16
virtually any species. Work with animal tissue is governed by the Animals 
(Scientific Procedures) Act, 1986 and for human tissue; permission must be 
obtained from the local research ethics committee.(55) Primary cells are grown 
in culture before subdivision and transfer to a sub culture. The majority of 
human cell lines are derived from tumour tissue due to the tissue availability 
and the inherent genetic changes causing unbridled growth, which make 
culturing relatively simple. Normal somatic cells are superior to tumour cells 
when studying genetics, molecular biology and cell signalling due to the lack of 
genetic and phenotypic alterations. However, normal somatic cells will die due 
to the normal life span of the cell with limited number of cell divisions, (cells 
from Galapagos tortoise can divide 110 times,(56) murine cells only 15 
times(57)) before entering a phase called replicative senescence or Hayflick's 
limit, making them harder to maintain in culture.(48) In senescent cells growth is 
arrested in the transition from first growth (G1) phase to synthesis (S) phase of 
mitosis.(58) Embryonic tissue allows greater potential cell divisions than adult 
somatic tissue. Nonetheless these tissues, such as the heart, have phenotypic 
differences between somatic and embryonic material that add inherent 
difficulties when studying physiological dynamics.(59)'(60)
1.3.3 Cell Isolation
Isolating cells from tissue can be achieved by several methods such as 
enzymatic digestion, perfusion, mechanical disaggregation and explant cultures. 
All of these have been used successfully and are briefly described:
(i) Enzyme digestion of tissue samples involves enzymes such as 
trypsin, collagenase, elastase, hyaluronidase, pronase and 
dispase.(61) Trypsin and pronase were the first enzymes used for this
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method however these enzymes can be destructive to cell 
membranes, giving lower viable cell yields, than later discovered 
enzymes such as collagenase and dispase.
(ii) Perfusion is an enhancement of enzymatic digestion as proteolytic 
enzymes are perfused through the tissue and cells collected as they 
are liberated.(61) This can be used for the disaggregation of tissue 
and organs where the large blood vessels can be secured at either 
end with the solution left within the vessels for an extended period of 
time, for example liver disaggregation.
(iii) Mechanical disaggregation is a method using mechanical measures 
such as a wire mesh, sieve, or syringe needles to retrieve cells.(62) 
The advantages for this method are that it is quicker, less expensive 
than using enzymes and does not suffer from enzyme batch 
inconsistencies. It can result in more cellular damage and lower 
viability rates than enzyme digestion.(63)
(iv) Explant uses tissue biopsies and is the slowest method of primary cell 
recovery. (64) It involves the cutting of tissue into small pieces in a 
Petri dish and covering with a small amount of medium for several 
hours to allow attachment of cells to the surface. With the addition of 
more media, cells can grow out from the tissue pieces and form a 
monolayer on the surface of the dish. This method is useful if there is 
a limited amount of tissue available, however this method tends to 
grow fibroblasts if the media is not supplemented.
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1.3.4 Formation and Properties of Immortal Cell Lines
Immortal cell lines have an infinite lifespan. Immortalization occurs when 
the cell line becomes continuously culturable with limited alteration in the growth 
phenotype and is the first step to 'transforming' the cells. Transformation occurs 
when cell lines acquire genotypic and phenotypic changes, which alter growth 
control such genetic events include point mutations,(65) telomerase 
reactivation(66) and gene insertions.(67) Cell transformation can be induced 
chemically; for example with methylcholanthrene and azoxymethane, and 
virally; for instance by Simian virus 40 and Epstein Barr virus.(68) Spontaneous 
transformation can also occur after a transient proliferative crisis, such as lack 
of nutrients, and is usually accompanied by abnormal morphology with a 
deterioration of cell numbers. This is then followed by the emergence of a fast 
dividing cell line that overwhelms the culture.(69, 70)
As described by Hayflick and Moorhead cells in culture grow, after an 
initial lag phase, exponentially in a logarithmic phase until a plateau is reached 
when cell division and cell death is balanced (stationary phase). This is 
followed by a death phase when cell death greatly exceeds cell division. Good 
practice in cell culturing dictates that cells should be kept in the logarithmic 
phase and therefore subculturing is necessary.
Subculturing or passaging is advantageous when suspension cells reach a 
density of between 106 and 107 cells ml" 1 of culture medium. Tumour cells do 
not desist from growth in these conditions as they have commonly 'lost' contact 
inhibition or density-dependent growth inhibition and continue to divide.(71)
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Subculturing involves diluting the cells by splitting and aliquoting into several 
culture flasks or continuing the growth of a proportion of cells in another suitable 
sized flask. It is standard practice to maintain a continuous supply of cells while 
experimenting with the remainder. It is vital that the number of subcultures 
(passages) is chronicled as 'normal' or nontransformed mammalian cells have a 
limited lifespan in culture, which is approximately 5 cycles.(72)
7.3.5 Explant Culture
Cell and tissue culture has provided invaluable information about cell 
dynamics. Tissue culture is often used generically or metaphorically to describe 
all in vitro cell techniques. Tissue culture involves a comparatively 
homogeneous isolation of cells whereas explant/organ culture utilises small 
samples or tissue slices which contain multiple cell types. Explant/organ culture 
can be defined as an in vitro technique that maintains sections or whole organs 
in culture using specialized media, vessels and atmosphere.(73) One of the 
main roles for explant culture is to isolate cells for culture as described in a 
previous section. However, isolated cells present a limited view of events within 
in vivo microenvironments, due to lack of tissue architecture, cell signalling 
molecules and cell diversity.(74) A number of lines of evidence indicate that the 
removal of cells from their usual immediate microenvironment may disturb 
normal signalling pathways.(75, 76) Removal of thymocytes from interactions 
with thymic stromal cells, for example, causes spontaneous upregulation of the 
ap T-cell receptor (ap TCR) complex occurring simultaneously with the 
dephosphorylation of the CD3£ chain.(77) Further studies have shown that 
activation of protein kinase with phorbol myristate acetate (PMA) induces rapid 
endocytosis of the CD4 coreceptor on immature thymocytes in suspension
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however; this is not evident on those cells within foetal thymus organ 
cultures.(78) Explant culture enables the normal architecture of the tissues with 
three-dimensional intercellular relationships to be retained in culture 
conditions. (73)
Since a review in explant culture in 1991(79) the focus of explant studies 
have moved from morphology to mainly cell signalling as shown in Table 2 as 
the value of explant culture has begun to be acknowledged by more and more 
research groups. In the beginning of research into explant culture, studies limit 
the culture period to only two hours to avoid the effects of tissue cell death, now 
studies using explant culture for longer periods, over seven days, have been 
successfully undertaken.(80, 81)
Human tissue can be acquired for explant studies from diagnostic biopsies 
obtained from surgery, autopsy or organ donation. When using human material, 
several factors need to be considered for improving the viability of the tissue. 
Factors that can affect explant viability include original health status of the 
patient, temperature and hydration of the material.(82)
Most, if not all, pathological episodes occur in organs that involve more 
than a single tissue or cell type (e.g. cancer, diabetes, etc.). Pathological and 
toxicological investigations are particularly appropriate for study within organ 
culture models. A well-preserved and viable explant with an appropriate dosage 
of the toxicant or carcinogen placed in culture can be used to characterize the 
morphological response,(83) cell injury/toxicity(84), metabolism(85) and cellular
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or molecular biological alterations. Many types of tissue have been studied, as 
shown Table 2, these are mainly neuronal tissue,(86) however more diverse 
tissues are now being studied such as cancer ((81) foetal (87) and cartilage.(88)
Table 2 Different types of explain culture studies
Tissue
Adipose
Neurons
Hormonal 
glands
Lungs
Kidneys
Cancer
Cartilage
Tendons
Foetal 
Tissue
Focus/Assay
Immune response, cell signalling, protein synthesis/RNA extraction, 
cDNA synthesis, rt-PCR, radioimmunoassay
Cell signalling, morphology, homostasis, cell growth/bioluminescence, 
rt-PCR, immunohistochemistry, biochemical
Protein synthesis, cell signalling/bioluminescence, radioimmunoassay, 
rt-PCR
Cell Signalling/bioluminescence
Cell Signalling/bioluminescence
Apoptosis, cell signalling, therapy design, protein synthesis/RNA, 
western blot, immunohistochemistry
Cell signalling, morphology/ biochemical
Cell growth dynamics, cell signalling/migration, western blot
Tissue development, regeneration, differentiation/gene expression, 
histology, immunohistochemistry, western blots, rt-PCR
Reference
(80, 89)
(86, 90-98)
(86, 89, 99, 
100)
(86)
(86)
(81, 101, 
102)
(88, 103)
(104)
(85, 87, 105, 
106)
Traditional assays of cell viability are often not directly applicable to organ 
culture models and require careful consideration and sometimes modification. 
The most common viability tests include Trypan Blue (TB) and lactate 
dehydrogenase (LDH) release. The former utilizes attached cells or single cells 
in suspension and determines viability by the percentage of nonviable cells on 
the basis of diffusion of the dye into cells with non-viable membrane 
pumps.(107) TB viability measurements are dependant on physical factors such 
as dye concentration, media osmolality and incubation temperature. LDH is a 
cytosolic enzyme that is released from the cytoplasm of injured or dead cells
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and the media concentrations can be used to assess the percentage of cell 
death. Explant cultures by definition are not single cell suspensions and 
therefore are difficult to evaluate by TB alone. LDH is more applicable but 
consideration must be given to the total of potential LDH release since absolute 
values are not necessarily predictive of injury. As an example, a quickly growing 
culture will have a significant number of cells; a certain percentage of cells will 
terminally differentiate and die. Although the LDH value in the media from these 
cultures could be high, the relative value may be low. Ordinarily, morphology is 
the technique of choice to evaluate viability of explant cultures(108, 109) yet, 
once the explants are prepared for histological analysis, they are fixed and no 
longer viable and available for further study.
Traditionally explants are set in culture vessels submersed with media with 
a rocking chambers, platforms or roller bottle equipment to improve diffusion of 
nutrients into the tissue.(79) Plastic Petri dishes are the most widely used 
labware for explant culture; some with spacers for mesh supports. The supports 
facilitate the attachment of explants to the culture vessel as well as promoting 
the maintenance of tissue differentiation through the continuance of cell junction 
and signalling cohesion with the surrounding cells and the extracellular matrix 
(ECM) which is secreted by the cells themselves.(79) Mesh substrates like 
collagen, fibronectin and laminin have positive effects on cell growth and 
differentiation as they mimic the ECM found in wVo.(110, 111) The typical 
explant response to organ culture is comparable to the wound response found 
in vivo such as increased DMA synthesis and mitosis after 7-20 hours after 
culture, and cell migration.(112-114) Studies have shown perfusions and 
washes of cultures with media have improved viability of cultures as compared
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with static culture, for example cartilage explant culture remains viable for up to 
14 days in static culture this increases to 56 days with perfusion 
conditions.(115, 116) The function of the explant is also modified depending 
upon the flow conditions of the culture. Placenta! explants exposed to various 
embryonic tissues modified human chorionic gonadotrophin (HCG) secretion in 
static cultures however, co-perfusion with embryonic tissue increased HCG 
secretion to levels comparable to those obtained from patients.(117)
The number of studies using explant tissue is increasing year upon year 
however; the numbers are still dwarfed by the number of cell-based studies as 
shown in Figure 9.
——cell culture ——explant OR organoirophlc culture
.?<*> ^
Year of Publication
Figure 9. Scientific articles published utilizing cell culture* or explant/organotrophic culture* in 
title, abstract or keywords from Scopus search engine.
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1.4 Current microfluidic applications within cell biology
The responses of defined cell types to specific physiological stimuli can be 
manipulated within the microfluidic cell culture environment to provide greater 
knowledge of key cellular responses. The high degree of fluidic control within a 
microsystem can make it possible to pinpoint different environmental conditions 
to a particular cell or groups of cells.(11) Conventional cell analysis is usually 
based on bulk averages of multiple cellular responses where it is impossible to 
isolate a single cell and analyse its output.(118) This is due to the fact that 
vessels used to culture, store, interrogate and analyse cell responses are 
considerably larger than the individual cell. The microfluidic environment can 
facilitate the continuous perfusion of fresh media at a scale that enables the 
contents of the microchannels to be continually replaced and analysed without 
disturbing individual cell dynamics.(119, 120) With these advantages, 
microfluidic devices have the potential to revolutionize the field of cell biology 
and open new avenues of research which were inaccessible such as for 
example; pinpointing individual signalling pathways in response to a single 
stimulus or the response of different cells to extracellular matrices.(11, 121) 
Growth in the use of microscale systems in the field of cell biology has been 
rapid over the past few years, as shown in Figure 7, largely due to the many 
practical advantages offered by such methodology.
In addition to the fundamental fluidic properties further advantages such 
as; portability, reusability or disposability of equipment, reduced costs and low 
cell number requirement make microfluidic devices superior to conventional cell 
culture in many assays. Whilst the main thrust of this study has not focussed on
U«HV6T8Sty 
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cell-based techniques, it is appropriate to review briefly the recent advances in 
cell-based methodology, as these are highly relevant to the effective 
development of tissue-based applications in the future.
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Figure 10. Scientific articles published using keywords microchannel* AND cell biology in the 
title, abstract or keywords from Scopus search engine.
1.4.1 Cell culture and viability using microfluidics
It is vital that any proposed methodology based on microfluidics will need 
to maintain the viability, and possibly growth, of cells or tissue in an 
environment as close to in vivo conditions as possible. After this has been 
established, then manipulation of their phenotypic and functional responses can 
be reliably evaluated. Traditional cell culture models use cells grown in batches 
within large culture vessels with the volume of 12.5 ml to 370 ml. Some of these
vessels are coated to initiate cell adhesion that increases viability and
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proliferation.(122, 123) Perfusion culture microdevices, in which media flows 
over adhered cells in microchannels, have been designed to provide 
microenvironments suitable for the culture of several mammalian cell lines as 
described earlier.
In the past few years there has been a move to perfusion of cells in 
traditional cell cultures, which is also present in microfluidic systems. However, 
the problems still remain in traditional cell culture with fluid stress, irregular 
temperature distribution, solute and dissolved gas concentrations together with 
less than one cell volume/medium volume ratios which can all contribute to 
undesirable artefacts to current cell culture methodology. (41) After 
understanding the need to perfuse cells to improve viability within 
microenvironments was achieved, the next progression in microfluidic research 
was to understand how cells react physiologically.
1.4.2 Microfluidic approaches to cell physiology research
Understanding the physiological norms of morphology and phenotypic cell 
behaviour in vitro is critical before endeavouring to understand in vivo 
physiological conditions. The functional characterization and evaluation of 
cellular responses to chemicals in microdevices has been demonstrated using a 
variety of cell types, including the application of glutamate to rat cortical 
neurons(124) and embryonic hippocampal neurons,(125) nerve growth factor 
(NGF) to adrenal pheochromocytoma (PC12 cells),(126) and caffeine to 
cardiomyocytes(127). While the cellular response shown in these studies has 
been demonstrated previously using traditional methodologies,(128-130) the
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use of microfluidic technology could be employed in the future to evaluate the 
effect of newly manufactured drugs on cells in culture.
Micro-scale models of vascular systems are required because vascular 
diseases often occur in arterioles or capillaries. MicroChannel systems, 
constructed to mimic blood capillaries, are directly comparable with an in vivo 
microcirculation. Such systems have been used to evaluate deformation of 
erythrocytes in order to understand the effect on microvasular perfusion. This 
can be used in the future to study many blood-associated diseases such as 
sickle cell anaemia, diabetes and malaria. This study has shown that network 
perfusion with deformed erythrocytes, after graded exposure to glutaraldehyde 
(0-0.08%) erythrocytes exhibit a higher sensitivity to small changes in 
deformability causing blockages in microchannels.(131) Conventional methods, 
such as filtration, to measure erythrocyte deformability does provide invaluable 
information on the cell's Theological property however, it delivers sparse 
knowledge on the effect on microvasular perfusion.
Another study on vascular cell behaviour used microelectromechanical 
systems (MEMS) sensors to link real-time shear stress with monocyte/ECM 
interactions in an oscillatory flow environment to understand leukocyte rolling, 
adhesion, and transmigration.(132) It demonstrated that monocytes in 
oscillatory flow conditions compared with pulsatile flow, significantly upregulated 
P-selectin, inter-cellular adhesion molecule 1 (ICAM-1) and monocyte 
chemotactic protein-1 (MCP-1) mRNA expression. Also presented was the 
increased probability of monocytes binding to epithelial cells, found on the base
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of the microfluidic channel under these conditions. Traditional methods of 
researching monocyte behaviour using histological cell culture techniques does 
not give insight in the binding kinetics found in vivo in response to oscillatory 
shear stress, adhesion molecules and chemokine gradients. Microvascular 
models in vitro in microdevices also include cultured human vascular 
endothelial cells which have been evaluated for high shear (25 dyn/cm2), 
response to inflammatory cytokine, tumour necrosis factor-a (TNF-a),(133) and 
depletion of erythrocytes from whole blood at high volume flow rates mimicking 
blood flow phenomena previously observed and characterized in the in vivo 
mammalian microvascular system.(134) These studies have shown that cells 
cultured in microchannels exhibit the same properties as those found in vivo 
with comparative microenvironments, such as arterial shear stress. Microfluidic 
analysis using assays for adhesion molecules can be undertaken in the same 
microchannel with detailed kinetic studies of cell activation and adhesion to 
chemotactic molecules revealed in seconds at concentrations in the picoMolar 
range. (134)
1.4.3 Extracellular signalling within microfluidic cell culture
The need to understand and control extracellular signalling under in vitro 
conditions has become a growing research trend in the last few years. 
Generally, cells found in vivo are located in a three dimensional structures with 
other cells of possibly different phenotypes, which affect surrounding cell 
behaviour by cell-cell (or cell-matrix) contact, and/or by secreting paracrine, 
endocrine, and autocrine signalling molecules. The microfluidic environment, 
also described in an earlier section, with its diffusion-dominant principal
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provides an ideal methodology for studying cell behaviour by incorporating, for 
example, different cytokines, hormones and antibodies.
Real-time monitoring in microsystems for cellular secretion phenomena 
has been investigated. The secretions examined include murine IgG from B 
cells using time-resolved luminescence analysis,(135) insulin secretion from 
islets of Langerhans, albumin secretion by the cultured primary rat adult 
hepatocytes,(136) both using serial immunoassays,(l37) reactive oxygen or 
reactive nitrogen species (ROS) or (RNS) respectively from macrophages using 
electrochemical detection.(138) These studies have shown the detection of 
released extracellular molecules at higher sensitivity than those found using 
conventional enzyme-linked immunosorbent assay (ELISA) and this can be 
accomplished in real time, using cell populations numbering in the 100s rather 
than 1000s as used in standard cell analysis systems.
A number of groups have investigated the biological effects of 
concentration gradients of different molecules on cells. These include 62 
gradients on murine C2C12 myoblasts to understand the effect of tissue 
oxygenation on intercellular mechanisms that play critical roles in many human 
diseases including cancer, heart disease and stroke.(139) Areas of 
hyperoxygenation (20% O2) were created using water electrolysis by noble 
metal microelectrodes to manufacture an effect on the C2C12 myoblasts. Using 
microscopy, it was reported that the cells took on a spherical shape and 
contracted away from the surface of the electrode. Although there were no 
signs of ruptured cell membranes through microscopic examination, use of a
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LIVE/DEAD assay indicated the initiation of apoptosis in the areas of 
hyperoxygenation as shown in Figure 11.
0.5
Figure 11. Hyperoxia-induced apoptosis in C2C12 myoblasts. a) 2 h after seeding (without 
oxygen input from OMA) b) LIVE/DEADl image of myoblasts after 72 h in anaerobic chamber 
(95% N2 : 5% CO2), with constant current density of 10 mA mm"2 , c) Oxygen concentration 
plot of b); this axi-symmetric array makes a linear, cone-shaped concentration profile, d) 2 h 
after applying current density of 10 mA mm"2 , e) Fluorescent image of d) with LIVE/DEAD 
stain, f) Oxygen concentration plot for hyperoxic condition, this oxygen profile was applied to 
d)ande).(139)
Another study examined the effects of chemokine gradients on T-cell 
chemotaxis which has been previously limited to studies in 3D matrices or 
under agarose assays, which does not allow precise control or variation in 
conditions.(140) Using single and competing chemokine gradients of 100 nM 
CCL19 and 100 nM CXCL12 showed that the chemotactic index and the speed 
in response to CCL19 in the competing gradients are similar to those seen with 
the single CCL19 gradient. A high percentage of the cells migrated toward the 
CCL19 gradient in both single CCL19 gradient and the competing gradients. In 
contrast, the chemotactic index and the speed in response to the CXCL12
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gradient in the competing gradients are significantly lower than those in the 
CXCL12 gradient alone. The advantage of microfluidic technology is the 
precise gradient control coupled with the lack of the previous techniques to 
study T cell chemotaxis in real-time, which may provide new biological insights 
into this important process. In addition, since only a small number of cells are 
required for seeding in the microfluidic system, chemotaxis of rare cell 
populations can be studied.
1.4.4. Measuring toxicological effects in cell populations using microfluidics
Microfluidic systems have also been used to analyse the toxicological 
effects of different stimuli on a diverse number of cells. The importance of 3-D 
cell cultures when recording the cytotoxicity results have included studies into 
the effects of three anticancer drugs (Cisplatin, CDDP; 5-Fluoro-uracil, 5-FU; 
paclitaxel, TXL) on human breast cancer (MCF-7).(141) The cells were 
embedded in a collagen-gel matrix and entrapped in a pyramidal-shaped silicon 
hole. By comparing microfluidic 3D culture to the standard 2D culture using 
scanning electrochemical microscopy analysis and colorimetric assays it was 
found that cells proliferation was lower compared with the 2D culture, and the 
results from the chemotherapy test showed little effect on the cells from CDDP, 
moderate effect from the 5-FU and the greatest effect from the TXL. This 
resulting difference is thought to reflect more accurately the in vivo dynamics of 
chemotherapy as proliferation rate is slower than in 2D culture, which is 
important when validating the effects of drugs which effect cell cycles. 
Continuous monitoring of chemosensitivity is important in drug screening, as the 
kinetics of anticancer drugs differ, depending on the agent's mechanism. These 
studies are advantageous due to the ability to continuously monitor cell
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response by using different drugs and/or different cancer cells, with the normal 
cellular activity as a control.
Microfluidic technological development in the field of hepatotoxicity has 
progressed towards the merging of tissue engineering, transport phenomena 
and biomaterial applications. Kane et a/(142) for example have demonstrated 
the ability to support metabolic and synthetic function with micropatterned 
primary rat hepatocytes and 3T3-J2 fibroblasts within a perfused, microfluidic 
array. Using this approach the capability of long-term synthetic and 
detoxification functions using albumin and urea synthesis was illustrated. The 
functions of the hepatocytes were compared to 'control 1 microfluidic devices 
which were kept in an 'open configuration', however it is not exactly clear from 
the article what this actually meant. There was no comparable data with other 
studies to determine whether the hepatocytes were functioning in parameters, 
which reflect previous in vitro or in vivo studies. However it was, to the author's 
knowledge, the first paper to cultivate hepatocytes with another cell type in a 
microfluidic system.
In a separate study, a heterogeneous-cell patterning microfluidic chip was 
described which facilitates the assembly of liver tissue in vitro using 
dielectrophoresis, with parallel manipulation, stable control, high cell viability, 
and cell modulation.(143) Later studies have continued to create 3D 
microenvironments for primary rat hepatocyte cultures to assess the 
heptocytotoxicity of drugs such as paracetamal and diclofenac, in dose- 
dependant manner.(144) These studies however, do not mimic the complex
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cellular and extracellular composition of the liver organ that has been shown, 
using traditional methodology, as invaluable when understanding how the liver 
manages and removes toxic drugs as will be shown in Chapter 3. Refinements 
of microfluidic liver analogues need to include connective tissue, satellite cells 
and other cell types.
1.4.5 Microfluidic separation and sorting of different cell populations
Separating in microfluidic-based devices offers the advantages of fully 
automated processing, portable instrumentation for field and point-of-care use, 
and small input sample volume (ul or less of blood) along with corresponding 
reagent volumes. Separating target cells from other cells or biological fluids 
prior to characterisation represents the first step in many bioanalytical 
procedures. Cells range in sizes from 130 urn to 8 urn, and exist in dense 
populations therefore; sophisticated separation methods are needed as shown 
in Figure 12.(145)
There have been over 250 articles published detailing the use of 
microchannels for the separation of blood and blood cell populations. These 
include, for example, the use of a simple array of microchannels to separate 
blood cells and blood plasma using high and low flow rates within the different 
channels.(146) The plasma separation volume percentage collected varied from 
15% to 25% with increasing 10% to 35% inlet hematocrit. Whole blood consists 
of 55% plasma and 45% cells. The traditional method of preparing blood 
plasma is by centrifugation of fresh blood with an anti-coagulant and the 
resulting plasma poured or drawn off.
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Figure 12. Overview of common cell separation strategies.(145) Affinity capture separations 
rely on the adhesion of cells to an immobilized, specific antibody (A). Unretained cells are 
washed to waste. The affinity format can be applied to array formats (B), where more than one 
capture molecule is attached to a surface. Here, antibodies corresponding to different cell 
surface antigens are used to separate blood cells. Affinity separations can occur in a column (C), 
facilitating elution and collection. Cells can also be separated by mechanical methods. (D).
This proposed microfluidic method seems cumbersome compared to the 
conventional method with the blood needing to be diluted before flowing onto 
the device and the collection of plasma seemingly inefficient compared to the 
volume of plasma in the initial blood sample.
Another area of study for separating and sorting blood cells uses 
magnetophoretic microseparators for the separation of erythrocytes and 
leucocytes from diluted blood based on their native magnetic properties. For 
example, experimental results for the single-stage paramagnetic capture (PMC) 
microseparator show that 91.1% of erythrocytes were continuously separated 
from the sample at a flow rate of 5 ml h" 1 . In addition, the three-stage cascade 
PMC microseparator continuously separated 93.5% of erythrocytes and 97.4%
of leucocytes from whole blood at the same flow rate.(147) The authors
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acknowledge that the methodology needs refinement as the flow rate required 
(2.5-20 ml h" 1 ) is relatively low for efficient enrichment of rare cells, such as 
circulating tumour cells and hematopoietic stem cells. This method however, 
allows the ability of separating different cell populations for further use 
downstream.
Another example of a blood cell separation and sorting technique currently 
being studied uses a hydrophoretic method to isolate leucocytes from 
erythrocytes in a 1:20 diluted blood sample with 13 mm high slanted obstacles 
and 4 mm filtration obstacles to focus them to a sidewall.(148) This was 
achieved by employing successive structures on the top and bottom of the 
microchannel with the height and gap of the pores set between the diameters of 
small and large cells, which defined the critical separation diameter. 
Erythrocytes have a biconcave disk shape, and their diameters are 6.2-7.9 mm, 
a similar size to that of leukocytes. Therefore, it can be difficult to separate two 
cell types based on their sizes. The thickness and deformability of the 
erythrocytes (1.7-2.6 mm) allowed them to pass through the 4 mm filtration 
obstacles while the leukocytes could not. Accordingly, the cells smaller than the 
criterion freely pass through the gap and kept their focused position. The 
device was also used to separate neutrophils and lymphocytes from a 1:10 
diluted blood sample. After the hydrophoretic filtration, neutrophils and 
lymphocytes were recovered up to 75 and 70%, respectively. The most 
commonly used methods for the differential separation of leukocyte 
subpopulations are magnetic-activated cell sorting (MACS) and fluorescence- 
activated cell sorting (FACS). In these methods, monoclonal antibodies tagged 
with magnetic or fluorescent compounds are used to separate cells based on
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their specific antigenic determinants. Refinements to this microfluidic method 
for example incorporating MACS and FACS could allow the separation, 
detection and analysis of whole samples on a single platform which at present 
is not available.
Investigations into blood cell separation and sorting are continuing and 
the techniques highlighted here are just some of the methods being examined. 
It is hoped by the various research groups that the range of on-chip stationary 
filtrations of blood cells could be used for further cell selections, manipulation, 
and possible point-of-care clinical diagnostics.
1.5 Tissue-based microfluidic applications
The rapid development of bioanalytical applications in microfluidic systems 
of cell culturing has shown many fallibilities of the current conventional 
methodology. Microfluidic literature over the last ten years has focused largely 
on tissue engineering with devices being described that create tissue-like micro- 
architectures for subsequent interrogation or transplantation. These include a 
microfluidic bioreactor for culturing high-density hepatocyte arrays in order to 
mimic physiological liver mass transport,(149) an engineered cardiac tissue-like 
structure with anisotropic properties,(150) a microfluidic analog of the alveolo- 
pulmonary barrier of the lung.(151) Also reported are polydimethylsiloxane 
(PDMS) gel modules which contain 108 - 109 cells cm'3 in a microfluidic 
chamber to combine microfluidics and soft-lithographic moulding(152) and the 
encapsulation of AML-12 murine hepatocytes within microfluidic channels
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formed from agarose hydrogel.(153) Whilst these models have made progress 
in providing in vivo microenvironmental phenomena such as diffusion and 
laminar flow, as previously discussed, they still lack the complexity of in vivo 
dynamics. The microenvironment cells occupy, can dramatically alter the 
genotype and consequently the phenotype of the cells, such as the addition of 
serum to fibroblast culture can alter the gene expression of the cell.(154) The 
chemical composition of the microenvironment is rigidly controlled by the 
release of signals from different cells, which may or may not be in close 
proximity. Therefore, a number of different cells are needed within an 
experimental model in order to give a greater approximation of typical cellular 
responses to external stimuli. Cell patterning of different cell types in 
microfluidic systems has only been achieved using two cell types(155, 156) 
whereas in vivo, organs are composites of several cell types such as exocrine 
cells (ceruminous cells), endocrine cells (pinealocytes), epithelial cells 
(squamous epithelium), neurons, and contractile cells (cardiomyocytes).
Many of the cell lines used in cell culturing both in traditional and 
microfluidic systems have been immortalized or are tumour-derived, which are 
genetically unstable, have intrinsic changes in gene expression, loss of 
proliferative regulation and signaling transduction pathways as described in 
Section 1.3.5. These cells therefore are not a replicate of the typical in vivo 
cell.(157) It has also been shown lately the importance of the ECM and its 
components. ECM is composed of structural proteins such as collagen and 
elastin, specialized proteins such as fibrillin, fibronectin, and laminin and 
proteoglycans. In their review article The extracellular matrix: At the center of it 
all' Bowers et al has compiled research into the relationships between cardiac
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myocytes, fibroblasts, endothelial cells and the surrounding ECM, which 
highlights the importance of particular cardiac cell populations and extracellular 
matrix factors that are critical to the development and regulation of heart 
function. These include the differences in ECM in conditions such as 
hypertrophy and aortic valve stenosis, increased fibronectin and collagens I, III, 
IV, compared with physiological hypertrophy where there is no increase in ECM 
factor expression.(158) There are at least 19 different vertebrate collagens with 
tissue-specific distributions and unique functional properties. (159) 
Proteoglycans, for example, are a diverse multifunctional component of the 
ECM, playing roles in regulating matrix organization, growth factor activity, cell 
proliferation, and differentiation.(160) The ECM used in both traditional and 
microfluidic 3D cell culture lacks these in vivo complexities.(161, 162)
Direct cell-cell contacts have also been shown to promote growth, transfer 
of soluble factors and differentiation. A recent tissue engineering article has 
demonstrated, for example, the impact of cellular interactions between umbilical 
cord blood (UCB) hematopoietic cells and bone marrow (BM)-derived 
mesenchymal stem cells (MSC) on the ex vivo expansion and differentiative 
potential of UCB CD34 enriched cells.(163) UCB cells were cultured in contact, 
non-contact, or non-stroma conditions. After 18 days of culture, cell expansion 
was significantly higher in contact (fold increase of 280 ± 37) compared with 
non-contact (85 ± 25) environment. Direct cell interaction with BM MSC 
significantly enhanced the expansion of early lymphoid CD7+ cells, yielding 
considerably higher (x3-10) progenitor numbers compared with non-contact 
conditions.
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It is also widely acknowledged that there is a need for preclinical models of 
human disease which better reflect the in vivo environment incorporating all 
components of the tissue in their in vivo configurations(164). However, tissue- 
based microfluidic applications are still in their infancy. The first article 
published, which could be said to use 'tissue', involved the culture of murine 
embryos in microchannels.(165) The objective of this study was to determine if 
static microchannels permitted the culture of murine embryos to the blastocyst 
stage. The embryos cultured in the microchannel exhibited a lower degenerated 
index (embryos at 8-cell stage and earlier stage) than the control. It should be 
recognized that the embryos at this stage of development are not yet 
differentiated and the phenotype of the cells are different from adult somatic 
cells. This is the first culture, using microfluidics however, that retains the native 
ECM with the cells instead of an attempt to replicate the environment using 
synthetic materials, as in the field of tissue engineering. Further research has 
used microfluidics to culture and study Drosophila and zebrafish embryos. 
Drosophila embryos are extensively used to examine genetic and phenotype 
changes in molecular biology. It has been demonstrated using traditional 
methodology that local temperature can have an effect on the signalling 
pathways of the developing embryo.(166) Using two laminar flow streams with 
different temperatures, signalling pathways have been manipulated in 
developing Drosophila embryos.(167) Intervention of developing organisms is 
highly appealing as it can give invaluable information into how physiology 
evolves and how different tissues develop. This type of research could be 
employed to study how gene therapy can be used to correct genetic disorders 
with pinpoint accuracy. (168) It show be noted however, that the simultaneous
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delivery of different compounds by microinjection is standard procedure in 
molecular biological research and was first published in 1988.(169)
The first microfluidic studies using tissue slices were the culture of ex vivo 
brain tissue employing either a hollow SU-8 microneedles on 2.7 mm circular 
disks within a microfluidic system(170) to perfuse 400 urn thick hippocampal rat 
brain tissue at 40 ul min"1 or a three-layer PDMS device incorporating 530 - 700 
urn thick medullary brain slices from neonatal rats perfused at 1 ml min"1 .(171) 
Using these approaches cell viability was found to be lost after 4 hrs at 36°C in 
the case of the microneedle device and 3 hrs in the PDMS system, this is a 
shorter viability period than traditional methods as shown in a earlier section. 
Liver explant culture is the latest development in microfluidic tissue studies. The 
first is detailed in this thesis; the second study used precision cut tissue slices 
(PCLS), in a 10 layer PDMS microfluidic device. The PCLS had 4 mm diameter 
and were 100 urn thick and perfused at 10 ul min" 1 , and maintained viability for 
24 hours. The PCLS were subsequently interrogated with 7-ethoxycoumarin (7- 
EC) and exhibited results comparable to PCLS cultured in 1.3 ml well 
plates.(172) The difficulties of using PCLS for testing novel drugs are described 
in depth in Chapter 3. Within this thesis two different types of tissue have been 
studied within a microfluidic system; liver and head and neck cancer tissue.
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1.6 The liver
The liver is the largest visceral and most versatile organ of the mammalian 
body. It is essentially an exocrine gland, which secretes bile into the digestive 
tract but is also important as an endocrine gland and blood filter.
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Figure 13. The liver and gall bladder with detailed structure of the liver highlighted.(173)
The liver as well as being a major physiological organ is also the major 
target of toxicity for a number of xenobiotics, chemicals and byproducts such as 
N-acetyl-p-benzo-quinone imine (NAPQI) produced during paracetamal 
metabolism.(174) This is due to its pivotal role in intermediary and energetic 
metabolism and in biotransformation processes such as glycogenesis, 
triglyceride oxidation and protein deamination.(175) Surrogate methodologies
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and approaches for in vitro hepatotoxicity testing are necessary, and these must 
be robust, reliable and truly reflect in vivo dynamics. An almost impossible 
problem arises however, when attempting to replicate the highly specialized 
organization and complexity of the liver within a laboratory setting using 
traditional methodologies.
1.6.1 Histology of the liver
There are several different cell types found in the liver. These include 
hepatocytes, sinusoidal endothelial cells, stellate cells, cholangiocytes, Kupffer 
cells, pit cells and hepatic stem cells. Hepatocytes are the major parenchymal 
cell of the liver and constitute 70-80% of the overall cytoplasmic mass of the 
liver.(176) The average life span of a hepatocyte is five months.(177) 
Hepatocytes are relatively large compared with other somatic cells, 
approximately 6800 urn3 in volume, with a diameter of 10-30 urn.(178)
Hepatocytes are complex and unique epithelial cells, which undertake 
important biological processes. They are involved in protein synthesis 
manufacturing albumin, fibrinogen, and the prothrombin group of clotting factors 
lipoproteins, ceruloplasmin, transferrin, complement components and a variety 
of glycoproteins.(179) Hepatocytes are also involved in carbohydrate and lipid 
metabolism synthesizing the former through gluconeogenesis and the latter 
from components supplied by the systematic circulation.(180) Hepatocytes 
synthesize bile salts(181) and importantly in toxicological studies metabolize, 
detoxify and inactivate both exogenous and endogenous compounds, for 
example, drugs and steroids.(182, 183)
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Histological organization of the lobes of the liver is controlled by 
connective tissue. The functional units of the liver, liver lobules, can number up 
to 100,000 and are separated by an interlobular septum as shown in Figure 14. 
The hepatocytes in the liver lobule form asymmetrical plates of only one cell 
depth (Remak's plates) with the exposed hepatocyte surfaces, top and bottom, 
are covered with short (O.Sum) microvilli. A characteristic cross section of a liver 
lobule has a hexagonal shape. Within lobule sinusoids, the capillaries are lined 
with fenestrated (gaps between cells) endothelial cells with no basement 
membrane, allowing the free exchange of water and solutes under 200 nm in 
size between blood and interstitial fluid.(184)
Liver lobule 
Pin A/an stain
Figure 14. Image of porcine liver lobule stained with Azan stain(185)
The diameter of the fenestrae can be transformed by several factors 
such as the neurotransmitter, serotonin (5-hydroxytryptamine), toxic compounds 
for example carbon tetrachloride (CCI4), alcohol, nicotine and high 
pressure.(186-188) The liver lobules are surrounded by a highly specialized 
layer of cells known as liver sinusoidal endothelial cells (LSEC) which act as a 
mechanical filter and are involved in multiple physiological and pathological
processes such as liver organogenesis, regeneration, chronic inflammatory
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disease and heptatocarcinogenesis.(189) LSEC are the second most abundant 
cells after hepatocytes and constitute 20% or 1 x 108 of the cells found in the 
liver. LSEC are the foundation of angiogenesis and vasulogenesis of the liver.
The area in between the hepatocytes and the sinusoids, as shown in 
Figure 15, is known as the perisinusoidal space or the space of Disse named 
after its discoverer, Joseph Disse (1852-1912).
Figure 15. Histological image of liver tissue showing the space of Disse, indicated by the arrows
Blood flows through the space of Disse and hepatocytes can be 
described as existing in direct contact with blood. Exo- and endocytosis takes 
place in the space of Disse and is a function of the sinusoidal plasma 
membrane. The space of Disse is principally made of connective tissue with 
reticular (collagen) fibres and is where the hepatic stellate cells (HSC) or Ito 
cells can be found. (190)
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Hepatic stellate cells are star-shaped phagocytes that have a three- 
dimensional structure consisting of a cell body with several long, branching 
cytoplasmic processes.(191) They constitute 5-8% of liver cell population and 
their structure and spatial augmentation in the liver lobule make them sufficient 
to envelop the entire hepatic sinusoidal microcirculatory network. The 
importance of this cell type within the liver was only recognized two decades 
ago and their significance within the liver is still being investigated.(192) HSC 
play a key role in the metabolism and storage of retinoids.(193) Nerve endings 
are localized in the Disse space and are oriented towards HSC and there is 
evidence of interplay with the autonomic nervous system.(194)
In a normal liver, ECM represents 0.5% of the wet weight.(195) Interstitial 
matrix structures, the ECM and basement membranes, support epithelial, 
endothelial and mesenchymal cells. The space of Disse is constructed from a 
network of collagen III and IV and non-collagenous laminin and nidogen.(196) 
Collagen I is associated with reinforcing the architecture of the perisinusoidal 
space in the form of large diameter fibre bundles. ECM in addition to collagen is 
made up of small amounts of several non-collagenous components, which 
include glycoproteins such as: fibronectin, laminin, nidogen, tenascin and 
undulin, sulphurated proteoglycans such as proteodermatan sulphate and 
hyaluronic acid, a carbohydrate polymer.(196) This non-fibrillar complex 
establishes optimal diffusion between hepatocytes and bloodstream.
Another group of cells found in the liver are the biliary epithelial cells or 
cholangiocytes, which envelop the biliary tree. These cells make up 3-5% of the
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liver mass. Bile manufactured by hepatocytes and secreted into a network of 
canaliculi, which progressively increase in size into bile ducts that empty into 
extrahepatic duct and is stored in the gall bladder. Cholangiocytes are polarized 
with one side facing the lumen (apical) of the bile canaliculi and the other side 
(basolateral) facing the sinusoidal space.(197) The apical membrane secretes 
water and electrolytes such as bicarbonate (HCO"3) through the driving force of 
CI" ions through the cystic fibrosis transmembrane regulator (CFTR).(198) 
Cholangiocytes also reabsorb bile components such as bile salts, glucose 
monomers and drugs through the apical membrane which are then 
subsequently effluxed into the peribiliary plexus via the basolateral 
membrane. (197)
Another important cell type found in the liver is the Kupffer cell (KC). 
Kupffer cells are the largest population of somatic fixed tissue macrophages. 
KC represent 30% of non-parenchymal cells and 15 % of all hepatic cells.(199) 
They are found in the hepatic sinusoids attached to the lumen of the sinusoidal 
endothelial cells and as a result of the fenestrae can contact the stellate and 
parenchyma! cells.(200) Due to their position, KC are in continual contact with 
the blood where their main function is to remove all foreign bodies from the 
blood by phagocytosis or pinocytosis. These are then eradicated by lysosomal 
degradation and consequently have lysosomal enzymes and superoxide.(201)
Kupffer cells have a pathophysiological role in several liver diseases. 
These include hepatic ischaemia-reperfusion injury,(202) drug induced liver 
failure(203) and alcohol-induced liver disease. In alcohol-induced liver disease,
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acute and chronic exposure to ethanol causes activation of KG, which leads to 
enhanced cytokine and chemokine release with an increase in ROS 
manufacture.(204)
Additional populations of cells located in the liver, which also have a role in 
the immune system are Pit cells. These cells are unique natural killer (NK) cells, 
resident in the liver that have the ability to kill certain tumour cells and virus- 
infected cells without prior sensitization.(205) Pit cells were named by Wisse et 
a/,(206) due to their characteristic cytoplasmic granules, called pits in the Dutch 
language. Although morphologically resembling large granular lymphocytes 
(LGL), pit cells are immunophenotypical and functional characteristics are 
different from blood NK cells. Pit cells exist in the liver sinusoids where they are 
frequently found adhered to endothelial cells but are sometimes found in 
combination with Kupffer cells. Pit cells produce IFN-y, TNF-a, IL-5, IL-10, and 
IL-13 cytokines,(207) and compared with blood NK cells they have be shown to 
be four to eight times more cytotoxic against syngeneic rat colon 
adenocarcinoma cell line (DHD-K12).(208)
The final group of cells found in the liver are the hepatic stem cells or 
Oval cells. This group of cells has only been recognized in the last few years by 
animal experimentation.(209) These cells are thought to reside in the terminal 
bile ducts (canals of Hering). While hepatocyte mitosis is responsible for the 
bulk of liver regeneration after the majority of hepatic injuries, stem cells are 
also thought to contribute to hepatocyte regeneration and in severe cases of 
injury, may take over this role.(210, 211) Hepatic stem cells are found to
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differentiate into cholangiocytes or hepatocytes during in vitro and in vivo animal 
studies.(212, 213) These cells have also been implicated in the development of 
dysplastic nodules, hepatocellular carcinoma and cholangiocarcinoma.(214- 
216)
/. 7 Cancer
Cancer is the second biggest killer in United Kingdom after cardiovascular 
disease. Almost 1 in 3 of the population will develop cancer in their lifetime and 
almost 75% of those will die directly or the cancer contributing to their 
deaths.(217) Cancer cells disrupt the ordered series of events that lead to 
normal cell division and exploit all opportunities to multiply.(218) Dysplasia is 
the disordered development of cells that result in modification in their size, 
phenotype and organization. This can be reversible however; dysplasia 
commonly precedes neoplasia, the process of tumour growth. A tumour is an 
abnormal mass of tissue and is the result of autonomous disordered growth that 
continues after the initial growth signal(s) have dissipated. Tumours are 
categorized as benign or malignant: benign tumours are localized, slow growing 
but can compress the surrounding tissue. Malignant or cancerous tumours 
invade and destroy adjacent tissue, metastasize, grow rapidly and are usually 
poorly differentiated.(219)
The treatment of cancer requires a comprehension of the principles of 
cancer evolution, multiplication and metastasis.(218) In brief, cell proliferation 
and division, is usually, kept in tight control by two opposing sets of critical 
genes, proto-oncogenes and tumour suppressor genes respectively. Loss of
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function in the tumour suppressor genes and the gain of function in the proto- 
oncogenes remove the cell's ability to control growth. Accumulations of 
mutations result in cells that are genetically different from each other. 
Eventually, fast-growing, less differentiated cells take over often begin invading 
surrounding tissue and proliferate in foreign sites, i.e. metastasis.
A solid mass of cancer cells can be removed surgically, destroyed by 
radiation and toxic chemicals as the latter agents preferentially kill rapidly 
dividing cells.(220) It is extremely difficult to remove every cell and there is 
always the possibility that tumours, through their ability to rapidly mutate, can 
become resistant to the reagent used to destroy them, or worse still the 
treatment itself causes further cancerous growths or cell damage.(221, 222) 
Nevertheless, effective cures have been found for many formally lethal cancers 
such as Hodgkin's lymphoma, testicular cancer and many childhood 
malignancies.(223, 224) Some cancers however, have proved more difficult to 
treat due to the stage of progression on detection such as locoregional spread 
and distant metastasis to secondary sites. One of these cancers is head and 
neck cancer.
/. 7. 1 Head and neck cancer
The majority of head and neck cancer (HNC) begin in cells that cover the 
mucosal surfaces of this anatomical region.(225) These malignancies include 
cancers of the buccal cavity, larynx, pharynx, thyroid, salivary glands and 
nose/nasal cavities as shown in Figure 16, and the majority are head and neck 
squamous cell carcinomas (HNSCC).
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Figure 16. Anatomy of the head and neck highlighting areas where HNSCC occurs. (226)
In the United Kingdom, HNC constituted only 3% of all the reported 
cancers in 2007 but is the 6th most common worldwide due to the high 
incidence in South East Asia and the Mediterranean area.(227-229) These 
cancers are more frequent in men and people over the age of 50,(230) in the 
UK however, evidence suggests that the incidence in the younger population is 
increasing.(231)
The major risk factors of HNC are tobacco (including smokeless tobacco, 
also known as 'chewing tobacco' and 'snuff) and alcohol.(232-234) Eighty-five 
percent of HNC are tobacco-related.(235) People who use a combination of 
both these major risk factors are significantly more likely to develop cancer, 
than those who just use either tobacco or alcohol; showing synergistic effects of 
these agents.(234) Other major risk factors recognized in the last decade 
include sun exposure (lips),(236) human papillomavirus (HPV) which alters the
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DNA of the cells (oropharynx),(237) industrial exposure from wood and nickel 
dust inhalation,(238) Epstein-Barr virus infection, which again alters the DNA of 
the cells (nasopharynx)(239) and Plummer-Vinson syndrome 
(hypopharynx).(240)
Diagnosis of HNC is achieved through medical history evaluation, clinical 
examination by an experienced clinician, fine needle aspiration cytology (FNAC) 
and ultimately biopsy of tissue.(241, 242)
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Figure 17. Diagnostic procedure of HNC
If the diagnosis of HNC is verified as show in Figure 17, then the clinician 
will want to know the stage (or extent) of the disease. Staging is an attempt to 
determine the spread of the cancer and if so, what other parts of the body are 
affected. Primary tumour is first described by site, and then graded on depth of 
invasion, tumour type, pattern of infiltration, excision margins, vascular and 
perineural infiltration.(243, 244) Nodal involvement through metastatic disease 
affects prognosis adversely. In a recent study, it was demonstrated that isolated 
tumour cells (ITC) were detected in 12 of 146 patients (8%), and 24 of 1694
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(1%) lymph nodes. After a median follow-up time of 28 months, ITC in 
pathological node-negative lymph nodes was associated with poorer outcomes 
compared with true node negative disease.(245) Public awareness of HNC is 
generally low and therefore many patients present with advanced cancerous 
growths that have a relatively poor prognosis.(231, 246)
The treatment plan of each individual patient depends on a number of 
factors, including the exact location of the tumour, its stage, and the age and 
general health of the patient.(247) Surgery may be the treatment of choice if the 
primary tumour can be excised with an appropriate margin of normal tissue 
without resulting in major function compromise. Surgical treatment through neck 
dissection can remove both the affected soft tissue and the lymph nodes, to 
avoid further spread.(247) Resections in the neck are small, most often ~0.5cm3 
in size but can be up to 10 cm3, compared with larger resections on other 
cancerous tumours like the liver and lung (>20 cm3).
Treatment after surgery is radiotherapy and/or chemotherapy.(248) 
Radiotherapy uses ionizing radiation to treat the malignancy. Ionizing radiation 
is delivered by external beam radiotherapy or by brachytherapy (implantation of 
radioactive source within the tumour). Radiotherapy can be delivered as radical 
radiotherapy with curative intent or as palliative to provide symptomatic relief 
only.(249) After locoregional therapy, HNC patients are treated with 
chemotherapy. No evidence has identified the approach of chemotherapy alone 
as a curative treatment for HNSCC.(250) Chemotherapy can be given as
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neoadjuvant, delivered in the weeks before locoregional therapy, adjuvant, 
delivered after locoregional therapy, or concurrent with radiotherapy.(251)
CDDP and 5-FU (Figure 18) are widely used in the treatment of human 
cancer. In HNC chemotherapy, current regimens use radiotherapy with a 
combination of 5-FU and a platinum based agent, usually CDDP.(252) The 
survival rates at 1 and 2 years were 81% and 76%, respectively. The 
progression-free survival rates at 1 and 2 years were 69% and 66%, 
respectively. (253)
Cisplatin (CDDP) Fluorouracil (5-FU)
Figure 18. The chemical structures of the commonest chemotherapeutic agents.
The cytotoxic effects of 5-FU are described in Table 3. 5-FU is an 
analogue of uracil and quickly penetrates into cells using the same non- 
facilitated diffusion and facilitated transport mechanism as uracil.(254) Inside 
the cell, 5-FU is converted intracellularly to several active metabolites including 
5-fluoro-2'-deoxyuridine monophosphate (FdUMP). The foremost mechanism of 
5 -FU cytotoxicity is theorized to be the inhibition of thymidylate synthase (TS) 
by FdUMP, although as yet the exact molecular mechanisms of TS inhibition 
are unknown. Inhibition of TS causes the depletion of thymidine
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5'monophosphate (dTMP) leading to the inhibition of DMA synthesis and 
interference with DNA repair.
Table 3 DNA-directed cytotoxic effects of 5-FU
Biochemical consequences of thymidylate Direct and indirect effects on DNA 
synthase inhibition synthesis and integrity
Deoxyribonucleotide imbalance
Depletion of thymidine 
monophosphate and thymidine 
triphosphate
Accumulation of deoxyuridine 
monophosphate
Elevation of extracellular deoxyuridine
Formation of deoxyuridine 
triphosphate
Accumulation of deoxyadenosine 
triphosphate
Inhibition of net DNA synthesis
'Uracil' misincorporation (fluoro- and 
deoxyuridine triphosphate)
Interference with nascent DNA chain 
elongation
Altered stability of nascent DNA
Induction of DNA single-strand breaks in 
nascent DNA repair
Interference with DNA repair
Induction of single-strand and double- 
strand breaks in parental DNA
[Adapted from (254)]
CDDP or cis-Diamminedichloroplatinum (II) is among the most active 
antitumour regents used in human chemotherapy.(255) It was the first platinum 
based drug introduced to the clinic after its medicinal effects were published in 
1969.(256) There is an extensive body of research that the success of platinum 
complexes in destroying tumour cells is mainly due to its ability to form various 
types of adducts on DNA.(257, 258) Bifunctional cisplatin contains two non- 
leaving ammonia ligands and two reactive chloride groups as shown in Figure 
19.
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Figure 19. DNA adduct formation with cisplatin leaving two amino groups coordinated on the 
platinum atom(259)
The major DNA adduct of cisplatin is the intrastrand cross-link (CL) formed 
between two neighbouring purine bases (1,2-GG or AG intrastrand CL) with 
CDDP coordinated to the N7 atom of the purine bases as shown in Figure 
49.(259) The full details of the underlying antitumour mechanisms are not 
entirely understood despite extensive study. One theory is that adducts are 
formed by CDDP that distort DNA conformation, inhibit replication and 
transcription.(260) Another hypothesis proposed is that a number of proteins 
exhibit an increased affinity for CDDP-modified DNA, for example transcription 
factors, effectively high jacking these proteins from their regular binding sites 
and disrupting fundamental cellular processes.(261)
Chemotherapy results in a small statistically non-significant (2%) overall 
survival benefit at five years if given neoadjuvantly (before treatment) and no 
survival benefit if given adjuvantly. The supplementation of chemotherapy to
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locoregional treatment with non-metastatic stage III and IV HNSCC significantly 
increases survival by 5% at two and five years.(251) Standard practice in the 
UK is the use of neoadjuvant chemotherapy using CDDP or 5-FU to treat HNC 
cancer. These chemotherapy agents give significant survival benefit compared 
with locoregional treatment alone. Other chemotherapy drugs are also being 
employed to treat HNC these include docetaxel, capecitabine, and 
cetuximab.(262, 263) When chemotherapy is dispensed concurrently with 
radiotherapy in HNSCC there is an overall survival benefit of 8% at five 
years.(250) The absolute survival benefit for concurrent single agent CDDP, 
compared to all other drugs, is 11% at five years. The reduction of death has 
been calculated for each subsite as these in many ways can be considered as 
distinct entities, shown in Table 4, the benefit of all types of concurrent 
chemoradiotherapy is also age-dependant, with greatest benefit seen in 
patients' aged 60 and below, as demonstrated in Table 5.
The survival benefits connected with concurrent chemotherapy are at the 
detriment of increased acute toxicity (mucosal and haematological) and dental 
problems relating to late toxicity however, these are usually considered 
acceptable. Single agent CDDP is recommended, by the National Health 
Service (NHS), as the chemotherapeutic agent of choice in concurrent 
chemoradiotherapy.(250) HNC is affecting a growing number of people in the 
population and public awareness is still low, and although treatment is available, 
mortality rates have not significantly improved, over the past thirty years despite 
improvements in clinical strategies.
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Table 4 Reduction of mortality rates after concurrent chemoradiotherapy compared to no 
chemotherapy
Subsite Percentage reduction in risk of death
Oropharynx
Larynx
Buccal cavity
Hypopharynx
23%
22%
17%
16%
[From (250)]
Table 5 Mortality reduction of death after concurrent chemotherapy by age
Age Percentage reduction in risk of death
60 or below
60-70
Over 70
22-24%
12%
3%
[From (250)]
As described in this chapter, cell culture has provided invaluable 
information on cell dynamics. Microfluidics has the ability to provide the in vivo 
microenvironment that is lacking in current in vitro cell based methodologies 
and allows an opportunity to increase our current knowledge. Cell based 
microfluidic applications have been continually evolving over the last 20 years 
with one of the latest developments being the maintenance of ex vivo explant 
biopsies in microfluidic systems. The following experiments describe the 
maintenance and interrogation of liver and cancer tissue in the microfluidic 
system for pharmacological, toxicological and fundamental studies in cell 
biology.
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2. Aims
The global aim of this thesis was to develop and validate a microfluidic 
system for the monitoring of cellular functions within an explant/organ biopsy. 
This was to be achieved by manipulating the microenvironment of a tissue 
biopsy to ensure the viability of the explant while also maintaining the 
extracellular architecture. Subsequently, the tissue will be interrogated to 
invoke an intracellular or extracellular response that mimics the same response 
found in previous in vitro and in vivo models. In reaching this aim the following 
objectives were met:
Development and validation of microfluidic systems for the 
maintenance of highly metabolically active biopsies, e.g. liver and 
head and neck cancer. This was achieved through epi-fluorescent 
and confocal microscopy, viability and functional biochemical 
assays and histological analysis of individual cells within prepared 
tissue sections.
Establishment of suitable methodology to stimulate and probe 
explant samples to mimic organ and/or cellular responses found 
within in vivo followed by analysis of cells in tissue and at the single 
cell level.
Detection and analysis of individual biomarkers from cancer 
biopsies after interrogation with chemotherapeutic drugs
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3. Development and validation of microfluidic devices for tissue- 
based methodologies
'No amount of experimentation can ever prove me right; a single 
experiment can prove me wrong.'
Albert Einstein 1879-1955
The concept of a 'system biology' platform, which would be more relevant 
than current cell-based applications and more appropriate than animal models 
in its representation of human organ functions is an ideal that has been alluded 
to by many researchers and practitioners in recent years. (1, 264) Bridging the 
gap between cell and in vivo models, removing the need for extraneous animal 
experimentation whilst allowing tissues and organs to be probed and monitored 
at the molecular and cellular level, has been of increasing interest to the 
biological, clinical and microfluidic communities. Research is commonly 
hampered by the lack of sophisticated pre-clinical in vitro models to replicate 
effectively the in vivo dynamics involving multiple cell types, complex ECM 
interactions and mechanical forces. These are vital in pharmacokinetic / 
pharmacodynamic (PBPK) models, where the lack of suitable preclinical models 
can ultimately lead to drug withdrawal with possibly useful drugs never getting 
to the clinical setting or some drugs reaching patients that cause deleterious 
effects and have to be withdrawn.
Tissue is maintained in vivo within a highly regulated environment with cell 
signalling acting via paracrine, autocrine and endocrine pathways. In order to
60
replicate the microenvironment of the cells and tissue, retention of these 
pathways is essential. Therefore to ensure that the tissue is successfully 
maintained, the microfluidic system has to be designed and optimized with 
viability, functionality and maintenance of the signal pathways being the 
paramount consideration. This chapter describes the design and fabrication of 
the microfluidic system and how this aims to maintain tissue and cell viability 
and function.
3.1 Fabrication of microfluidic device
In order to maintain and interrogate the tissue, the microfluidic device 
needs to have the following properties. It must be able to hold an appropriate 
sized tissue sample, to comprise all the different specialized cell types, 
connective tissue, stroma and cell products that perform the relevant functions 
within the tissue. This must be achieved whilst maintaining the viability, 
functionality and the architectural structure of the tissue. The design of the 
chamber should allow efficient perfusion of the tissue across its entire surface 
with nutrients and oxygen while preserving the laminar flow. Efficient perfusion 
is essential to ensure all the cells are experiencing the same conditions within 
the tissue therefore avoiding erroneous artefacts. The channels in the device 
have to be large enough to permit adequate flow and the flow rate must allow 
the accumulation of signalling molecules while removing waste products but not 
be too large to disrupt paracrine and autocrine signalling by removing excess 
fluid from the tissue microenvironment; in effect creating a effective culture 
volume. The device must be transparent, with the base being thin enough to
allow the analysis of the tissue morphology and functionality through optical
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means including epi-fluorescent and/or confocal microscopy. It also needs to be 
dismantled sufficiently to allow cleaning and sterilization to be performed or be 
made of inexpensive materials to allow single use.
The material from which the microfluidic device is fabricated in is also 
important; it must be biocompatible, chemically and thermally stable. Glass has 
been extensively used in biology for cell culture and has all of the properties 
mentioned. The surface properties of glass were also well characterized 
allowing these devices to easily be tailored to several applications.(265) 
However there is a significant problem associated with using glass, principally 
that it is gas impermeable and further mechanisms are needed to ensure 
oxygenation. Over the last ten years theirs been a steady progression from 
glass to several different polymers that are gas permeable, with the principal 
elastomer being PDMS.(266) PDMS is a polymeric organosilicon compound 
that has applications ranging from contact lenses and medical devices to 
shampoos and lubricating oils. PDMS has been widely used, with other 
polymers also being explored such as poly methyl methacrylate (PMMA) and 
poly-lactic-co-glycolic acid (PLCA). The benefits of both glass and polymers are 
summarized in Table 6. However, due to the previous in house experience of 
micromachining glass microdevices, only the bung, which sealed the chamber, 
was manufactured from PDMS and the main body of the device from standard 
glass.
The microfluidic device is to be used to facilitate the study of cells within a 
tissue environment therefore the recreation of the in vivo microenvironment is
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essential. Cells in macroscale culture vessels confront the problem of 
mechanical forces from fluid motion and bubbles.(267)
Table 6. A comparison between polymers and glass properties with respect to their use for 
microfluidic applications
Polymers Glass
Manufacturing 
costs
Fabrication
Clean room 
facilities
Properties
Operation 
temperature
Optical properties 
and fluorescence 
detection
Bonding
Surface treatment
Compatibility with 
organic solvents or 
strong acids
Joule heating
Electro osmotic 
flow (EOF)
Geometrical 
flexibility
Permeability to 
gasses
Relatively low in cost compared with glass, 
especially for mass-production
Fabrication steps are simpler than glass, and no 
wet chemistry is needed.
Clean-room facilities are necessary for aseptic 
techniques In certain cases, particles may 
become pressed into the polymer during 
processing without having an effect on device 
functionality.
Wide selection of polymers, hence mechanical, 
optical, chemical and biological properties can 
be tailored
Limited for polymers because of relatively low 
vitrification temperature (Tg) compared to 
glass.
Optical transparency is lower than glass. 
Except for special grades, polymers also have 
higher auto fluorescence relative to glass
Different bonding options are available, e.g. 
adhesives, thermal fusion, ultrasonic welding 
and mechanical clamping.
Surface treatment methods are available for 
polymers, but routine, well-established 
denvatization techniques are not available
Except for some special grades, polymers are 
generally not compatible with most organic 
solvents nor in some cases, strong bases or 
acids.
Subject to significant Joule heating because of 
low thermal conductivity
Smaller EOF produced relative to glass, because 
of lack of iomsable functional groups.
Polymer processing techniques offer more 
flexibility for geometrical designs, including for 
example different cross- section (curved, 
vertical or V-groove), high aspect ratio square 
channels, channels with a defined but arbitrary 
wall angle, or channels with different heights.
High gas permeability.
High in cost, especially for 
relatively large-area 
substrates Higher costs are 
also associated with clean- 
room facilities.
Time consuming and 
expensive, and wet chemistry 
is used.
Clean-room facilities are 
needed to avoid 
contamination
Less variability.
Wider range of operation 
temperatures
Excellent optical properties; 
auto fluorescence levels do 
not affect detection 
capabilities.
Time consuming Bonding 
options include thermal, 
adhesive and anodic bonding.
Established chemical 
modification procedures for 
glass are available using 
organosilanes
Good resistance to organic 
solvents and acids
Relatively resistant to Joule 
heating relative to polymers.
Higher EOF relative to 
polymers.
Due to the isotropic nature of 
the etching process, only 
shallow, low aspect ratio, 
mainly semicircular channel 
cross-sections possible
Impermeable
[Adapted from (268)]
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Stirring and rocking is standard procedure for explant culture within 
biological laboratories though the fluid motion can cause cell damage through 
shear forces. Bubbles, which are essential for aeration, can cause damage to 
cell membranes especially when they rupture.(269) Bubbles can arise through 
low air pressure created by the fluid flow. Bubbles can be minimized if the 
media is filtered before flowing through the device. Media replacement is 
necessary to meet the nutritional requirements of the cells, but can also be 
responsible for the creation of shear stress on the tissue, especially for the cells 
on the periphery of the tissue. Shear stress is felt by an entity when a force is 
applied to its surface.(41) In liquids, the shear stress present throughout a 
channel can be represented mathematically using Newton's law of viscosity:
T = -\a (dv/dx) Equation 5
Where T is the shear stress, ^ is the viscosity, v is the velocity, and x is the 
position within the channel.
When tissue is placed in a microchannel, intercellular space plays an 
important role on determining the effect of shear stress on individual cells. A 
mathematical model has been developed to determine the influence of cell 
spacing within a microchannel(41) however, this is not relevant to tissue 
mechanics as the model is too ordered and less complex compared with in vivo 
tissue. Extensive studies into the mechanical properties of soft tissue such as 
the liver have focused on compression (pushing force), indentation (hardness of 
a material to deformation), uniaxial tension (stretching in one direction) and
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aspiration (drawing or suction motion).(270) Experiments into the shear 
properties under finite deformation have been limited. A study used 130 ex vivo 
porcine liver tissue samples conducted two types of pure shear test, unconfmed 
compression and uniaxial tension.(27l) A Digital Image Correlation (DIG) 
technique was used to measure the deformation field. The most important facet 
of the pure shear (or planar tension) test used was that the specimen was much 
shorter in the direction of stretching than in its width dimension. The specimen 
was constrained in the lateral direction such that all specimen thinning occurs in 
the thickness direction. Due to gravity, the deformation field was not uniform in 
the vertical direction and the authors proposed two new constitutive models to 
describe the full range of deformation for both compression and tension, and 
also good for representing tissue deformation in pure shear. There have 
however, been no results published about the effect of shear stress on soft 
tissue in a microenvironment.
Other factors that are of consequence in tissue culture are SAV ratio and 
effective culture volume. Cells that are cultured in the macroscale have 
extremely low SAV ratios. This is contrary to in vivo dynamics, which have high 
SAV ratios that allow the efficient transport of gases and nutrients to the tissue. 
Effective culture volume is an indicator of the cell's ability to control its 
environment. In macroscale vessels, cells are cultured in relatively large 
volumes and therefore the biomolecules secreted by the cells are diluted into 
the relatively vast quantity (> 5 ml) of media or buffer. In the microscale, like in 
vivo, cells are bathed in small volumes (< 20 ul) allowing the accumulation of 
signalling molecules allowing effective communication between the cells.
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3.1.1 Fabrication of glass devices
Dr. Stephen Clark produced all the glass microfluidic devices used in this 
thesis. The first step in constructing the glass microdevices was to draw the 
channel structure using AutoCAD LT software computer assisted design (CAD) 
software package. The drawing was transferred to a mask or thin film with the 
channels left blank on a black background; this allows light to penetrate through 
to expose the channel design on to glass wafers (Telic, Valencia, USA) during 
the procedure to produce the devices.
The B-270 glass wafers, 1mm thick, used to manufacture the devices 
were coated with a chromium layer and a photoresist layer, which was required 
for photolithography as illustrated in Figure 20. Photolithography is a process to 
remove selectively either the channel or the bulk of a substrate. This was 
achieved by placing the mask on a ultra-violet (UV) exposure unit with glass 
wafers placed on top of the channel design. This was called contact printing and 
was used for small volume (10s) production. The exposed plate was immersed 
in developer solution (Chestech Ltd., Rugby, UK) for 60 s. The plate was then 
rinsed under running water and dried it by blowing N 2 over it. The plate was 
then placed into a small basin containing Chrome Etch MS8 solution (Chestech 
Ltd., Rugby, Warwickshire, UK) for 60 s, or until the pattern is fully exposed on 
the glass. The plate is then rinsed with deionised water and blown dry with N2 . 
The glass was then wet etched using hydrofluoric acid (48 %), ammonium 
fluoride (40 %), hydrochloric acid (38 %) and deionised water. Etching time 
depended on the depth of the channel required. For this study, the channel 
dimensions were 190 urn width and 70 urn depth. The depth was subsequently
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verified using light microscopy. Due to the nature of the etching process, 
etching occurs both widthways as well as downwards, creating channels with a 
cross section that is approximately trapezoidal.
photoresist
chromium layer
chromium layer removed
photoresist 
removed
lop plate bonded 
to etched wafer
final chip. 
ready for use
Figure 20. The photolithography and wet etching method of microfluidic chip fabrication.(272)
The glass underneath the photoresist and chrome layers was etched 
whilst the top two layers remain intact. The etched plates were then immersed 
in a small basin of acetone for several minutes until all of the photoresist was 
removed, rinsed with water and dried them with N2 . At the next stage the 
chrome layer was removed using a chromium etchant, Chrome Etch MS8, for 
several minutes removed then allowed to dry. Access holes were drilled in the 3 
mm thick top plate, using 1.5 mm drill bits by standard drilling techniques as 
shown in the schematic in Figure 21 .
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PDMS
Outlets Microport & Adapter
Inlet
3 mm
30 mm _
30mm
Figure 21. Schematic of microfluidic device used for these studies.
A central hole with a diameter of 3mm was drilled into the top plate to provide a 
chamber for the tissue. The tissue chamber is cylindrical with an internal volume 
of 21 \i\. The top plate with the drilled holes was then thermally bonded onto the 
etched bottom plate in a furnace at 590 °C for 3 h. The bonding temperature for 
B-270 must be above the transition (or transformation) temperature of 520 
degrees, but below the softening point of 710 degrees. Above the transition 
temp the glass starts to become "rubbery", allowing two plates to be bonded, as 
they will be soft enough to press into each other slightly (hence the fact two 
distinct layers in a bonded chip). Above the softening temperature, the glass is 
essentially molten and therefore is not suitable for bonding.
The microfluidic system used during the study comprised of the glass 
device, Teflon tubing, incubator and hydrodynamic pumps. The microfluidic 
device was fitted with a microport fitting (Anachem, UK) that was attached to the 
surface of the top 3 mm glass layer. This was in order to seal the circular tissue 
cavity using an English threaded adapter (Anachem, UK). The adapter was
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filled with PDMS (Dow Coming, UK) to allow gaseous exchange to occur as 
shown in Figure 22.(142)
Figure 22. Images of the microfluidic devices with and without the bungs. In the image on the 
left, tissue can be seen in the tissue chamber, as indicated by the arrow. In the image on the 
right, media is collected hi two individual 1.5 ml microcentrifuge tubes for later analysis.
A Baby Bee syringe pump (Bioanalytical Systems Inc., UK) was 
connected to the device via 1/16" Tefzel tubing (Anachem, UK), this was 
subsequently upgraded to a Harvard PhD 2000 syringe pump (Harvard, UK) for 
more precise measurements with the tubing changed to 0.8 mm ID x 1.58 OD 
TFE Teflon® tubing due to the letter's greater flexibility. The length of the tubing 
from 1-20 ml syringe (BD , UK) to the device was 30 cm and outlet tubing was 
8 cm long as shown in Figure 22. In between the syringe and the tubing, a 0.22 
p,m filter was fitted; this reduced the possibility of bacterial and particulate 
contamination as well as minimising the occurrence of bubbles into the device. 
A 1.5 ml polypropylene centrifuge tube, with a hole in the lid covered with 
parafilm to stop contamination and leakage, was placed on the end of each 
outlet tubing to collect eluent as shown in Figure 23. The entire system, except 
the pumps, was placed in an egg incubator at 37°C.
Figure 23. Images of the microfluidic systems. Left: each pump connected to four different 
individual devices; Right, inside one incubator.
3.2 Tissue Harvesting
Wistar Rats, obtained from B&K Universal Ltd, were used for all 
experiments. All animals had free access to food and water until being 
anaesthetized. The animals killed using Schedule 1 of the Animals (Scientific 
Procedures) Act 1986 and were anaesthetized (10 ml kg"1 of 10mM sodium 
thiopentone, intraperitaneal) before undergoing a total hepatectomy. Liver 
biopsies were used immediately or frozen as described below.
3.3 Materials
All chemicals and reagents were supplied from Sigma, UK and were of 
tissue culture or molecular grade as appropriate unless otherwise attributed.
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3.4 Preparation and cryopreservation of tissue samples
Due to the inherent wastage from using fresh samples for every 
experiment, cryopreservation for subsequent use was imperative. Two methods 
of cryopreservation were tested. The first approach was rapid freezing without 
cryoprotectant, where the sections were rapidly placed into 1 ml cryovials 
(Alpha Laboratories, Hampshire) that were immediately plunged into a Dewar of 
liquid nitrogen for 2 minutes before being transferred into a -80°C freezer for 
long term storage. The second approach was vitrification.
Vitrification is the solidification of a liquid not produced by crystallization 
but by a radical increase in viscosity, so the solution becomes glassy and cell 
damage by ice crystal formation is impeded.(273) A fluid can be effectively 
vitrified during this process if the cooling rates employed are higher than the 
critical cooling rate (vcrc); the formation of ice-crystals has been shown to be 
low.(274) Prevention of devitrification by using warming rates above the critical 
warming rate of the fluid (vcrw) stops ice-growth formation in the nuclei of the 
cells on thawing. In order to achieve vitrification, a high concentration of 
cryoprotectant (18% (v/v)) Dimethyl sulfoxide (DMSO), (CHa^SO, was used.
Williams Media E (WME) was set on ice and 18% (v/v) DMSO was added 
and left for 10 minutes. Into individual cryovials, 1 ml of the solution was added 
and the vials were set into crushed ice, subsequently the liver was cut into 
samples of approximately 1 cm 3 dimensions and a single sample placed into 
each of the vials. The vials and tissue were left a further 10 minutes on ice
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before being sealed and the vials plunged into liquid nitrogen for approximately 
5 minutes after which they were stored at -80 °C until required.
3.4.1 Rewarming and DMSO removal
Liver sections cryopreserved by either method were returned to 
physiological temperatures by placing the cryovials in an incubator at 37°C until 
ice crystals were no longer visible in the vial (approximately 1 min). The 
sections were then removed from the cryogenic media, set in fresh WME in 1.5 
ml centrifuge tubes and incubated at 37°C until required. All thawed tissue was 
used within 60 minutes of being removed from storage. To investigate the 
action of disaggregation enzymes in a later experiment however, the tissue was 
cut frozen into 3 mm3 before being allowed to thaw, in order to visualise the 
edges of the tissue in Section 3.12.
3.4.2 Morphology Analysis
To visualize cell architecture within the tissue, it was first embedded on a cork 
tile covered with Tissue-Tek® (Sakura, Netherlands) and plunged immediately 
in liquid nitrogen cooled 2-methyl butane solution. Frozen sections (12 urn thick) 
were then cut using a Microm HM505E cryostat. Sections were selected from 
the centre of the sample and these were stained with Haematoxylin and Eosin 
(H&E). The sections were then fixed with 10% (v/v) formalin for 10 minutes in a 
fume cupboard, stained with Delafield's Haematoxylin for 5 minutes before 
rinsing with running cold tap water. After rinsing for 10 minutes the tissue was 
dehydrated with sequentially higher concentrations of 25%, 50%, 75%, 85% 
and 95% (v/v) ethanol over 8 minutes. The tissue was then stained with 100% 
Eosin for 1 minute before being quickly dipped with 95% (v/v) and absolute
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ethanol. The tissue was finally placed in Histoclear for five minutes to remove 
any excess stain and non-specific stain and then mounted in Depex using a 
coverslip. The tissue was imaged by light microscopy.
3.4.3 Cryopreservation Results
The aim of this experiment was to determine which method of cryopreservation 
was appropriate for the banking of liver tissue that would otherwise be lost. 
Eight liver samples were removed from -80°C after 2 weeks and stained with 
H&E. Representative results of the different cryopreservation methods are 
shown in Figure 23. Both images show little effect on cell and tissue 
morphology. The cords of hepatocytes have remained intact in both procedures 
with little loss of cytoplasm through shrinkage or ice crystal damage. The cell 
membranes can be seen in several places, with the hepatocytes preserving 
their original hexagonal shape. In addition there is minimal to moderate 
heptocellular dissociation, indicative of disruption of intercellular junctions.(275) 
Minimal apoptosis was randomly distributed within the parenchyma. Three 
independent liver biopsies were frozen using the two different methods with 
twelve sections taken and stained from each biopsy. This gave a total 72 
sections that were imaged and analyzed. There have been inconsistent findings 
regarding hepatocyte viability following storage time. Some researchers state a 
significant loss of viability and functionality of hepatocytes after 
cryopreservation. In one study, hepatocyte viability was investigated for the 
possible transplantation into patients as an alternative to whole liver transplants 
and the aim was to assess cryopreserved hepatocyte proliferation 
capacity. (276)
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Figure 24. Images of rat liver tissue with H&E staining. The tissue was frozen using two 
different methods (A) vitrification by incorporating a high percentage of cryoprotectant, 18% 
(v/v) DMSO, in the storage media. (B) Snap frozen in liquid nitrogen with no cryoprotectant. 
The tissue was stored at -80°C for 2 weeks before staining and imaging. Arrows indicate cells 
that still retained the hexagonal shape with membranes intact. There is minimal to moderate 
heptocellular dissociation. Magnification 40x.
Fresh and frozen/thawed mouse hepatocytes were transferred 
separately into the livers of recipient mice with transgene-induced liver disease. 
It showed that after storage for 32 months in liquid nitrogen, cryopreservation 
decreased hepatocyte viability. The study proved that individual viable 
frozen/thawed hepatocytes demonstrated clonal replicative potential identical to 
that of fresh hepatocytes. In a later study, human hepatocytes derived from 
unused liver segments from transplants showed that after cryopreservation, 
viability, attachment efficiency, enzyme activity, and albumin production of 
hepatocytes were all significantly decreased, with lactate dehydrogenase (LDH) 
leakage significantly increased.(277) The viability and attachment efficiency of 
cryopreserved hepatocytes isolated from liver resections for tumours were 
significantly higher, and the LDH leakage significantly lower, than those isolated 
from all donor tissue. The viability and attachment efficiency of cryopreserved 
hepatocytes isolated from liver resections for tumours were significantly higher, 
and the LDH leakage significantly lower, than those isolated from all donor
tissue.
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Another group also reported that in general, hepatocyte viability 
decreased appreciably within 60 minutes of thawing. (278) Cells suspended in 
5% dextrose lactated Ringers solution (D5LR) however, maintained greater cell 
viability. Hepatocytes from normal liver donors showed less LDH enzyme leak 
in comparison with cells from fatty liver donors. Mild hypothermic temperature 
(32°C) inhibited cellular damage that otherwise significantly increased at 60 
min. Hepatocytes did not proliferate until 12 h from thaw, regardless of 
supernatant or conditions of suspension.
There have been many assertions about the correct method of freezing 
rates and protocols with equally as many claim for a particular protocol as 
against it. This can be seen from the number of articles published on different 
methodologies, which has been accelerating in the last ten years as the push 
for tissue engineering increases. In the experiments that follow all the tissue 
used were cryopreserved using snap freezing as it was easy and less time 
consuming. In some cases, the tissue was over six months old when used in 
the microfluidic device. Throughout the study there was little variation in the 
results between the different experiments.
3.5 Determination of tissue viability on cavity slides
To analyse tissue viability and concentration of fluorescent probe before 
placing in a microfluidic device, liver samples were analyzed on cavity slides.
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The tissue biopsies were cut into approximately 3 mm 3 sections. The samples 
were placed on separate cavity slides and covered with 20 ul of WME. Cell 
viability was evaluated using Calcein-aceyloxylmethyl ester (Calcein AM) and 
Propidium Iodide (PI). Calcein AM is modified carboxylic acid with an additional 
ester group that allows entry through the plasma membrane of a cell, when 
hydrolyzed within a viable cell, it becomes a membrane impermeant carboxylate 
which fluoresces as shown in Figure 25.(279)
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Figure 25. Image of Calcein AM metabolism in the cell. Calcein AM is a non-fluorescent, 
electrically neutral, non-polar analogue of fluorescein diacetate, which passively crosses cell 
membranes and is cleaved to a fluorescent derivative by non-specific intracellular esterases. 
Once cleaved in viable cells, the resultant fluorescent salts are retained by intact cell 
membranes. Image taken from Molecular Probes.
PI enters cells with disrupted plasma membranes and intercalates with the 
DNA making non-viable cells fluorescent.(280) The structure of PI is shown in 
Figure 26. PI is impermeant to viable cells; fluorescence is therefore inversely 
correlated with cell viability. Consequently, both probes are useful for measuring 
parameters of cell viability via complementary mechanisms.
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Figure 26. The structure of Propidium Iodide from Molecular Probes
Each tissue biopsy was first incubated with 50 uL of 10 uM Calcein AM 
(Invitrogen, UK) in phosphate buffered saline (PBS) for forty minutes. This time 
period allows for the cells in the tissue to take up and cleave relatively large 
amounts of calcein probe. The liquid was subsequently removed by pipette and 
replaced with PBS to remove any excess probe; this was repeated thrice. The 
tissue was subsequently incubated with 50 uL of 3.75 mM PI in PBS for ten 
minutes. The PI stain was removed and the tissue washed thrice with PBS. 
Finally, the tissue was visualised an epi-fluorescent Nikon Eclipse 80i 
microscope (Nikon, Japan) employing 10x Plan Fluor (0.30 NA) objective and 
4x Plan Fluor (0.13 NA) objectives. The following excitation and emission 
wavelengths were used: for Calcein (Aex = 494, Aem = 517nm) and for PI (Aex = 
536, Aem = 617nm). Images of the tissue samples were recorded using 
Hamamatsu orca ER camera and analysed using Metaview 6.1 image 
processing computer software.
3.5.1 Analysis of tissue viability on cavity slides
On examination of the tissue under epi-fluorescent microscopy, the native 
tissue was verified to be non-fluorescent. The liver tissue was incubated with
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Calcein AM and PI separately and consecutively to verify areas of live/dead 
liver cells. Higher incidence of fluorescence from the calcein indicates the 
viability of the cells; i.e. healthy cells actively metabolize more probe than cells, 
which are dying as shown in Figure 27.
Figure 27. Image taken of the periphery of the liver tissue on a cavity sh'de using epi-fluorescent 
microscopy. The fluorescence of the tissue is caused by the retention of fluorescent probe, 
calcein, in the cytosol of the individual cells. Some of the structual organisation of the tissue can 
be observed, as indicated by arrows, known as Space of Disse. Focus is blurred due to the 
undulations of the tissue. Magnification lOx
The primary area of dead cells stained with PI was determined to be 
around the periphery of the tissue where the area was cut to allow the 
placement of the tissue on the cavity slides, as shown in Figure 28. This 
experiment was repeated ten times on ten different liver samples.
78
Figure 28. Epi-fluorescent image of cells on the surface of rat liver sample exhibiting nuclei 
staining from propidium iodide (PI) on a cavity slide. The spots of fluoresence are from PI 
intercalating with DNA in the nuclei of dead cells. Cells are in and out of focus due to the 
morphology of the liver surface. Magnification lOx
3.6 Determination of cell death in liver tissue on cavity slides using 
fluorescent probes and hydrogen peroxide
To determine cell death in the liver tissue and the time frame for cell death to 
occur, hydrogen peroxide was used. This analysis would specify the parameters 
required to envoke cell death when interrogating the tissue in the microfluidic 
device. Hydrogen peroxide (HfeOa) is a ROS, which induces apoptosis via 
several cell signalling pathways as shown in Figure 29.(281) H 2C>2 is the first 
product from the conversion of the superoxide anion radical (O2") by superoxide 
dismutase enzyme or by spontaneous disproportionation. H2C>2 damages cells 
through the production of the extraordinarily powerful oxidant, hydroxyl (OH) 
radical. Free radicals are atoms, molecules, or ions with unpaired elections in 
an open shell configuration. An oxidant is a chemical that readily transfers 
oxygen atoms or a substance that gains an electron(s) in a redox reaction. An 
antioxidant is a molecule capable of inhibiting the oxidation of other molecules.
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In hepatocytes, this production is enhanced by the metal cation Fe (II) that is 
stored within the cell from erythropoiesis.(282) These free radicals cause 
extensive damage to cellular membranes leading to cell dysfunction and death. 
Therefore, the disposal of H2O2 by peroxidases and catalase-catalyzed 
reactions to O2 and 2H20, is critical to prevent the accumulation of such 
radicals. Liver tissue, approximately 3 mm3 was set in cavity slides and was 
treated with the probes as indicated in previous section to highlight cell viability 
and death before interrogation.
GENE EXPRESSION CHANGES
Cell 
Survival
Cell 
Death
Figure 29. Oxidative stress activates numerous signalling pathways. Reactive oxygen species 
(ROS) are highly reactive and can directly or indirectly modulate the functions of many 
enzymes (boxes) and transcription factors (ovals) through a multitude of signalling cascades. 
Ultimately these signals result in changes in gene expression, which influences apoptosis 
mechanisms. The magnitude and duration of the stress in combination with the cell type 
involved are significant factors in the determination of which pathways are activated and the 
ultimate cellular outcome. ATM, ataxia-telangectasia mutated; ERK, extracellular signal- 
regulated kinases; HSF1, heat shock transcription factor 1; JAK, Janus protein kinase; INK, c- 
Jun N-terminal kinases; NFKB, nuclear factor KB, P13K, phosphoninositide 3-kmase; PKC, 
protein kinase C, PLC-yl, phospholipase C-vl; STAT, signal transducers and activators of 
transcription.
The tissue was then interrogated with 50 ul aliquots of H202 in concentrations of
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50 uM, 0.5 mM, and 10 mM in distilled water for 5, 10, 20, 30, 60 minutes. 
These concentrations were chosen because they had been used by other 
groups(283, 284) investigating apoptosis in various cell types and would allow 
the comparison of results when applied to tissue. The tissue was washed three 
times with PBS to remove any residual reagent as described earlier. The tissue 
was examined via epi-fluorescent microscopy with 10 x magnification then 
subsequently 'reinterrogated' with Calcein AM and PI probes, as described 
earlier, and re-examined with epi-fluorescent microscopy. All concentrations 
were duplicated on separate cavity slides with individual liver samples. This 
experiment was repeated three times.
3.6.1 Cell death within liver tissue on cavity slides after interrogation with 
H202
The aim of these experiments was to determine the concentration of H2O2 
needed to kill liver cells in the tissue sample. A series of H2O2 concentrations 
were used to induce apoptosis in the cells of the tissue, as indicated in the 
methodology. Cell death was determined by the loss of calcein fluorescence in 
the cytosol and the increase of PI fluorescence in the nuclei of dead cells as 
determined by epi-fluorescent microscopy. After five minutes, oxygen bubbles 
began to form on the tissue surface, which increased in size and number with 
time and H2O2 concentration. It is most likely that oxygen formation was due to 
the cells' antioxidant enzyme, catalase, decomposing the H 2O2 to 02 and H2O. 
Catalase is ubiquitously found in all mammalian cells with its highest activity 
found in liver and kidney cells.(285) After incubation with H202 but before the 
addition of the fluorescent probes, the tissue was examined visually and epi- 
fluorescent microscopy. Under visual examination the tissue appeared
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bleached. The tissue was imaged before the addition of further probe and 
depletion of the calcein fluorescence, with no discernible change of the PI 
fluorescence was noted within all tissue specimens. This was true for all the 
H2O2 concentrations in the initial inspection by epi-fluorescence microscopy. 
However, there was a total cessation of fluorescence from calcein in the tissue 
treated with 10 mM H 2O2 indicating cell death in the sample. Following the 
reapplication of calcein AM and PI however the calcein fluorescence was 
returned. This was a problem when distinguishing areas of cell death after the 
reapplication of the probes. This was thought to be due to the retained probe in 
the viable cells underneath the dead cells. Cells on the surface of the tissue 
were the first to be exposed to H202 and underwent oxidative stress and 
subsequent cell death. Cells beneath the surface layer of cells were only 
exposed to H2O2 after it flowed through the gaps in the tissue through diffusion. 
The H202 concentration determined the depth of cell death in the sample as 
cells on the periphery would come in contact first and use catalase to neutralize 
the chemical prior to any contact with underlying cells.
Epi-fluorescent microscopy did not allow the discrimination between cell 
layers in the tissue. It was impossible to determine the effectiveness of the 
H2O2 concentration and the length of time needed to cause apoptosis or 
necrosis due to the underlying fluorescence from the cells underneath those 
that were subjected to the interrogation.
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3.7 Determination of oxygen within microfluidic system using ruthenium 
tris (2,2'-dipyridyl) dichloride hexahydrate
Before studying the responses of the ex vivo explants under a simulated 
physiological microenvironment, it was necessary to investigate the chamber 
environment to ensure that there is sufficient distribution of nutrients, oxygen 
and temperature. Dissolved oxygen (DO) is a paramount concern when 
culturing cells and tissue. Solubility of oxygen in the media is relatively low (7 
mg/l at 37°C) making it vital that fresh supplies are maintained and 
supplied.(286) PDMS at 25°C has a relatively high diffusivity D = 3.55 x 10"5 cm2 
/s, which is advantageous for cell-based applications.(287) Thus the passive 
gas exchange of oxygen through PDMS is adequate for supplying the required 
amounts of oxygen for mammalian cell cultures that have moderate oxygen 
uptake rates.(288) Through the uptake of oxygen by the cells, DO levels drop 
leading to the formation of oxygen concentration gradients and hypoxia. When 
this occurs within tissue the cells in the centre, where oxygen is relatively low, 
they produce paracrine signals to the surrounding cells such as Hypoxia 
Inducible Factor-1 (HIF-1), which is a key regulator of cellular adjustment to 
oxygen deprivation. This signal acts as a survival factor of hypoxic cells, 
primarily by activating transcription of genes involved in angiogenesis, glycolytic 
metabolism and oxygen consumption.(289) If critically low oxygen 
concentrations at the centre of the tissue persist, cell proliferation rate 
decreases and ultimately, these interior cells die off creating a necrotic 
core.(290) To study the issue of oxygen supply in the microfluidic environment, 
an optical-based method was used. Fluorescent probes are suitable for the 
small geometries and volumes associated with these devices, as they do not
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expend oxygen during measurement, are relatively non-harmful to cell functions 
and are suitable for temporal studies.
Oxygen fluorescent imaging studies on cell-based microfluidic applications 
using ruthenium tris (2,2'-dipyridyl) dichloride hexahydrate (RTDP) have been 
documented.(291, 292) RTDP relies on fluorescence quenching; this is a 
physical mechanism resulting in a decrease of fluorescence from a fluorophore. 
Collisional quenching of fluorescence relates to a process whereupon an 
excited fluorophore is de-excited, non-radioactively, to its ground state due to 
physical contact (collisions) with an agent (quencher). Oxygen has been found 
to be an effective Collisional quencher of nearly all fluorophores.(293) Collisional 
quenching decreases the fluorophore quantum yield (the ratio of emitted 
fluorescence photons to adsorbed excitation photons) causing a reduction in 
emitted fluorescence intensity, in addition to the fluorophore excited-state 
lifetime.
The relationship between fluorescence intensity (or lifetime) and dissolved 
oxygen concentration is described by the Stern-Volmer equation(291):
Equation 6
where I 0 or TO is the uninhibited sensor dye intensity or lifetime (i.e. 0% 
oxygen), I or T is the sensor dye intensity or lifetime at oxygen level [O2 ] and Kq 
is the Stern-Volmer quenching constant.
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To determine the maximum and minimum fluorescent signals from 
deoxygenated and oxygenated media two bungs were used in the device, one 
filled with epoxy resin, which is gas impermeable, and one containing gas 
permeable PDMS. Polypropylene tubes were filled with 1.5 ml WME media 
containing 1 mg ml"1 RTDP were sonicated for 15 minutes. To ensure that no 
oxygen was remaining, nitrogen gas was bubbled through for 5 minutes. 
Conversely, oxygen gas was bubbled through a second sample of WME for 10 
minutes to give positive oxygenated sample of media. A 1 ml syringe was filled 
with either the oxygenated or deoxygenated media and put on the microfluidic 
system. The device was sealed with a resin filled bung and the media pumped 
through at 20 ul min"1 until media had flowed through the outlets. The speed of 
the media was then decreased to 2 pi min"1 and left to flow for 10 minutes 
before images were taken.
To determine the amount of dissolved oxygen in the media sample under 
different flow conditions, a 1 ml syringe was filled with ungassed WME with 1 
mg ml"1 RTDP and put on the microfluidic system. The microfluidic device was 
sealed with the PDMS bung with the media pumped through at 20 ul min"1 until 
it had flowed through the outlets. The speed of the media was then decreased 
to 2 ul min"1 and left to flow for ten minutes before imaging. The device was 
then flushed using deionised water to remove all media traces for the next 
sample. This procedure was repeated for 5 and 10 ul min"1 flow rates. These 
flow rates were chosen as they closely replicate in vivo flow rates found in 
interstitial fluid.(294, 295)
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A Zeiss Axiovert S100 inverted Epi-florescent microscope fitted with 4x 
objective was used to measure the intensity of the RTDP dye in the tissue 
chamber. Images were recorded using a CCD camera and subsequently 
analysed using Image J computer imaging analysis software (National Institutes 
of Health, US). The fluorescent images were taken at an exposure time of 0.1 s 
for each observation and the chamber was imaged three times in rapid 
succession for each condition.
3.7.1 Analysis of dissolved oxygen in microfluidic tissue chamber
After testing a range of concentrations of the RTDP from 0.1 mg ml"1 to 1.0 
mg mr1 in a deoxygenated media, it was found that 1.0 mg ml" 1 give the best 
fluorescent image within the channels and the chamber. Consequently, all 
experiments were carried out using this concentration. The intensity and lifetime 
of the fluorescent signal was observed in the chamber and the channels leading 
to and from it for the intensity at zero oxygen content, as shown in Figure 30. 
The positive control, used media perfused with oxygen for the observed 
intensity at the three different locations at high oxygen content. The observed 
average intensities of the chamber deoxygenated samples were 238 ± 20 AD 
and the oxygenated samples were 83 ± 14 AU. These were calculated from 
three experimental repeats for each sample. By using the Stern-Volmer 
equation, this corresponds to 708 ^M of dissolved oxygen in the oxygenated 
media in the microfluidic device, as demonstrated in previous fluorescent 
oxygen detection studies.(296) It was determined by visual and graphically 
analysis, as shown in Figures 30 and 31, that oxygen was diffusing through the 
PDMS bung into the untreated media in the tissue chamber at the experimental 
flow conditions. DO levels in the whole chamber at 2 \il min"1 were 279 \M; at 5
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\iL min"1 were 187 ^M; and at 10 [xl_ mirr1 were 118 ^M. These DO levels are 
within the venous to arterial range (90 - 260 \M) found in v;Vo.(296) The media 
in all the flow experiments was not pre-oxygenated and the device was placed 
within an egg incubator, which while maintaining the temperature did not have 
any additional gaseous support. Indeed the movement of air achieved in the 
incubator was by means of vents and fans allowing fresh atmospheric air to be 
continuously circulated into and around the incubator and the microfluidic 
devices. Usual cell based methodology grow culture in incubators that provide 
5% carbon dioxide (CO2) into a humidified atmosphere of the interior of the 
incubator. This is because most media contain buffers that require a COa 
atmosphere. Severe pH shifts, media becomes acidic, can occur if adequate 
COa levels are not maintained.
The media used in the current studies were WME and Dulbecco's modified 
Eagle's medium (DMEM). WME and DMEM use phenol red as a pH indicator. 
The colour of phenol red gradually changes from yellow to red over the pH 
range of 6.8 to 8.2 and is routinely used in cell culture. When cells are necrotic, 
cell products will cause a pH change, which is due to the acidification of the 
media, turning this from pink to yellow.(297) A similar colour change can also 
occur when the culture is overgrown with a bacterial contamination. Cell 
biologists use the indicator within media as an expedient way to quickly confirm 
the health of tissue culture. In addition, waste products produced by mammalian 
cells will slowly decrease the pH if accumulation occurs.(298) In this study, no 
changes of pH from the media indicators by eye were recorded in any of the 
experiments.
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Figure 30. Epi-fluorescent images of microfluidic tissue chamber showing oxygenation of the 
media using RTDP probe (A-E). Using the oxygen reactive fluorescent probe ruthenium tris 
(2,2'-dipyridyl) dichloride hexahydrate (RTDP) images were taken of the 3 mm diameter tissue 
chamber to determine dissolved oxygen content within different flow conditions. Images show 
the chamber filled with Williams Media E (WME) incorporating 1 mg ml" 1 RTDP (A) 
oxygenated sample (no fluorescent signal) (B) deoxygenated sample (C) ungassed WME media 
flowing at 2 ml min'1 (D) ungassed WME media flowing at 5 ml min"1 (E) ungassed WME 
media flowing at 10 ml min"1 .
——oxygenated sample (A) ——degassed sample (B) ——2 ul/lnln (F) ——5 ul/mln (G) ——1O ul/irtn (H) 
3OO
Diameter (micrometres)
Figure 31. Comparisons of the fluorescent intensities of the oxygenated sample and untreated 
media in the tissue chamber shown in Figure 29 presented graphically from which all the 
calculations and analysis were drawn.
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3.8 Determination of flow profiles in channels and chamber
The first stage in investigating the use of microfluidics to interrogate tissue 
was to determine the flow profiles within the microfluidic device. Two parallel 
laminar flows allow the modification of the microenvironment of a single tissue 
sample within the same experiment. When using multiple laminar flows for 
interrogation, it is important to determine flow within the chamber to establish 
the position of the interface between two or more flows over a tissue specimen. 
The interface in these microfluidic experiments needs to be aligned 
approximately over the middle of the tissue to allow for a reagent to be 
effectively measured against its equivalent control section. If the reagent 
containing stream covers too much of the specimen, it will be difficult to analyse 
the impact on the cells as there will be insufficient native tissue to compare it 
with and vice versa. In these experiments, the two split microchannels were 
used as inlets as illustrated in Figure 21 and the single channel was used as the 
outlet. To visualise the different flows, one stream contained only PBS and the 
other PBS and 10 mM rhodamine solution. A range of flow rates, 2 - 20 ^l min"1 , 
were investigated to analyse the flow profile in the chamber. The rates of both 
flows were independently controllable.
3.8.1 Analysis of flow regimes within the microfluidic device
To determine the position of the interface of the two laminar flows, images 
were taken of the microfluidic channels and chamber as shown in Figure 32. 
Determining flow within the chamber is important for establishing the position of 
the interface between two or more flows over a tissue specimen. Laminar flow 
was achieved in the main channel as shown in Figures 32A and 32B. However, 
problems became evident when the flows entered the chamber. The fluorescent
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probe seemed to pool near the entry point as demonstrated in Figure 32C and 
32D. Changes in flow rate in one stream had no effect on the phenomena as 
shown in Figure 32D. The experiments were repeated using different flow rates 
over a period of a month and the problems with the probe pooling in the 
chamber were repeated with every experiment. These problems where thought 
to be from backpressure caused by the outlet microchannel having the same 
dimensions as the two-inlet channels.
3.9 Determination of tissue viability in microfluidic device using 
fluorescent probes
Before the tissue was placed in the system, the system was sterilized by 
the passage of 70% (v/v) ethanol for twenty minutes at 10 nl min" 1 . Autoclaved 
for 5 minutes before the experiment was commenced. The PDMS bung was 
removed and the flow rate was then raised to 20 \n\ min"1 in order to quickly fill 
the tissue chamber before the addition of the tissue. When the chamber was 
full, the flow rate was reduced to 10 nl min'1 . During this preparation time, the 
tissue was cut into approximately 3 mm3 sections and weighed on a four place 
analytical balance. Tissue samples between 5 and 10 mg were selected for 
experimental use and placed in the tissue chamber. The chamber was then 
sealed using the PDMS bung. Two 1 ml syringes containing 10 uM calcein AM 
in WME were fitted to the outlets of the device and the flow continued at 2 ul 
min"1 for increasing amounts of time up to one hour, recommended by the 
manufactures, to determine diffusion profile into the tissue. This flow rate was 
chosen as it displays had the highest concentration of DO entering the media
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Figure 32. Flow dynamics in the microchannels and the chamber. (A) The intersection of the 
two inlet microchannels into the main channel. 10 mM rhodamine solution is in the bottom 
channel and PBS is flowing in the top channel at 10 ul min" 1 . (B) Laminar flow in the main 
channel before entrance of the chamber. Both flow rates are equal and the interface between the 
two streams is in the centre of the channel. (C) Shows the entrance of the chamber with the 
main channel. The flow rates of both streams are 10 ul mm"1 . The two flow rates in (D) are as 
follows; 10 mM rhodamine solution flow is at 3 ul min"1 and PBS flow is at 15 ul min"1 . 
Magnification 10 x, (n=30)
through the bung as described in a Section 3.7.1. After this time period, the flow 
was stopped and the syringes containing PBS were refitted on the system and 
flow reinstated for increasing amounts of time up to twenty minutes, 
recommended by the manufactures. A syringe containing 3.75 mM PI was then
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installed on to the system and left for twenty minutes to run at 2 ul min"1 . A PBS 
wash of the tissue followed in the same manner as described after the addition 
of calcein AM. The tissue containing microfluidic chamber was analysed using 
confocal microscopy, as epi-fluorescent microscopy would not give sufficient 
detail for analysis due to its inability to 'analyse fluorescence in focal planes 
within the tissue. The PBS was replaced with WME overnight with the flow rate 
unchanged. The media was collected overnight, approximately 18 hours, 
outside the incubator in 15 ml tubes sealed with cling film with a hole inserted to 
allow the passage of the tubing into the tube. Imaging of the tissue was then 
repeated after twenty-two hours, after leaving overnight, to determine any 
changes in tissue viability over time.
3.9.1 Confocal imaging
To understand the complex interactions between cells and their 
environment it is important to be able to examine cells free of possible 
damaging or inaccurate artefacts. However, the main problem is to achieve this 
without causing significant disturbance to the cells or tissue by the 
experimentation and analysis methods. The optical sectioning facility of the 
confocal microscope allows visualization of thin sections of intact cells, microns 
(<200 nm) below the surface the sample.(299) In doing so, possible surface 
contaminants can be optically removed and the underlying cells can be 
examined.
The confocal imaging techniques used in this study were: Time-Lapse 
fluorescence imaging, multi-channel time-lapse imaging, three dimensional 
time-lapse (4D) imaging, three dimensional multi-channel (5D) and time-lapse
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fluorescence imaging. These techniques were achieved by the use of a spectral 
laser-scanning confocal microscope Nikon Eclipse TE2000-E (Nikon, Japan) 
equipped with Helium/Neon and Argon laser and images were visualised using 
Lazershop 2000 software. Scanning resolution was 1024 x 1024; 4x and 10x 
objectives were used for visualisation.
Time-lapse fluorescence imaging entails repeated imaging of fluorescently 
labelled samples at specific time instances.(300, 301) This procedure can 
involve different spatial dimensions: repeated line scans, repeated imaging of a 
single focal plane, and repeated imaging in multiple focal planes within a 200 
nm thick specimen. Multi-channel time-lapse fluorescence imaging includes all 
of the time-lapse fluorescent imaging with the additional use of different probes 
with different spectral properties. This attribute allows for multi-labelling of 
cellular structures simultaneously.(302) Three-dimensional time-lapse (4D) 
imaging involves the repetitive compilation of z-series stacks of images over 
time. This allows the researcher to analyse how far a probe has penetrated a 
cell or tissue specimen over time, (303) three dimensional multi-channel (5D) 
time-lapse fluorescence imaging is when this is done over time.
3.9.2 Confocal microscopy analysis of the viability of liver tissue in 
microfluidic device
The objective of these experiments was to verify the viability of the tissue 
in the microfluidic device using fluorescent probes and confocal microscopy and 
whether viability is sustained over time. As with the cavity slides and epi- 
fluorescent microscopy experiments, the tissue was incubated with calcein AM
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and PI separately and consecutively to verify areas of live/dead liver cells in the 
liver tissue. Calcein fluorescence can be seen across the tissue as well as the 
periphery after one hour of probing as seen with the previous experiment with 
the tissue on the cavity slides indicating cells are actively metabolizing the 
probe as shown in Figure 33A.
Figure 33. Confocal images of rat liver tissue in microfluidic chamber after incubation with (A) 
calcein AM for over 1 hour, there is a high incidence of fluorescence in the tissue which 
demonstrates viability. The tissue has filled the entire chamber however, as evident from this 
image there are small bubbles trapped with the tissue (illustrated by arrows). (B) PI for over 20 
minutes, there is a high incidence of fluorescence around the periphery of the tissue indicating 
cell death hi these areas. The images were taken from below the tissue chamber through the 1 
mm base plate and taken approximately 200 nm into the tissue. Magnification 4 x and the 
resolution was 1048 X 1048. Representative of over 200 images.
The primary area of dead cells, where PI had entered and intercalated 
with the DMA, was determined to be around the periphery of the tissue where 
the area had been cut to allow the placement of the tissue in the microfluidic 
device as shown in Figure 33B. These experiments were repeated 120 times 
over six months and these images are representative of those results. No PI 
was seen in any of the centres of the samples in any of the experiments even
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after lengthening the exposure time to up to an hour, this was further verified 
when the samples were sectioned and stained in Section 3.10.1
The system was removed from the confocal platform and the tissue 
returned to physiological temperatures and left for twenty-two hours with WME 
flowing through the system overnight and collected. No evidence of 
contamination or pH change was seen in the collected media.
The tissue was then reimaged after the re-application of fresh probe to 
distinguish areas of viability and cell death. As seen by the image shown in 
Figure 34A, the tissue had remained viable during the incubation period of 
twenty-two hours. However, as seen in Figure 34B, although some PI 
fluorescence can be determined, cell death once again is limited to the edges of 
the tissue. This experiment was repeated three times.
These images show that liver tissue can be probed with different probes to 
visualize areas of cell viability and death. It has also been proved that by using 
fluorescent probes it is possible to verify viability of the tissue after twenty-two 
hours. However, it should be noted that the probes used in these experiments 
are transported by diffusion and that areas of little or no fluorescence could be 
due to limited penetration of probes to those areas of the tissue, which is 3 mm 
thick as stated earlier.
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Figure 34. Images of rat liver tissue after twenty-two hours in the microfluidic system. (A)The 
tissue was reprobed with calcein AM for 1 hour before the image was taken. Due to the difiuse 
green fluorescence, the tissue is viable and healthy. (B) The tissue shows areas of cell death still 
around the periphery of the tissue but areas are showing no fluorescent signal indicating no cell 
death. Magnification 10 x and the resolution was 1048 X 1048. Representative of 50 images.
3.10 Morphological examination of tissue after microfluidic maintenance
It is important that the morphology and architecture of the liver tissue and 
the ECM is not destroyed during culture within the microfluidic system. The 
tissue was analyzed using epi-fluorescence and histology. In these sets of 
experiments, the calcein AM was replaced with LavaCell  because of reasons 
explained in Section 4.3.2. Firstly, the tissue was probed with LavaCell  
(Active Motif, UK) to determine areas of viability. LavaCell  is a naturally 
occurring compound from the fungus Epicoccum nigrum that has be used to 
fluorescently stain cells.(304) LavaCell  is a neutral azaphilone (fungal 
metabolite) molecule that diffuses into live and dead cells staining cell 
membranes and lipophilic organelles within 2-15 minutes. Unbound probe is 
non-fluorescent. Limiting the concentration of the probe with the cells 
determines whether the cells are alive or dead as viable cells are able to store 
increased amounts of probe more effectively and quicker than non-viable cells.
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The tissue was maintained within the microfluidic system as described 
earlier in Section 3.9. After 70 hours, the WME was removed and replaced with 
WME containing 10 ^M of LavaCell for 30 minutes. The length of time was 
increased from the recommended amount as the probe is usually used for cell- 
based methods and time was extended to allow diffusion into the liver tissue. 
The microfluidic device was then disconnected from the pumps and set on the 
stage of a Zeiss Axiovert S100 inverted epi-florescent microscope fitted with 
10x objective which was used to capture the image of the liver tissue in the 
tissue chamber. Images were recorded using a Hamamatsu orca ER CCD 
camera (Hamamatsu Photonics Ltd, UK) and subsequently analysed using HC 
imaging software (Hamamatsu Photonics Ltd, UK). The following excitation and 
emission wavelengths were used for LavaCell (Aex = 488, Aem = 610 nm).
Using the methodology previously described in Section 3.4.2, the tissue 
was also sectioned and stained using H&E to determine whether any 
histological changes could be detected.
3.10.1 Morphology analysis of liver tissue
The aim of these experiments was to determine whether liver tissue 
retained viability after seventy hours of maintenance in the microfluidic device 
with imaging using Lavacell  and whether the liver tissue retained the normal 
in vivo architecture using H&E staining. Histomorphology was analyzed before 
and after liver tissue culture in the microfluidic device as shown in Figure 35. 
Tissue sections taken through the full depth of samples were analyzed for 
structural changes. The cell nuclei of the hepatocytes have maintained their
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rounded appearance, with little or no shrinkage after 70 hours of culture in a 
microfluidic device.
Figure 35. H&E stained cryostat section of tissue before culture in the microfluidic device (a) 
and after 71 hours (b) using x 40 magnification. Brightfield (c) and epi-fluorescence images (d) 
of rat liver tissue, after incubation with LavaCell™, following maintenance in a microfluidic 
device for 53 hours; showing the edge of the tissue distinguished from background. A 40 x 
objective was used for the histology and 10 x was used for the brightfield and epi-fluorescence 
microscopy. Representative of nine experiments
The cell membranes can be seen in several places, with the hepatocytes 
preserving their original hexagonal shape. In addition there is no discernible 
loss of the ECM between the cells. These results show that the cells within the 
tissue have retained their in vivo morphology with the surrounding ECM 
remaining intact and indicate that the microenvironment provided in the 
microfluidic system is sufficient to maintain tissue structural and cellular 
properties. The experiment was repeated nine times with ~30 sections taken 
from each sample and 10 slides were analysed with H&E for every experiment.
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3.77 Determination of bacterial contamination within the eluent samples
Bacterial contamination of the samples can give results, which reflect the 
bacterial growth rather than the tissue viability. In order to establish whether the 
samples were contaminated, eluent was collected for a further hour at the end 
of every completed experiment before the addition of lysis buffer, when used, 
and plated on individual antibiotic-free agar plates. Bacterial growth medium 
(TYG agar) was made in 1.5 L flasks, which had been washed and autoclaved 
before use. 5 g of yeast extract (OXOID, UK), 10 g tryptone (OXOID, UK), 8 g 
sodium chloride (Melford Laboratories, UK), 15 g bacterialogical agar were 
added to the flask and made up to one litre using distilled water. The flask was 
then stoppered with cotton wool covered with foil and secured in place with 
autoclave tape. The mixture was stirred using a magnetic stirrer for ten minutes, 
then autoclaved at 121 °C for twenty minutes. The growth medium was allowed 
to cool to approximately 50°C before being poured into bacterial plates, in the 
confines of a Level 2 laminar flow cabinet, with enough added (>10 ml) to cover 
the bottom of the plate with 5 mm thick agar. After the agar was set, the lidded 
plates were turned upside down to stop condensation and sealed with tape and 
placed in a 4 °C refrigerator for the maximum of 24 hours before use due to 
possible contamination from microbes in the refrigerator. The collected media 
was divided into two and spread on two individual agar plates using a glass 
spreader within a laminar flow cabinet. Aseptic techniques were used 
throughout the experiment. These plates were then placed in an incubator and 
checked at 12 and 24 hours after inoculation for any bacterial growth.
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3.11.1 Bacterial contamination analysis of collected eluent
Media that had previously flowed through the microfluidic device was 
checked at the end of each experiment. Eluent was collected from over 100 
microfluidic devices in the study and showed no bacterial contamination at any 
point. It must be noted that only aerobic bacteria, not anaerobes, were actively 
screened for, this was because the environment was aerobic by design and the 
possibility of anaerobe contamination was considered low.
3.12 Disaggregation of tissue to individual cells in microfluidic 
environment
To analyze individual primary cells isolated from tissue held within the 
microfluidic device, the tissue was enzymatically disaggregated. The perfusion 
method, which was modified from Bayliss and Skett,(305) used Eagle's 
Balanced Salt Solution (EBSS) (Gibco, UK) in place of WME. The 
disaggregation of cells from the liver explant involved many refinements in 
enzyme such as collagenase IV varied between 10 - 48 U ml" 1 and DNase I 
varied between 10 - 40 ug ml"1 . Chemical concentration, such as of ethylene 
glycol bis- (p-aminoethyl ether) N, N, N', A/'-tetra acetic acid (EGTA) was varied 
between 4-8.3 mM solution, time of exposure of reagents, such as thirty 
minutes to two hours for the second collagenase stage, temperatures of the 
device and solutions (4 - 36 °C) at different stages, and flow rates before the 
preceding method was found to achieve results.
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The liver sample was first perfused at 2 ul min"1 for 20 minutes with an 8.3 
mM solution of EGTA, to chelate extracellular calcium. After EGTA treatment 
the tissue was perfused with EBSS at 2 ul min"1 for a further 10 minutes to 
remove any chelator, as EGTA is known to inhibit collagenase action. 
Collagenase IV (48 U ml'1 ) was dissolved in EBSS (pH 7.4) (2 ml) with the 
addition of 0.4 mg trypsin inhibitor and 2 mM calcium chloride (CaCI2). The 
tissue was then perfused with this collagenase solution for 2 hours at 2 ul min"1 . 
The perfusate was allowed to drain to waste.
Following collagenase treatment the microfluidic device was removed from 
the incubator while still connected to the perfusate system and set on an ice 
pack. Ice-cold dispersal buffer containing 10 mM 4-(2-hydroxyethyl)-1 - 
piperazineethanesulfonic acid (HEPES), 142 mM sodium chloride (NaCI), 7 
mM potassium chloride (KCI), 5% (w/v) bovine serum albumin (BSA) in water 
adjusted to pH 7.4, supplemented with 40 ug ml" 1 DNase I and 5 mM 
magnesium chloride (MgCI2) was then perfused through the tissue sample at 
500 ul min"1 for 2 minutes. The enzymatically-disaggregated cells in the eluent 
were collected in 1.5 ml micro centrifuge tubes and centrifuged at 100g for 5 
minutes. The supernatant containing cell debris was removed by aspiration. The 
cells were resuspended in the dispersal buffer containing 40 ug ml"1 DNase I 
and 5 mM MgCI2 , and equal volumes of 2% (w/v) TB and cell solution were 
mixed and the cell count enumerated using a haemocytometer. Counts were 
measured in duplicate and the percentage viability determined.
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The disaggregation method was then repeated three times using the 
above method however, the tissue probed first with Calcein AM and PI and 
imaged using confocal microscopy as described in Section 3.9. After 
disaggregation, the liver tissue was again probed with the fluorescent probes 
and reimaged to distinguish areas of disaggregation. At the end of the 
experiment, an aliquot of the cells collected in the eluent was pipetted onto a 
microscope slide and imaged using epi-fluorescence microscopy as described 
in Section 3.6.
3.12.1 Analysis of liver tissue and single cells after disaggregation
Individual cell analysis is advantageous when detecting minute 
differences between individual cells and could improve medical tests and 
treatments. Parameters based upon averages of large cell populations are 
frequently deceptive.(306) Cellular heterogeneity in vivo is widespread as 
described in Chapter 1. Therefore, analyzing cells individually with high 
spatiotemporal resolutions will lead to a more precise portrayal of cell-to-cell 
variations instead of the stochastic average shrouded by bulk measurements.
Following in situ collagenase disaggregation of primary cells from the tissue, 
viability was determined using TB exclusion. The results indicated that 78% 
±2.4 (n=3) of cells were alive which is comparable to values expected from 
traditional disaggregation methods, these are between 60-90%.(305) A two 
hour collagenase disaggregation treatment, which offered a relatively gentle 
method of cell removal, resulted in a total of approximately 30,000 cells 
being released from a 3 mm 3 biopsy; based on haemocytometer 
measurements.
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Fluorescent images of tissue, before and after collagenase 
disaggregation, were obtained using calcein and PI probes as shown in 
Figure 36. The images confirm that both live and dead cells are removed 
using this procedure and indicate that the 'new' tissue surface generated has 
a greater proportion of live to apoptotic/necrotic cells. The disaggregated 
cells were also imaged after collection to verify the viability of the cells and to 
detect whether the cells were single cells or clusters of cells. Ten images 
were taken of each sample in all three experiments.
Figure 36. Confocal images of liver tissue after staining with calcein and propidium iodide (PI). 
Tissue pre- (a) (c) and post- disaggregation (b) (d) was probed with calcein and PI. Changes in 
the tissue edge shape are evident after enzymatic treatment. Data shown are representative of 
four independent experiments. Scanning resolution was 1024 x 1024 using a 4 x objective.
As shown in Figure 37, the cells collected were both live and dead however, 
the viabile cells fluoresced brightly indicating that the cells had metabolized 
relatively large amount of the probe. The cells themselves were individual
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with no clusters occuring in any of the samples indicating they would be 
suitable in further downstream analysis of single cell characteristics and 
function.
Figure 37. Fluorescent images of disaggregated cells collected from microfluidic system. (A) 
calcein probed cells and (B) PI probed cells. Magnification 10 x, representative of three 
experiments.
5.73 Interrogation of tissue within a microfluidic system using lysis 
buffer
To determine whether the previous results were valid and not just an 
artefact of the experiment, the tissue was probed using lysis buffer. Lysis buffer 
is usually used to envoke cell death by rupturing the cell membranes releasing 
LDH, DMA and other cell contents into the surrounding media. This is usually 
utilized as a positive control, as it should give the maximum death within a 
sample.
3.13.1 Viability analysis
To quantify cell viability and cell death within the tissue sample, a 
colorimetric cytotoxicity assay (Cytotoxicity Detection Kit Plus, LDH, Roche, UK)
104
4.3.3 Analysis of the use of multiple laminar flows to pattern tissue
This experiment was repeated on twenty separate occasions but only once was 
it successful in achieving a defined interface over the middle of the sample. 
Adjusting the individual flow rates at each inlet to control the position of the 
interface, as described in Section 3.8.1, was attempted to repeat this 
achievement however, was ultimately unsuccessful. In the single experiment, 
where there was an interface between the MeOH and PBS, a line of 
fluorescence defining the interface can be seen in the tissue, as shown in 
Figure 42.
Flow rate 10 pi mirr 1
Figure 42. Composite of 4 confocal images of the rat tissue in the microfluidic device over the 
schematic of the tissue chamber showing cell death in the upper half of the tissue chamber and 
the interface between the two different solution streams using Propidium iodide (PI). The tissue 
was interrogated with 50% (v/v) methanol in the upper stream and PBS hi the lower stream 
(n=20). The flow rate for both flows was lOul min'1 . PI was applied after the 2 interrogation 
streams and these confocal images taken at the same tissue depth (120 urn). The interface 
between the two streams can clearly be seen hi the lower two quadrants. Small areas of naturally 
apoptotic cells are shown in the lower left quadrant.
Whilst cell death was seemingly universal on the half of tissue, which was 
treated with methanol by the incidence of PI fluorescence, the other half treated 
with only with buffer showed little cell death. This was demonstrated by an
increase of PI in the cells in this area as shown in the upper two quadrants of
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Figure 38. There was also an increase in cell death in the region treated with 
PBS near the entry to the chamber as shown by a slight drop in the interface in 
the lower right quadrant. This was due to the geometry of the chamber and the 
difference in pressure within this region compared with the microchannel. There 
was also an area (upper left quadrant), where there is a deformation of the 
interrogation profile. This was due to a bubble residing in this area diverting the 
MeOH flow away from the cells. When analysing the images recording the 
instance of calcein fluorescence, the interface is not so clearly defined, as 
shown in Figure 43.
Flow rate 10 pi mirr 1
Figure 43. Composite of 4 confocal images of the rat tissue in the microfluidic device showing 
cell viability in the upper half of the tissue chamber and the interface between the two different 
solution streams using calcein AM. The tissue was interrogated with 50% (v/v) methanol in the 
upper stream and PBS in the lower stream (n=20). The flow rate for both flows was 10u,l min"1 . 
Calcein AM was applied and these confocal images taken at the same tissue depth (120 urn). 
The fluorescence in the lower quadrants depicts areas of metabolically active cells, which have 
not been subjected to methanol.
Calcein fluorescence is however, retained in the lower half of the chamber 
where it was treated with PBS and little or no fluorescence is noted in the upper 
half except for an area in the upper right hand quadrant. One theory for this 
area of fluorescence could be due to the calcein probe diffusing further into the
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tissue than the MeOH. The other theory for this occurrence could be that at the 
depth of the fluorescence, the MeOH had not yet been metabolized into its toxic 
metabolites and therefore had not yet affected the cells. The calcein 
fluorescence was also not as high as the fluorescence found in previous 
experiments. This could be due to the effect of chelatable iron on intracellular 
calcein. Fluorescent calcein binds with both Fe2+ and Fe3+ to form a metal-ligand 
complex which is non-fluorescent and has been used to estimate cellular iron 
levels.(323) Iron is ubiquitous metal in cells and is essential for the viability of 
the cell. The pool of cellular chelatable iron is usually found within the cytosol, 
the region of the cell where calcein AM is cleaved to form calcein. Petrat et al 
showed that rat hepatocytes and liver endothelial cells showed a substantial 
concentration (5.8 ± 2.6 uM in hepatocytes, 7.3 ± 2.6 uM in endothelial cells) of 
chelatable iron in the cytosol of these cells, compared to 0.3 -1.6 uM in other 
somatic cells.(324) Therefore, there was a high probability that some of the 
calcein probe bonded with the free iron within the cell, quenching the signal. In 
this thesis, tissue biopsies were used instead of precision cut tissue slices. The 
morphology of the tissue biopsy has undulations in the surface, which made it 
difficult to maintain the interface on the tissue. Another problem could be 
backpressure and has been discussed in Section 3.8.1.
Using multiple laminar flows to interrogate tissue slices has previously 
been successful and published by another group as discussed in Section 
4.3.(171) Distilled solution containing concentrated unknown fluorescent dye 
was used in conjunction with a standard solution to verify flow over the 650 urn 
brain slice in a microfluidic chamber. The two solutions maintained equal flows
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ranging from 0.5 to 1 ml min"1, thereby exposing the two halves of the brain 
slice to different environments.
Ultimately, these sets of experiments were unsuccessful, as the result from one 
experiment could not be repeated even with adjustments to the flow profiles.
4.4 Interrogation of liver samples with different ethanol concentrations
The association of alcohol abuse with liver tissue damage has been the 
focus of considerable research, which has shown ethanol to be the direct cause 
of various abnormalities in liver architecture and functionality such as fatty liver, 
apoptosis, necrosis, cancer, fibrosis and cirrhosis.(325-327) However, the 
understanding of the mechanisms of alcoholic liver disease (ALD) progression 
has been difficult due to the lack of appropriate in vitro models that simulate the 
microenvironment of the liver organ. Whilst extensive knowledge has been 
gained through the application of primary hepatocytes in culture and hepatoma 
cells lines, both in tandem and isolation, these studies cannot provide a 
complete understanding of the complex intracellular interactions and regulatory 
factors that are exhibited in native tissue.
Ethanol is metabolized through various metabolic pathways in the liver as 
shown in Figure 44. The foremost oxidative pathway for the metabolism of 
ethanol includes alcohol dehydrogenase (ADH) that is present in the cytosol of 
hepatocytes and converts ethanol to acetaldehyde. Acetaldehyde is a highly 
reactive and toxic by-product, which damages tissue more significantly than 
ethanol alone and is also thought to contribute to the addictive development of
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alcohol abuse.(328) At increased concentrations of ethanol (>100 mM) several 
enzymatic systems with high activity levels such as class II ADH, (33-ADH and 
cytochrome P450 2E1 (CYP2E1) are in attendance within the cell. The 
conversion of ethanol to acetaldehyde involves an intermediate carrier of 
electrons, NAD+ that is reduced by two electrons to form NADH.
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Figure 44. Oxidative pathways of ethanol metabolism. Image from S. Zakhari review(328) 
shows the enzymes alcohol dehydrogenase (ADH), cytochrome P450 2E1 (CYP2E1) and 
catalase all contribute to oxidative metabolism of ethanol.
As a consequence of these reactions the cytoplasm of the cell shrinks, 
and is exceptionally susceptible to injury from free radicals and further 
acetaldehyde concentrations. CYP2E1 is present in microsomes and has an 
essential role in metabolizing ethanol to acetaldehyde at increased ethanol 
concentrations. Acetaldehyde is metabolized mainly by aldehyde 
dehydrogenase 2 (ALDH2) in the mitochondria to form acetate and NADH. 
Catalase is located within peroxisomes and is a minor pathway in ethanol 
metabolism and requires H202 to oxidize ethanol. Chronic ethanol intake shows 
an increase in catalase activity and overall H202 production in rat models before
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the pathway becomes overwhelmed through high concentrations of ethanol 
over time. (329)
After setting up as described in Section 3.13, the media was replaced 
with media supplemented with 20 mM, 50 mM, 100 mM, 150 mM and 200 mM 
ethanol in five parallel devices; a sixth device in which only unsupplemented 
media was run acted as a negative control. The eluent from the outlets of each 
of the microfluidic device was collected every hour in 0.5 ml microcentrifuge 
tubes for cell viability and functionality analysis.
4.4.1 Functionality analysis
To assess the functionality of the tissue within the microfluidic device 
production of albumin and urea was investigated. Serum albumin is an 
important carrier protein found in blood plasma, which is synthesized by the 
hepatocytes in the liver, where it helps maintain osmotic pressure and is a 
carrier of low water soluble molecules such as bile salts and free fatty acids. 
Increase in ethanol concentration is known to affect general protein 
synthesis.(330) Albumin levels in the eluent were determined by ELISA (Bethyl 
Laboratories Inc., USA) according to the manufacturer's guidelines. A 96-well 
flat bottom ELISA plate (SLS, UK) was coated overnight with 100 \d primary 
sheep anti-rat albumin antibody diluted in 0.05 M carbonate-bicarbonate buffer, 
pH 9.6 at 4°C. A 200 pil wash solution containing 50 mM Tris, 0.14 M NaCI, and 
0.05% (v/v) Tween 20, pH 8.0 was used after each step and repeated three 
times. Plates were subsequently blocked with 200 ^l 50 mM Tris, 0.14 M NaCI, 
containing 1% (w/v) BSA pH 8.0 for 30 minutes at ambient temperature. The rat 
serum reference standards (10,000, 500, 250, 125, 62.5, 31.25,15.625 and 7.8
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ng ml'1 were diluted in 50 mM Tris, 0.14 M NaCI and 0.05% (v/v) Tween 20, pH 
8.0 and 100 p,l of each dilution was incubated on the plate with eluted samples 
for 1 hour. Next, the plates were incubated with 100 \i\ Horse Radish 
Peroxidase-conjugated detection antibody 1:5,000 in 50 mM Tris, 0.14 M NaCI 
and 0.05% (v/v) Tween 20, pH 8.0 for 1 hour. Finally, a colorimetric reaction 
was carried out by the addition of 50 ul undiluted tetramethyl benzidine (TMB) 
solution. The reaction was stopped with 25 ul of 2 M sulphuric acid and the 
absorbances were measured at A = 450 nm.
Urea production has been commonly used as a specific marker of liver 
function.(331) Production of urea is a part of a cycle biochemical reactions that, 
in mammals, occurs only in hepatocytes. Ammonia is an extremely toxic waste 
product which has to be converted into a less toxic substance, urea. The 
conversion of ammonia to urea takes five steps; two in the mitochondria and 
three in the cytoplasm of hepatocytes as shown in Figure 45.
Urea concentrations in the media were determined using a colorimetric 
assay (QuantiChrom  Urea Assay Kit, BioAssay Systems, USA) carried out 
using the manufacturer's protocol. Aliquot of 50 ul from the samples, blank 
(WME media) and the urea control (100 mg dl_~ 1 ) was transferred in duplicate 
wells in a clear 96-well flat bottom plate. 200 ul of the working reagent was 
added to each well and tapped lightly to mix. The plates were incubated for 10 
minutes and read at an optical density at 520 nm, with 690 nm reference.
122
Cytoplasm
NCO3 +NH4
CPSI
Carbamyl phosphate 
OTC \
I SI« » N-acetylglutamate\ Aspartate
Citrulline
Mitochondria Qmithlne
ORNTV
Omithine
CitrirT
Argininosuccinate
x
Arginine
ASL
Fumarate
Urea
Figure 45. The urea cycle is composed of five catalytic enzymes, Carbamyl phosphate synthase 
I (CPSI), Ornithine transcarbamylase (OTC), Argininosuccinic acid synthetase (ASS), 
Argininosuccinic acid lyase (ASL) and Arginase (ARG), and at least two transport proteins 
(indicated with *) Citrin and ORNT1.
4.4.2 Fatty liver
The first pathologic alteration that occurs to the liver as a consequence of 
ethanol consumption is the development of fat in the liver, a condition called 
steatosis. It has been proposed that ethanol sensitizes the liver through the 
accumulation of fat to additional oxidative injury that leads to alcoholic liver 
disease.(332) The accretion of fat in the liver has been recognized as a factor 
that can be involved in more serious liver injury.(333) To discover whether there 
was a build up of fat in cells of the rat liver tissue after interrogation with 
increasing ethanol concentrations, an Oil Red O lipid stain was used. Oil Red 0 
is a lysochrome (fat-soluble dye) diazo dye used for staining of neutral 
triglycerides and lipids.
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Frozen sections (12 urn thick) were cut from the liver samples after 
maintenance in the microfluidic system using a Microm HM505E cryostat. 
Sections were selected from the centre of the sample and these were allowed 
to dry for 60 minutes and subsequently fixed with 10% (v/v) formalin for 10 
minutes in a fume cupboard, then allowed to dry again for another 60 minutes. 
The slides were placed in absolute propylene glycol for 2 minutes before being 
immersed in Oil Red O for 10 minutes before rinsing with distilled water. The 
tissue was then placed in 85% (v/v) propylene glycol for five minutes to remove 
any excess stain, rinsed under running water and finally mounted in Depex 
using a coverslip. The tissue was then imaged using light microscopy using 40 x 
magnification.
4.4.3 The effects of increased ethanol concentration on liver sample viability 
and functionality
The concentrations of ethanol were selected as 20 mM, roughly equates 
to the legal drink drive limit in a blood sample in the United Kingdom (18.5 mM). 
Levels over 100 mM ethanol equate to the blood concentration of ethanol 
associated with a heavy consumer of alcohol.(334) Hourly aliquots were 
analyzed for WST-1 and LDH concentrations and all the individual absorbance 
results were subsequently averaged to give an overall result for the eight-hour 
monitoring period. The untreated tissue sample results (negative control) were 
used to establish the 'normal' baseline for WST-1 and LDH measurements as 
described in Section 3.13.1.
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The WST-1 results gained from the different concentrations of ethanol 
were represented as percentage of the negative control and compared against 
each other as shown in Table 7.
All samples show an initial decrease in WST-1 metabolism occurred in 
the first day however by the fourth day, the liver tissue treated with 20 mM 
ethanol concentration shows approximately 80% parity with untreated liver 
samples.
Table 7. Percentage of viable rat liver tissue using WST-1 metabolism as an indicator after 
interrogation with 20, 50, 100, 150 and 200 mM compared with negative control of untreated 
liver samples (from aliquots collected over 8 h period). Data are expressed as the mean % of 
three separate experiments.
Day 20 mM 50 mM 100 mM 150 mM 200 mM
1
2
3
4
40.7 (± 19)
52.7 (± 23.3)
54.4 (± 7.6)
79.3 (±17)
33.5 (±14.1)
59.4 (± 23.6)
42.2 (±12.8)
51 .3 (± 8.6)
23.0 (±13.6)
58.1 (±23.9)
31 .8 (±11. 3)
46.7 (±12.3)
17.3 (±5. 8)
53.7 (±12.6)
36.7 (± 16)
46.2 (±9.5)
14.0 (±5.21)
32.5 (± 9.5)
21. 9 (±8.7)
33.9 (±12.8)
By comparison the 50, 100, 150 mM ethanol concentrations show a ~50% 
depression in enzyme activity compared with the untreated tissue in the 
same time period, with the 200 mM ethanol concentration showing only 34% 
activity after 4 days.
Ethanol is known to be a significant source of energy through its NAD 
metabolism as shown in Figure 44. NADH rapidly reduces WST-1 to formazan 
however; this reduction is strongly inhibited by superoxide dismutase (SOD), 
which is upregulated in ethanol metabolism.(335) In order to combat oxidative
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stress, SOD is among the first line of defence in the detoxification of superoxide 
radicals to H2O2 . As SOD is upregulated, inhibition of WST-1 occurs resulting in 
lower formazan production. This may impact the results of the test samples 
giving a lower indication of viability of the tissue than may actually be present.
Measurement of LDH activity in the eluent showed that cell death in the 
control liver sample remained at low levels for the 96 hours as show in Figure 
46.
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Figure 46. LDH activities in rat liver tissue samples after maintenance within a microfluidic 
device during interrogation with increasing ethanol concentrations. Liver samples were 
maintained at t0 , 24, 48, 72, 96 h in the absence of ethanol, control (dashed line, black), and in 
the presence of 20 mM (solid line, purple), 50 mM (dashed line, blue), 100 mM (solid line, 
green), 150 mM (dashed line, orange) and 200 mM (solid line, red) ethanol. Data are expressed 
as the mean % of three separate experiments, repeated in duplicates. ±S.E.M. of three separate 
experiments.
Exposure to ethanol levels above 100 mM resulted in an increase in LDH
activity indicative of increased levels of cell death at these concentrations
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compared to the control levels over the same time periods assayed. LDH 
activity at 20 and 50 mM show no marked difference compared with the control. 
This maybe attributed to the findings of an earlier study that indicated exposure 
to low ethanol concentrations reduces cell necrosis through the reduction of 
intracellular oxidative stress.(336) Both the LDH and WST-1 data signifies that 
ethanol concentrations in excess of 50 mM, after a period of two days 
resulted in a marked decrease in cell viability.
The ability of the liver tissue sample to continue to produce both serum 
albumin and urea under interrogation from increasing ethanol concentrations 
are shown in Figures 47 and 48.
Figure 47. Albumin secretion by of rat liver tissue samples after maintenance within a 
microfluidic device and incubated with increasing ethanol concentrations. Aliquots were 
collected for eight hours every day and the levels of albumin determined. Data are expressed as 
the mean albumin levels ng ml" 1 in the liver sample eluent ±S.E.M. of three separate 
experiments.
127
Increases in ethanol concentration are known to affect protein 
synthesis.(330) As shown in Figure 47, albumin was secreted by all the liver 
samples despite the interrogation with ethanol. As the ethanol concentration 
increases the amount of albumin decreases over the range of samples. Liver 
samples however, interrogated with 100 mM ethanol concentrations and below 
show a steady increase over the four-day exposure period although this level 
remains below the control (OmM). Ethanol concentrations of 150 mM and 200 
mM show depressed secretion, evident at Day 1 with further decreases over 
time. The maximum concentration (200 mM) shows a decline of albumin 
secretion of two-thirds compared with the control.
As shown in Figure 48, urea was secreted by all liver samples regardless 
of their treatment. The control shows a 30% decrease of urea production from 
the start to the finish of the experiment. The sample treated with 20 mM ethanol 
exhibited an initial 80% increase, which dropped to a 37% increase over the 
four-day exposure period but still remained higher than the control. Ethanol 
treatment with 50 mM and 100 mM demonstrates an increase of urea 
production over the first three days however by day four, urea levels have 
dropped to between 75 - 50% compared with the control. Urea production in 
liver samples interrogated with 150 mM and 200 mM initially remain stable and 
comparable with the control. However by Day three, urea levels are depressed 
by 25-30% and at the end of day four; the levels were only 45% and 33% 
respectively. These results suggest that the metabolism of ethanol is involved in 
the decrease of albumin secretion and the increase of urea production at 
relatively low ethanol concentrations however; constant exposure over the 
period with concentrations above 50 mM causes urea levels to drop.
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Figure 48. Urea production by of rat liver tissue samples after maintenance within a 
microfluidic device and incubated with increasing ethanol concentrations. Aliquots were 
collected for eight hours every day and the levels of urea determined. Data are expressed as the 
mean albumin levels ng ml" 1 in the liver sample eluent ±S.E.M. of three separate experiments.
These results correlate with the viability of the cells as cell death is 
increasing over time. This is supported through finding from a previous study 
using isolated perfused liver.(337) This experiment was completed because the 
liver produces both albumin and urea and shows the effect of alcohol on the 
synthesis of proteins and removal of waste products.
H&E staining of the rat liver tissue after maintenance and interrogation 
with different concentrations of ethanol was used to analyze the integrity of the 
tissue and cell morphology. Figure 49 shows the control liver sample after four 
days maintenance in the microfluidic device. These samples were taken from 
the centre of the sample between 120 urn and 180 urn from the periphery. As
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shown the cell nuclei of the hepatocytes have maintained their rounded 
appearance, with little or no shrinkage after 96 hours of culture in the 
microfluidic device. The cell membranes can be seen in several places, with the 
hepatocytes preserving their original hexagonal shape. In addition there is no 
discernible loss of the extracellular matrix between the cells. However, there are 
small gaps seen appearing in the structure of the tissue and the cells are 
beginning to look misshaped and there is evidence of some loss of cytoplasm 
as concentration increases (Figure 49b) as reported in a previous study.(338) 
As the concentration of ethanol increases (Figures 49c, d, e, f) the loss of ECM 
can be seen to increase with larger gaps appearing and the cells losing their 
shape, structure and cohesion this is exacerbated by the lost of viable 
hepatocytes. Ethanol has been shown to arrest the cell cycle and impair the 
replication of normal hepatocytes, even though the liver usually has a 
tremendous capacity to replace cells that are lost or damaged from other 
cytotoxic injuries.(326)
Fatty liver is a reversible condition associated with alcohol consumption 
where the liver stores triglycerides.(339) Oil Red 0 staining of the rat liver tissue 
biopsies treated with increasing ethanol concentrations are shown in Figure 50. 
No staining of fatty infiltration was observed in samples interrogated with 20, 50 
and 100 mM over the exposure period (not shown). In contrast with the control 
(Figure 46A), the liver sample exposed to 150 mM ethanol demonstrates a 
small increase in staining by Oil Red O (Figure 46B) and the liver sample 
exposed to 200 mM ethanol showed a marked increase in staining (Figure 
46C).
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Figure 49. Haematoxylin and Eosin (H&E) staining of rat liver tissue samples after maintenance 
within a microfluidic device and incubated with increasing concentrations after maintenance hi 
a microfluidic device. Liver samples were maintained hi (a) 0 mM ethanol, (b) 20 mM ethanol, 
(c) 50 mM ethanol, (d) 100 mM ethanol, (e) 150 mM ethanol and (f) 200 mM ethanol. Samples 
were chosen between 200 um and 300 um from edge of tissue. Light microscopy images were 
taken at random on under x40 magnification and are representative of three separate 
experiments.
A recent study using PCLS and traditional explant culture methods, 
demonstrated that there was an increase in Oil Red O staining after the slices 
were incubated for over 48 hours with 25 mM ethanol compared to the 
control.(317) However, they also noted that there was an increase of Oil Red O 
staining in the control PCLS after culture compared with the PCLS examined 
before culture. High (>100 mM) concentrations of ethanol decrease the viability 
and functionality of the cells in the liver biopsy. Histological analysis of the liver 
sections showed the loss of ECM in the tissue and the increase of fatty deposits 
in the cells. Further analysis of the effects of ethanol on liver tissue in the 
microfluidic system could in the future give more information on the 
mechanisms involved in ethanol metabolism and how these can be used to 
treat ALD.
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Figure 50. Oil Red O staining of rat liver tissue samples after maintenance within a microfluidic 
device and incubated with increasing ethanol concentrations. Liver samples were maintained in 
(A) 0 mM ethanol, (B) 150 mM ethanol and (C) 200 mM ethanol. Samples were chosen 
between 200 um and 300 jim from edge of tissue. Light microscopy images were taken at 
random under x40 magnification and are representative of three separate experiments.
4.5 Anti-oxidant protection of vitamin C and E during interrogation with 
ethanol
As described in the last section, ethanol is an oxidant, which causes 
significant damage to cells. Within the hepatocyte, in addition to the enzymes 
used in metabolizing ethanol as discussed previously, there are anti-oxidant 
systems involving enzymatic and non-enzymatic pathways. Enzymes
132
concerned in the removal of ROS are: SODs, glutathione peroxidase, 
glutathione reductase along with the co-factors glutathione (GSH) and reduced 
nicotinamide adenosine dinucleotide phosphate (NADPH). Other important non- 
enzymatic anti-oxidants are vitamin E (a-tocopherol) and vitamin C (ascorbate) 
and have been the primary choice for investigating anti-oxidants as ALD 
patients have the greatest access to them. Vitamin E is found within the lipid 
phase of cell membranes and is a powerful anti-oxidant, it has also been shown 
that patients with ALD frequently exhibit reduced vitamin E levels.(340) The 
majority of studies into the effect of nutritional anti-oxidants to treat alcohol 
related injury are performed in cell culture, while the majority of alcohol studies 
are performed in animal models.(341-343) This is due to the relatively new 
concept of anti-oxidant use to treat ALD and the complexity of the disease 
progression.
After setting up the microfluidic systems with tissue as described in 
Section 3.13, the WME was replaced with WME supplemented with 250 mg I" 1 
Vitamin E and 100 mM ethanol in two parallel devices, two more devices 
contained 250 mg I" 1 Vitamin E, 100 mM ethanol and WST-1 regent. Due to 
Vitamin E being lipid soluble, the media was shaken vigorously for 5 minutes to 
mix. The media was then filtered using 0.22 mm syringe filter to remove as 
many bubbles as possible before being put on the system. The eluent from the 
outlets of each of the microfluidic device was collected every hour in 0.5 ml 
microcentrifuge tubes for cell viability and functionality analysis. These 
experiments were repeated thrice. The Vitamin E was replaced in a subsequent 
set of experiments with 250 mg I" 1 Vitamin C for comparison of effectiveness of
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the different vitamins. The vitamin concentrations used were chosen as they 
had been previously been employed in earlier studies.(343-345)
4.5.1 Analysis of anti-oxidants effect on alcohol interrogation
As said previously, levels over 100 mM ethanol equate to the blood 
concentration of ethanol associated with a heavy consumer of alcohol and were 
shown in the previous experiments to be the lowest concentration of ethanol to 
cause cell damage and loss of function.(334) Using this ethanol concentration, 
the effect of the anti-oxidants, Vitamin E and Vitamin C on the viability and 
functionality of the liver samples were determined. Hourly aliquots were 
analyzed for LDH and WST-1 concentrations and the individual values were 
subsequently averaged to give an overall result for the eight-hour monitoring 
period. The untreated tissue sample results (negative control) were used to 
establish the 'normal' baseline for LDH and WST-1 measurements. All values 
were expressed per mg wet weight and all test conditions expressed as an 
increase or decrease of this baseline value.
Cell viability within the tissue sample, using WST-1 and LDH as markers, 
show that there is an improvement in viability of the liver sample by the addition 
of Vitamin E and Vitamin C to the media when treating the tissue with 100 mM 
ethanol. Both vitamins caused increases in WST-1 absorbance over ethanol 
alone, although the effects of Vitamin E were less marked by Day 3 and 4. As 
shown in Figure 51A, there was an increase of 60% in the viability of the 
Vitamin C treated biopsies than the ethanol sample however this increase is 
only 40% of the viability exhibited by the control sample on the first day. Vitamin
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E treatment showed an 89% increase on the first day but this was not sustained 
over the course of the experiment.
A :- lOOmM einanol and 25O mg vuamin c « lOOmM ethanol and 25O mg Vitamin E 100 mM ethanol Untreated tissue
Days
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Figure 51. (A) WST-1 metabolism by of rat liver tissue samples after maintenance within a 
microfluidic device and incubated with 100 mM ethanol, 250 mg I"1 Vitamin C, 250 mg I"1 
Vitamin E compared with untreated sample. (B) LDH release by of rat liver tissue samples after 
maintenance within a microfluidic device Aliquots were collected for eight hours every day. 
Data are expressed as the mean absorbance (a.u.) in the liver sample eluent ±S.E.M. of three 
separate experiments.
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By Day 3 and 4, the biopsies treated with Vitamin C exhibited a higher 
viability index than those treated with Vitamin E, although both vitamins had 
limited effect when compared with the untreated samples.
Using the LDH marker, there is a 250% increase in cell death within the 
ethanol/vitamin C combination sample compared with the untreated sample on 
the first day as shown in Figure 51B. The vitamin E treated liver biopsy showed 
again a decrease in LDH release however, as shown by the WST-1 assay this 
was not sustained. The viability however, increased 60% in the vitamin C 
sample compared to the ethanol sample, which also reflects the WST-1 
metabolism results. By the final day, cell death was 132% higher in the vitamin 
C sample than that in the untreated sample. The effect of the vitamin C 
compared to the ethanol sample increased the viability of the liver sample by 
53%, just over half. This also reflects the effects from the WST-1 assay. Vitamin 
E however decreased the viability of the liver sample compared with the ethanol 
sample.
Previous studies in cell models have shown the same effects that the 
addition of vitamin C can mitigate the effects of ethanol.(346, 347) These same 
studies have also shown than Vitamin E has even better effect than Vitamin C, 
which was not observed in this thesis. The main problem that can be identified 
from the methodology was the process of actually getting the Vitamin E into the 
media for testing, as the vitamin is lipid based and therefore getting into the 
liquid phase was extremely difficult. It cannot be sure how many cells in the
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tissue had access to the vitamin, and at what concentration during the testing 
but some effects were observed as shown above.
Albumin synthesis in the liver samples treated with vitamin C to combat 
ethanol damage as shown in Figure 52 showed slightly higher levels in the first 
2 days of the experiment than the samples with ethanol alone (30% higher on 
Day 1 and 9% higher compared to 100 mM ethanol samples). However, this is 
not maintained in the last 2 days and the level of albumin in the media 
decreased to only 46% on Day 3 and 56% on Day 4 compared with the sample 
treated solely with ethanol. Urea production decreased in the combination test 
in all the days of the experiment compared with both ethanol and untreated 
samples Figure 53. The effect of vitamin E on the production of albumin and 
urea was abandoned due to time constraints.
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Figure 52. Albumin secretion by of rat liver tissue samples after maintenance within a 
microfluidic device and incubated with 100 mM ethanol with and without 250 mg ml" 1 Vitamin 
C compared with untreated sample. Aliquots were collected for eight hours every day and the 
levels of albumin determined. Data are expressed as the mean albumin levels ng ml" 1 in the liver 
sample eluent ±S.E.M. of three separate experiments.
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The results presented are different from previous animal studies that have 
shown that vitamin C attenuate alcohol effects on albumin production, rather 
than decreasing it.(348, 349) However another study indicates that ethanol 
increases the production of uric acid in rat animal models and the addition of 
vitamin C reversed these effects, which correlates with these results presented 
in this section. (345) The exact mechanisms involved are yet unknown as there 
has been little research into the effect of alcohol intoxication on the production 
of urea in cell and animal models.
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Figure 53. Urea production by of rat liver tissue samples after maintenance within a 
microfluidic device and incubated with 100 mM ethanol with and without 250 mg ml1 Vitamin 
C compared with untreated sample. Aliquots were collected for eight hours every day and the 
levels of urea determined. Data are expressed as the mean urea levels mg ml" 1 in the liver 
sample eluent ±S.E.M. of three separate experiments.
In this chapter, it has been shown that rat liver samples were kept viable 
and functional over ninety-six hour time period. WST-1 was metabolised and 
reduced to formazan, which was subsequently detected off-chip along with the 
detection of LDH release from cells maintained and/or interrogated on-chip. 
Addition of different ethanol concentrations decreased the amount of formazan 
detected over the time period indicating the ethanol was affecting cell viability
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over the time period compared to a control. The addition of ethanol to the liver 
samples exhibited many of the same characteristics noted in other studies 
which have used isolated hepatocytes and in vivo rat models of chronic ethanol 
intoxication including the decrease in viability, fatty liver progression, reduction 
of albumin production, change in cell morphology and decrease in urea 
levels.(317, 350) In this thesis, liver samples millimetres in thickness were used 
to ensure that even the cell types that were sparsely represented within the 
tissue such as cholangiocytes were included and the native complex ECM was 
maintained which is not present in cell-based models. Using microfluidic 
technology we have also mimicked the in vivo flow dynamics, which is not 
present in conventional cell and tissue representations.(116) Therefore, it is 
proposed that rat liver samples retain their biological functions and appeared to 
a novel and valuable model for the study of not only pathological but also 
physiological mechanisms. Using the concept of tissue based microfluidic 
systems to personalize medicine regimes; this became the focus of the final 
stage of the study.
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5. Microfluidics for head and neck cancer diagnostics
'One changes one's ideas the way an animal sheds its coat, in patches: 
it's never a wholesale change from one day to the next.'
UmbertoEco 1932-
5.1 Introduction
Every year millions of patients worldwide will undergo tests to diagnose 
cancer. Male patients over the age of 50 years old, for example, will have their 
prostate-specific antigen (PSA) levels measured in an attempt to discover any 
possible prostate malignancy. Women will undergo mammograms to detect 
any potential breast tumours. However these tests are primitive, routinely 
producing false positives or false negatives and rely heavily on human 
observations rather then definitive results. For example, among 1,087 
individuals participating in a cancer screening trial who received a battery of 
tests for prostate, ovarian, colorectal and lung cancer, 43 percent had at least 
one false positive test result. (351)
Discovering a better diagnostic technique than those used at present has 
been high priority for clinicians for several decades. The rise of molecular 
biology and the human genome project in 1980s and 1990s gave hope that 
numerous questions about prognosis and diagnosis of several pathological and 
physiological conditions would be answered as the code to the human genome 
was unlocked. (352) Unfortunately, as yet these questions remain largely 
unanswered because of the complexity of disease progression, in addition to
social and economic differences between individuals.(353, 354) For the past 
several years, pharmaceutical companies and research groups have become 
increasingly interested in biomarkers. A biomarker is a chemical that can be 
found in blood serum or nucleotide sequence in the DMA of the patient, such as 
the BRCA1 and BRCA2 gene sequence.(355, 356) The main objective of these 
studies is the possible exploitation of biomarkers. Ideally these markers can be 
detected early to save the expense of multi-year studies, for diagnostic tests to 
determine malignancy and the effectiveness of targeted therapies.(357, 358)
Previous research and marketing strategies in the pharmaceutical 
industry have been to develop drugs that can be administered as widely as 
possible to as many patients as feasible, with the aim that sufficient numbers 
benefit without detriment to those that do not.(359) These 'carpet' drugs give 
high monetary returns, which consequently drives the development and 
marketing of new therapeutics.(360) However in oncology, this model can break 
down due to the high cost of treatment coupled with the disinclination of NHS 
health trusts to pay for treatments that do not work in the minority (or possibly 
the majority) of cases.(361) This has given rise to 'niche1 drugs or personalized 
medicine, whereby patients will only be prescribed drugs and funded, if the 
drugs demonstrate a significant probability that the patients will benefit. 
Therefore, several research groups are exploring biomarkers and techniques to 
identify positive responders in a patient cohort that is efficient, reliable and cost 
effective.
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5.2 Microfluidic innovation in cancer research
Current studies of cancer dynamics within microfluidic systems have 
focused on evaluating the steps involved in cancer cell metastasis, detecting 
circulating tumour cells (CTC) and detection of biomarkers for diagnostic 
purposes. Exposure of tumour cells to different environmental conditions, such 
as shear stress and chemokine gradients, which represent changes found in 
capillaries in vivo, have been studied to measure the tractile force exerted by a 
cell.(362, 363) While these studies do not expand on chemokine research, they 
do present microfluidic systems that could be used to do so in the future.
Researchers have examined the site of attachment and adhesion of 
fibroblasts and tumour cells through isotrophic silicon microstructures and 
matrigel lined with human microvasular endothelial cells, highlighting the 
biomechanical properties.(364, 365) These studies present 3-D model systems 
for investigating the microenvironments of tumour tissue by trapping and 
culturing different cell lines in defined structures. The methods for detecting 
disparities in cell lines used in these studies seems cumbersome when 
compared to traditional analysis methods such as FACS. Others have 
examined cell deformability, to distinguish between normal, benign and 
metastatic cancer cells using microchannels, to develop a test for metastatic 
disease.(366, 367) These studies have demonstrated the effectiveness of 
cancer cells to deform to different sized gaps in the channels however, other 
previous studies have also examined deformability using traditional filters and 
culture systems and further analyzed the effect of anti-invasive drugs.(368, 369)
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These microfluidic studies have not yet, given any new insight into the 
mechanisms of metastasis.
Microfluidic-based technology is ideally suited to diagnostic applications 
due to the inherent benefits described earlier, with many studies describing the 
design and testing of antibody-based microwell arrays and electrochemical 
detection within microfluidic channels for various secreted and surface- 
expressed tumour markers having been published.(370, 371) These studies 
include the capture of breast cancer cell lines using epithelial membrane 
antigen or EMA (CA 15-3) and epidermal growth factor receptor (EGFR) for 
further analysis. Chemotherapy resistance in cancerous cell lines has been 
assessed within a microchannel array that provided a more realistic 
representation of how cells would react in vivo than simply adding the drug to 
the cells in a static culture flask. (372) Another study has examined a 
multicellular tumour spheroid culture in a microchannel and described the 
assessment of oxygen and glucose concentration in static culture compared 
with perfusion, and shown that cell demand on nutrients quickly overtaking 
supply within static cultures. The study also assessed shear stress effects on 
spheroid growth, which had not been previously examined, and demonstrated 
the ability to grow several spheroids in a single culture.(373) These few studies 
while demonstrating the power of microfluidics to culture and identify different 
cancer cell properties are still in their infancy and have yet to answer any critical 
questions that have been proposed by traditional cell biology methods.
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In a recent Gap analysis document(374) of cancer research, a document 
which analysed the gaps in current cancer research, several recommendations 
were highlighted: 'the need for improved preclinical models, research agents 
and technologies; development of three-dimensional cell culture models 
containing multiple cell types, which reflect the tissue architecture of the normal 
and diseased tissue; and an increase in research efforts into the role of the 
microenvironment in the development and treatment of cancer'. The work 
presented in this chapter will show how tissue-based microfluidic systems can 
address these points.
5.5 Tissue harvesting and preparation
Histopathological-confirmed samples from 9 patients undergoing surgery 
for HNC were studied. Ethics and NHS Trust approval was obtained from Hull 
and East Yorkshire Research Ethics Committee (07 / H1304) and Hull and East 
Yorkshire Hospitals NHS Trust (RO568) respectively. Samples were provided 
with no patient details apart from the origin of tumour. Tissue biopsies were 
removed during neck dissections and placed in containers filled with DMEM 
media at 4°C for transportation to the laboratory. Within 1 hour, the tissue was 
cut into approximately 3 mm3 pieces, with the weight of each individual sample 
recorded.
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5.4 Measurement of viability using LDH release, WST-1 metabolism and 
epi-fluorescent microscopy
To validate the application of microfluidics to model in vivo cancer 
microenvironment, HNSCC tissue samples were maintained in simulated in vivo 
conditions in a microfluidic system while the viability was examined using 
biochemical biomarkers, LDH release and WST-1 metabolism as described in 
section 3.13.1. A modification of this protocol was used to include HNC biopsies 
instead of rat liver tissue, with the application of 10% lysis buffer to the tissue 
after seventy hours of incubation in the microfluidic system to further 
demonstrate viability. Further experiments to analyze the viability of the tissue 
using epi-fluorescence microscopy and LavaCell™, as described in section 
3.10, were taken after seventy hours incubation.
5.4.1 Analysis of the viability of HNSCC biopsies during maintenance in a 
microfluidic system
After an initial peak at the beginning of the experiment, thought to be 
due to damage caused to the surface of the tissue in harvesting, the LDH 
release decreased and then remained at low levels for the next 48 hours as 
shown in Figure 54. On the application of the lysis buffer after 70 hours, 
there was a significant increase in LDH release as the cytolytic agent 
penetrated the tissue causing disruption of the cell membranes. LDH levels 
remained high for the following 4 hours as more cells were exposed to the 
lysis buffer.
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Figure 54. LDH release and WST-1 metabolism of primary HNSCC tissue with the addition of 
10% lysis buffer after 70 hours. Aliquots were collected for eight hours every day. Data are 
expressed as the mean absorbance (a.u.) in the liver sample eluent ±S.E.M. of three separate 
experiments.
In contrast to LDH release, WST-1 metabolism showed a significant 
increase after 45 hours, with more formazan product being detected. The 
delay in detection of product is most probably due to the fact that only the 
outer cell layers would initially be exposed to the WST-1 reagent, therefore 
only relatively small amounts would be actively metabolized. As the reagent 
diffused further into the tissue, through the extracellular spaces, more cells 
would become exposed hence increasing the amount of metabolized 
reagent. The formazan salt would also take time to diffuse out of the tissue 
sample into the flowing media, analysis of more than fifty experiments of liver 
and different types of cancerous tissue have always shown a 35 - 50 hour 
delay in WST-1 detection in the eluent. After the application of lysis buffer at 
70 hours of tissue maintenance, the amount of formazan detected decreases 
rapidly as the number of viable cells is reduced. These complementary 
analyses show that NHC tissue remains viable within the microfluidic system 
over the length of the experiment. The application of lysis buffer at the end of
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the experiment showed that as cells were lysed the opposing viability biomarker 
levels reversed indicating cell death occurring which was not present before the 
application of the lysis buffer.
The experiment was repeated again thrice without the application of lysis 
buffer after seventy hours and instead LavaCell fluorescent probe was added to 
the system to assess viability. As shown in Figure 55, the tissue fluoresced 
highly in all areas examined showing that it was viable. Images collected using 
epi-fluorescence microscopy provide in situ assessment of tissue viability, along 
with ease and rapidity, which corroborates the biochemical results described 
above.
Figure 55. Image of HNC tissue following maintenance in the microfluidic device for 75 hours 
showing Lavacell™ fluorescence, highlighting the edge of the tissue distinguished from 
background. A 10 x objective was used. Image is representative of three separate experiments.
5.5 Viability of primary tumour tissue and secondary tumour (nodal) 
tissue
To understand whether the characteristics of the tumour tissue had an 
effect on the results, primary tumour tissue was compared with secondary
147
tumour tissue found in dissected lymph nodes using LDH release and WST-1 
metabolism using the method described in Section 3.13.1.
5.5./ Comparison of primary and secondary cancer using LDH and WST-1
The samples used in these experiments were of similar size and weight as 
discussed in Section 3.9. When comparing LDH release there was no 
significant difference as shown in Figure 56A, suggesting that the effects 
observed with WST-1 are more likely to be an inherent feature of the tissue 
biology rather than a facet of the architecture. The primary tumour biopsies 
showed markedly higher levels of formazan product, indicating increased 
mitochondria! activity, as compared with tissue from the secondary tumours as 
observed in Figure 56B.
The observed difference could be due to there being lower numbers of 
highly-proliferative tumour cells in the node or be a reflection of the distinct 
tissue architecture, i.e. that the nodal tissue was less diffuse and thus uptake of 
the WST-1 was slower. It could also be inferred that the incubation period in the 
current microfluidic experiment was too short for the secondary tumour tissue to 
enter the synthesis period and this could be another reason for the difference in 
WST-1 profiles in the primary and secondary tumour tissue; this hypothesis 
would need prolonged incubation times to test.
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Figure 56. Comparison of (A) LDH release and (B) WST-1 metabolism in primary tumour 
tissue and secondary (node) tissue in microfluidic device Aliquots were collected for eight hours 
every day. ±S.E.M. of three separate experiments.
Comparisons between in vitro primary and secondary in vitro cancer tissue 
viability have been studied. A study using a murine model has shown that 
primary tumours inhibit secondary growth and when the primary tumour is 
removed accelerated metastatic tumour growth. (375) This study also assessed 
the time between the removal of the primary tumour and the administration of 
the chemotherapy drug, cyclophosphamide, and the effect on secondary 
tumours. They demonstrated that if the time period between surgery and
chemotherapy was shorter than three days, the more effective the
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chemotherapy. They also showed that if the time period was over seven days 
then the secondary cancer tissue grew, although very small, in size. The study 
concluded that the secondary tumour, because of the suppression of growth 
from the primary tumour, needed time to enter the synthesis period of the cell 
cycle and early intervention with chemotherapy drugs killed the cells as they 
entered this phase. Further investigations by another group using C57/BL6 mice 
[10/group] inoculated with Lewis lung carcinoma (3LL cells) [5 x io5 per animal] 
showed that tumour removal was followed by accelerated growth of locally 
recurrent tumours and metastases.(376) Using one group of mice as a control, 
another group was subdivided into two, with one (2A) killed after two weeks with 
the tumours and lungs excised and the second sub-group (2B), the tumours 
were removed and recurrent tumour growth evaluated for a further two weeks. 
Four weeks from the onset of the study, all remaining primary tumors and lungs 
were excised from both groups. After four weeks undisturbed growth, primary 
tumours in the control group reached a mean size of 2.85 ± 0.33 cm. After two 
weeks growth, primary tumours in groups 2A and 2B were comparable at 1.36 ± 
0.44 m and 1.53 ± 0.29 cm, respectively. Two weeks after primary tumour 
excision, recurrent tumours in group 2B had reached a mean size of 2.65 ± 0.74 
cm. Moreover, for several animals, recurrent tumours rapidly reached similar 
volumes to that of primary tumors in the control group. Primary tumours were 
typically encapsulated and nonadherent. In contrast, recurrent tumours were 
locally invasive and adherent to chest wall and wound. Histological examination 
revealed increased mitosis in recurrent tumors when compared with primary 
tumours. Recurrent tumours were also more locally invasive than primary 
tumours.
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The microfluidic experiments have shown the ability to maintain and 
analyze the difference in primary and secondary tumours with further work 
needed to understand the mechanisms relating to the growth dynamics of both 
tumour categories and to establish whether the further results correlate with 
those found in the murine models.
5.6 Comparison of chemotherapy regimes on head and neck cancer in 
microfluidic microenvironment using extracellular biomarkers
Fast, obvious and easily accessible markers of cell death are needed for 
appraising early therapeutic efficiency for chemotherapy so that patients and 
their oncologists can choose whether to remain with a specified therapeutic 
strategy. Currently image based analysis of the response of a patient's tumour 
can take weeks, if not months after the start of treatment.(377) In recent 
laboratory studies, it has been shown that tumour cells undergoing apoptosis 
release cellular components into the culture media for example cytochrome c, 
DMA and nucleosomes.(378-380) In this last study, these biomarkers have 
been used to identify the effectiveness of 5-FU, CDDP and a combination of 
both drugs to kill HNC cancer tissue in a microfluidic system.
5,6 Chemotherapy Regimens
The eight microfluidic systems were set up as described in section 4.5. For 
the first 12 hours of the experiment, only DMEM media flowed through all the 
systems. After 12 hours, the media was changed in six of the microfluidic 
systems with two systems remaining with media only flowing through the tissue. 
For the six systems to receive drugs; two systems had 0.2 ^g ml" 1 CDDP in 
DMEM, two systems had 1.0 fig ml"1 5-FU in DEM and the remaining two had
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both 0.2 ng ml" 1 CDDP and 1.0 ^g ml" 1 5-FU in DMEM. These concentrations 
were taken from a previous study that was examining a 3D cell culture system, 
constructed from silicon and PDMS with multi-microchannels, for evaluating the 
effect of chemotherapy drugs on cancer cells and closely resemble the 
concentrations found in a patient's plasma undergoing chemotherapy 
treatment. (381) The treatment period was seven days with the total experiment 
lasting eight days. Eluent was collected constantly in 4 hourly aliquots 
throughout the day and night for the seven days of treatment. This change was 
necessary to capture any changes in the eluent as soon as they occurred. 
These samples, six for every twenty-four hours, were analyzed in duplicate and 
then the results averaged for the whole twenty-four hours to give daily totals.
5.6.1 Analysis of LDH release and WST-1 metabolism in HNSCC biopsies 
treated with chemotherapeutic drugs
The aim of these experiments was to determine the viability of cancer tumour 
tissue whilst treated with chemotherapeutic agents within a microfluidic system. 
As shown in Figure 57, all chemotherapy regimens invoked a greater release of 
LDH than untreated tumour tissue over the 7 day treatment period. LDH was 
released in the greatest concentration in the combination therapy of 5-FU and 
CDDP. In the first 5 days of treatment, the amount of LDH released was 
approximately double the amount released by the untreated sample. By the final 
2 days, the amount of LDH released triple the amount released by the control. 
CDDP induced a greater death response than 5-FU alone. The combination 
therapy however, showed the greatest variation between samples as shown in 
the error bars on the graph.
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Figure 57. LDH released from HNC tissue during treatment with different chemotherapy 
regimes compared with untreated cancer tissue biopsies. Data are expressed as the mean 
absorbance levels of LDH in each the cancer sample collected every 24 hours. ±S.E.M. of three 
separate experiments.
In Figure 58, the effects of the chemotherapeutic agents on WST-1 
metabolism are highly noticeable from Day 5. In the untreated control samples, 
WST-1 metabolism at Day 5 is over four and half times more than the samples 
treated with the chemotherapy drugs and this is maintained over the next two 
days of treatment. There is no marked difference in the amount of WST-1 
metabolized between the three different regimes however, in these tests 5-FU 
treated samples seem to have a slightly greater effect over the two other 
treatments. This could be a reflection of the 5-FU and CDDP acting via different 
mechanisms and differences in the tumour viability before the incorporation into 
the microfluidic system.
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Figure 58. WST-1 metabolism in HNC tissue during treatment with different chemotherapy 
regimes compared to untreated cancer tissue biopsies. Aliquots were collected every 4 hours 
over the 7 day period. Data are expressed as the mean absorbance levels in the cancer sample 
eluent ±S.E.M. of three separate experiments.
This current study effectively mimics previous in vivo data using 
concurrent chemotherapy, with 5-FU and CDDP, and radiotherapy (CCRT) that 
were shown to be effective in the treatment of locoregionally advance 
nasopharyngeal carcinoma (NPC). A study of prognostic factors after CCRT in 
34 patients demonstrated that increased serum LDH levels after treatment were 
strongly associated with distant metastasis-free survival.(382) A later study with 
111 NPC patients showed that elevated serum LDH before treatment correlated 
with adverse prognostic factors of survival.(383) The most recent study into 
serum LDH levels as a prognostic factor in 61 patients with NPC treated with 
chemotherapy has revealed that pre-treatment LDH level as the only statistically 
significant prognostic factor for disease-free survival (DPS) and overall survival 
(OS). Four year DPS and OS rates for patients with normal serum LDH levels 
were 55.9% and 68.7% respectively. However, patients with high serum levels 
the DPS and OS rates were 21.3% and 28.5% respectively.
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Previous work using WST-1 has been restricted to cell lines where the 
effect of tamoxifen alone and tamoxifen plus 5-FU on the proliferation of two 
types of gastric adenocarcinoma cell lines (KATOIII and MKN28 cells) was 
studied. (384) The effect of the combination of drugs resulted in anti-proliferative 
activity in KATOIII cells but MKN28 drugs continued to proliferate in a dose- 
dependant manner suggesting that some tumours have resistance 
mechanisms. Metabolism of WST-1 by the cell lines treated with 5-FU showed 
similar results to those treated with tamoxifen. Research published investigating 
the effect of CDDP using WST-1 demonstrated that Saos2/p53 cells were twice 
as sensitive to CDDP alone than Saos2 cells.(385)
These microfluidic experiments have shown the ability to model cell 
death by chemotherapeutic agents in HNC explants and these results are 
similar to those published using cell models and most importantly those found in 
cancer patients. Future work could include the use of other chemotherapeutic 
agents such as docetaxel, and the maintenance and subsequent interrogation 
of different cancer explants such as lung or liver tumour biopsies.
5.6.3 Viability analysis of metastatic cells
Metastasis is the spread of cancer cells from a primary tumour and 
subsquent colonization of distant secondary sites.(386) Metastases to regional 
lymph nodes are discovered at diagnosis and surgery in approximately one- 
third of breast, colorectal, uterine cervix and oral cavity and pharynx cancer 
patients.(387) High mortality rates associated with cancer are largely caused by 
the metastatic spread.(218) Metastasis is a multi-process involving cancer cell 
motility, intravasation, transit in the blood or lymph, extravasation and growth at
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a new location.(388) Microfluidics has the ability to maintain tissue in its native 
interconnected state as shown and replicate the conditions for all the 
parameters of metastasis especially motility and transit in microchannels, which 
mimic circulatory vessels.
Cancer cells were collected in the eluent from the microfluidic system after 
the seven day incubation period. Eluent was collected for 3 hours in 1.5 ml 
micro centrifuge tubes and centrifuged at 100g for 5 minutes. The supernatant 
containing cell debris was removed by aspiration. The cells were resuspended 
in DMEM. To quantify cell viability equal volumes of 2% (w/v) TB and cell 
solution were mixed and the cell count enumerated using a haemocytometer. 
Counts were measured in duplicate and the percentage viability determined.
5.6.4 Analysis ofmetastatic cell viability after chemotherapeutic intervention
The aim of the experiment was to determine whether chemotherapeutic 
agents destroyed 'metastatic' cells released from the tumour tissue in the 
microfluidic system. The cells collected at the end of experiment resulted in 
approximately 3,000 cells being released from an untreated 3 mm3 biopsy; 
based on haemocytometer measurements and are shown in Figure 59. The 
percentage of cancer cells, which survived the chemotherapy interrogation, is 
shown in Table 8.
The results indicate that 72% (n=3) of cells were alive from the untreated 
tumour biopsy, which is comparable with values determined previously in 
Section 3.12.1. The viability of the cancer cells treated with the chemotherapy
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decreased to only 63 - 42% of the untreated tumour biopsy. The combination 
therapy showed the greatest reduction in cell viability in the treatment regimens 
in correlation with the LDH data in Section 5.7.1.
Table 8. Percentage of viable metastatic cancer cells recovered after primary tumour tissue was 
maintained and interrogated in microfluidic system for seven days (n=3)
^f^fDrug Regimen^^^f Percentage of viable cells collected in eluent from 
''"'' microfluidic system
Untreated samples
5-FU only
CDDP only
5-FU and CDDP combination
72% ±15.6
45% ± 22.3
44% ± 20.2
30% ± 23.7
Figure 59. Cancer cells collected from untreated tumour tissue maintained in a microfluidic 
system. (n=3) Magnification 10 x
Furthermore this would be expected as present clinical practice of HNC 
management advocates the combination therapy as the desired method of 
treatment.(250)
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5.6.5 Cytochrome c analysis
Cytochrome c is a 14.5 kDa protein, as shown in Figure 55, that is located 
in the inner mitochondria membrane in healthy cells and is a key component of 
the electron transport chain in the respiration, functioning as an electron 
shuttle.(389) It an efficient biological electron-transporter and it plays a vital role 
in cellular oxidations in both animals and plants. It is regarded as a common 
catalyst of respiration, forming a necessary electron-bridge between the 
respirable substrates and oxygen.
Figure 60. Cytochrome c with heme, currently the focus of many studies in biomarker 
research.(390)
During apoptosis, cytochrome c is liberated from the mitochondria into the 
cytoplasm, where it is then released into the culture media.(391) Within 1 hour 
after treatment, cytochrome c was found in the media whereas LDH was 
released much later.(392) In necrosis, a study has shown that cytochrome c 
remains within the cell and not found within the media. There is much 
speculation of the biological significance of the release of cytochrome c, with 
studies showing various anti-inflammatory effects, guiding phagocytes to sites
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of injury, and increasing the effect of apoptosis and cell shrinkage by inducing 
K+ efflux from cells.(392-394)
To quantify the release of cytochrome c within the tissue sample, a 
quantitative sandwich enzyme immunoassay technique (Quantikine®, Human 
Cytochrome c, R&D Systems, USA) was carried out following the 
manufacturer's protocol. A 96-well flat bottom ELISA plate was provided coated 
with monoclonal antibody against human cytochrome c. The cytochrome c 
reference standards (20, 10, 5, 2.5, 1.25, 0.625 ng ml"1 ) and 100 \a\ of each 
standard and sample was incubated on the plate with 100 \i\ of the Calibrator 
Diluent RD5P for two hours. After the plate was washed a total of four times 
with wash buffer, the plates were incubated with 200 ul of Cytochrome c 
Conjugate for two hours. After another four washes, a colorimetric reaction was 
carried out by the addition of 200 ul TMB solution. The reaction was stopped 
with 50 ul of 2 M sulphuric acid and the absorbances were measured at A = 450 
nm. The individual four hours samples, six aliquots in twenty-four hours, were 
analyzed in duplicate with the results averaged over the twenty-four hours and 
are expressed as daily results. The experiment was repeated three times. The 
blank used was the unused media. Cytochrome c has a half-life of eight 
days(395) and therefore samples were kept at 4°C until the experiment was 
completed after seven days and all samples were analyzed on the same plate.
5.6.6 Determination of Cytochrome c release from HNSCC biopsies
The aim of this experiment was to determine whether cytochrome c was 
released from tumour biopsies maintained within a microfluidic system. Eluent
collected from the microfluidic system was analyzed using the commercial
159
start of therapy. Cancer patients that responded to treatment and survived three 
years later however had lower serum levels of cytochrome c (25 ng ml"1 ) within 
the first three days. In another in vivo based study it was also shown that 
elevated cytochrome c levels were observed in serum from patients with 
haematological malignancies and that during treatment these levels increased, 
that correlated with increased cell death determined through LDH release.(392) 
A study aimed at investigating the prognostic significance of several 
biomarkers, including cytochrome c, in surgically treated parotid cancer patients 
treated with adjuvant radiotherapy showed, through immunohistochemical 
examination of paraffin-embedded tissue specimens, from 27 patients that 
cytochrome c expression does not predict survival in parotid cancer 
patients. (396)
5.6.7Nucleosomes andDNA analysis
Nucleosomes supply a mechanism for chromatin condensation and 
consist of four pairs of histones, encircled by dsDNA as shown in Figure 62. 
dsDNA is methodically cleaved by endonucleases between the 
histones/nucleosomes during apoptosis and fragments are released into the 
extracellular space.(397)
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Figure 62. Electron micrograph shows chromatin from the nucleus of a chicken red blood cell. 
The arrangement of DNA on nucleosomes has been described as 'beads on a string'.(98)
To quantify the release of dsDNA within HNC biopsy a Quant-iT™ 
PicoGreen® dsDNA Assay Kit was used as described in Section 3.12. The 
release of dsDNA was plotted against the release of LDH, as described in 
Section 3.12.1, to determine whether there were any corresponding trends. The 
results are expressed as an average determined from triplicate samples. The 
blank used was the unused media.
To quantify the release of nucleosomes within the tissue sample, a 
quantitative sandwich enzyme immunoassay.technique (Cell Death Detection 
ELISAPLUS, Roche, UK) was carried out following the manufacturer's protocol. A 
96-well flat bottom ELISA plate was provided coated with streptavidin. A 20 JA! 
aliquot of each sample and a positive control containing lyophilized and 
stabilized DNA-Histone-Complex was incubated on the plate with 80 \JL\ of the 
immunoreagent. The immunoreagent contains a mixture of anti-histone biotin 
monoclonal murine antibodies (clone H11-4) and Anti-DNA-horseradish
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peroxidase monoclonal murine antibodies (clone MCA-33). The microplate was 
subsequently placed on a shaking platform at 300 rpm for two hours. During 
the incubation period, the anti-histone antibody binds to the histone-component 
of the nucleosomes and simultaneously captures the immunocomplex to the 
streptavidin-coated microplate via biotinylation.
Additionally, the Anti-DNA-horseradish peroxidase antibody reacts with the 
DMA-component of the nucleosomes. After the plate was washed for a total of 
three times with wash buffer, a colorimetric reaction was carried out by the 
addition of 100 pi 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) 
and placed back on the shaking platform at 250 rpm. The reaction was stopped 
after twenty minutes with 100 ul of ABTS stop solution supplied by the 
manufacturer and the absorbances were measured at A = 405 nm. The 
individual four hour samples, six aliquots in twenty-four hours, were analyzed in 
duplicate with the results averaged over the twenty-four hours and are 
expressed as daily results. The experiment was repeated three times. The 
blank used was the unused media. The samples were kept at 4°C until the 
experiment was completed and all samples were analyzed on the same plate.
5. 6.8 dsDNA and nucleosome release from HNC biopsies
Measuring changes in dsDNA and nucleosomes release from NHC tumour 
tissue within a microfluidic system was the purpose of these experiments. 
Eluent collected from the microfluidic system was analyzed firstly using a 
fluorescent dye for dsDNA and secondly, an immunoassay containing a 
monoclonal antibody specific for histones and dsDNA. The graph in Figure 63 
shows the release of dsDNA from an untreated cancer sample. This experiment
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was conducted only once as the release of DNA appeared erratic and bears no 
resemblance to the underlying LDH trend after 29 hours of maintenance in the 
microfluidic system. It can therefore be assumed that dsDNA has been released 
from viable cells within the biopsy as the LDH results denote negligible numbers 
of apoptotic or necrotic cells. The rises and falls could be due to proliferating 
cells, as it has been shown previously in Sections 5.4.1 and 5.5.1 that the WST- 
1 absorbance also increased after two days of incubation, and the flow 
dynamics of the system such as diffusion into the tissue of WST-1 and the 
release into the media of formazan from inside the tissue biopsy.
-LDH DNA
Time or Incubation (h)
Figure 63. DNA release compared with LDH release from an untreated HNC tumour biopsy in 
microfluidic device. Gaps in the graph equate to times unmonitored overnight.
There is no other possible explanation for the enormously fluctuating DNA 
concentrations such as with loss of DNA to other surfaces within the device 
(chip surfaces, tumour surface) and is more likely due to the erratic nature of 
the cell cycle of the cancer cells, as described in the introduction chapter.
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Circulation cell free DMA (cfDNA) has gained considerable interest for 
oncology researchers seeking to isolate specific cancer markers over last 
decade. Previous studies have reported DMA fragments in the serum of cancer 
patients, apparently because apoptosis and necrosis are happening in and 
around the tumour.(399) Macrophages would usually remove this debris, 
however due to limited circulatory access movement of macrophages around 
the tumour can be restricted. Soluble DNA fragments have been identified in the 
supernatant of Jurkat T cells induced to undergo apoptosis with 1.2 M 
staurosporine, or necrosis with 2.5 M oligomycin and 1.2 M staurosporine in
WfAD.(400)
The prevalent belief within the oncology field presumes that cfDNA arises 
from apoptotic or necrotic cancer cells in relation to cancer metastasis. (401) 
However, reanalysis of the current literature has proposed that cfDNA is 
principally secreted by living cancer cells rather than from apoptotic or necrotic 
cells. For example in response to radiotherapy, in high percentage of patients 
with lymphoma, lung, ovary, uterus and cervical cancers, cfDNA was 
significantly decreased to 66-90% of pre-treatment rather than being increased. 
These results suggest that the significant portion of cfDNA may derive from 
living cancer cells. (399)
Secondly, oncogene-containing cfDNA may behave like oncoviruses and 
represent an alternative pathway for cancer metastasis as circulation DNA 
contain oncogenes, hypermethylated tumour suppressor genes and aberrant
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microsatellites, that are identical to those found in the patient's tumour 
tissue. (402) In vitro experiments have also demonstrated that free DNA can 
enter and transform normal cells and these can grow into neoplasms when 
injected into mice. (403)
Lastly, cancer has the propensity to colonize in specific tissues (such as 
lymph nodes) since there are DNA binding proteins or receptors on the cell 
surface.(404-407) Further analysis regarding the origin and function of cfDNA 
could have major implications for cancer biologists and medicine if these 
conclusions are accurate.
To complement the DNA analysis, nucleosomes were examined using an 
immunoassay. In Figure 64, all of the eluent collected from the treated samples 
showed an elevated level of nucleosomes compared with the control sample.
'5-FU 5-FU and CDDP "CDDP "media
I•s
f
t 0.4
Days
Figure 64. Nucleosomes and DNA released from HNC tissue during treatment with different 
chemotherapy regimes compared to untreated cancer tissue biopsies. Data are expressed as the 
mean absorbance levels over 24 hours in the cancer sample eluent ±S.E.M. of three separate 
experiments.
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The nucleosomes released in the control sample remained relatively 
stable over the experimental period with the average absorbance levels per mg 
of tissue remaining at 0.44 AU ±0.01. The samples with the highest level of 
nucleosome expression over the entire experiment were the HNC biopsies 
treated with only CDDP with the average absorbance per mg of tissue recorded 
at 0.481 AU ±0.149. This was almost 11 times higher than the levels recorded 
from the control sample. The 5-FU administered biopsies showed the same 
profile with the highest absorbance from all treatments on Day 4 at 0.676 AU 
±0.0338, this was 13 times higher than the control sample on the same day. 
However from Day 5 the concentration of nucleosomes released from the 5-FU 
biopsies steadily decreases to only 12% of this high by Day 7.
The cancer biopsies treated with both chemotherapeutic agents showed a 
similar profile however, they exhibited lower concentrations than the single drug 
samples (three times lower than CDDP and 5-FU) and by Day 5 the 
concentration was almost parallel to those in the control samples. This was 
surprising, as it would be assumed that the effect of the combination of drugs 
would cause a higher degree of cell death than the single drug regimen. The 
study of released nucleosomes as a biomarker of cancer effectiveness is still 
developing. A previous study demonstrated the release of nucleosomes from 
tumour cells in vitro and in vivo after treatment with CDDP.(379) Using HeLa 
cells in vitro, nucleosome expression increased after 24 hours however, in 
subsequent murine models bearing HeLa tumours a decrease in nucleosome 
expression after 24 hours was shown. A study of non-small cell lung cancer
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patients undertaking chemotherapy (8 mg/m2 mitomycin c, 25 mg/m2 vinorelbin, 
and 80 mg/m2 CDDP) showed, using the same assay as was used in this 
thesis, that there was an increase in nucleosomes within serum samples 
followed by a decrease during intervals in between treatment.(408) Patients 
who responded to treatment or were in remission encountered less of an early 
increase (pre-therapeutic value, 344 AU; maximum value, 436 AU) in 
nucleosomes level followed by a significant decrease (140 AU) after 8 days. 
Patients that did not respond exhibited a higher initial increase (pre-therapeutic 
value, 442 AU; maximum value, 632 AU) and these levels did not decrease as 
rapidly (290 AU) as those patients that did respond to treatment. The reason put 
forward for these phenomena is the variable rates in cell death and proliferation 
in the aggressive tumours along with greater access to blood vasculature in 
patients with metastasis. At time of writing, there has been no research into 
nucleosome expression in HNC patients during treatment.
Head and neck cancer has a low survival rate and while there have been 
advances in clinical treatment regimes, translation of these improvements into 
decreases in the mortality rate have not been achieved. Developments in in 
vitro pre-clinical models to assess the effectiveness of established and novel 
chemotherapy drugs in patients before treatment commences, would allow a 
more informed decision by both the clinical team and the patient. Both the 
scientific and medical fields have acknowledged that the measurement of 
biomarkers would be an effective tool in clarifying whether the cancer treatment 
has been successful. To this end, many studies in cancer biomarkers have 
been completed, utilizing cell lines and patients themselves. These studies 
have been productive in providing invaluable information nonetheless; they all
168
have their limitations. Models that use cell lines lack the complexity of the in 
vivo microenvironment. Patient studies have been the most informative, but 
there have been questions about the exact nature of the results and what is 
actually being demonstrated. Tissue-based microfluidic systems are able to 
replicate the in vivo microenvironment of the tumour, while also containing 
multiple cell types and maintaining the native tissue architecture. It has been 
shown that the viability of the tumour biopsy remained intact and by 
implementing current chemotherapy regimens, a response has been observed 
in several clinically relevant biomarkers. This work provides an important first 
step into the development of a pre-clinical model, which can be used to provide 
further intelligence into the progression and treatment of cancer.
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6. Conclusion
'It's more fun to arrive a conclusion than to justify it.'
Malcolm Forbes 1919-1990
The last decade has been an exciting time for biological microfluidic 
studies however; there has been little investigation into tissue-based systems. 
The reason for the lack of interest in tissue-based microfluidics is twofold; firstly, 
cell culture has been used in biological studies for over ninety years with a high 
degree of success in modelling physiological and pathological dynamics. The 
parameters of maintaining and growing different cell types have been 
extensively examined and defined. The success of this research is that there 
has been little change in the cell culture methodology since the 1980s. The 
second reason is that even though tissue and organ culture has been shown to 
be more reflective of the mechanisms found in vivo, maintaining tissue viability 
and more importantly functionality in vitro through traditional methods is 
exceedingly difficult. However, the research presented in this thesis 
demonstrated the potential that microfluidics has in mimicking in vivo dynamics 
through the maintenance of tissue.
The first experimental section of this thesis focused the design and 
fabrication the microfluidic device and system. The preliminary investigations of 
maintaining tissue viability and morphology where examined using microscopy, 
histology and biochemical assays. This work showed that the microfluidic
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chamber system provided sufficient oxygen and nutrients for the tissue to 
remain healthy without any major loss of ECM or increase of non-viable cells 
within the sample and that these patterns were repeatable for individual 
biopsies over time. The ability to interrogate the tissue to envoke a response 
was also tested and proven, alongside the ability to study the cells both within 
tissue environment and individually through disaggregation. After constructing 
the microfluidic device and verifying the flow profiles and with the success of the 
viability studies using LDH measurements and fluorescence assays showing 
that the tissue was remaining viable within the microfluidic system with the 
addition lysis buffer verifying the viability.
The second section examined the possibility of using the system as a 
future model of hepatotoxicity by insulting the tissue with several different 
chemicals, the main being ethanol. The functionality of the liver was assessed 
both prior to interrogation and afterwards, and demonstrated not only the ability 
to maintain function of liver tissue over five days but also the ability to effect the 
function of liver sample over the same time period. Models of in vivo liver 
dynamics are being actively sought and whilst this system was not used to 
examine fully liver tissue differentiation and function, it is a vital step forward. It 
has been shown that rat liver samples were kept viable and functional over 
ninety-six hour time period. WST-1 was metabolised and reduced to formazan, 
which was subsequently detected off-chip along with the detection of LDH 
release from cells maintained and/or interrogated on-chip. Addition of different 
ethanol concentrations decreased the amount of formazan detected over the 
time period indicating the ethanol was affecting cell viability over the time period 
compared to a control. The addition of ethanol to the liver samples exhibited
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many of the same characteristics noted in other studies which have used 
isolated hepatocytes and in vivo rat models of chronic ethanol intoxication 
including the decrease in viability, fatty liver progression, reduction of albumin 
production, change in cell morphology and decrease in urea levels.(317, 350) In 
this thesis, liver samples millimetres in thickness were used to ensure that even 
the cell types that were sparsely represented within the tissue such as 
cholangiocytes were included and the native complex ECM was maintained 
which is not present in cell-based models. Using microfluidic technology we 
have also mimicked the in vivo flow dynamics, which is not present in 
conventional cell and tissue representations.(116) Therefore, it is proposed that 
rat liver samples retain their biological functions and appeared to a novel and 
valuable model for the study of not only pathological but also physiological 
mechanisms.
The final chapter examined the feasibility of the microfluidic system to 
model the cancer microenvironment for future pre-clinical and personalized 
patient models. Viability of the head and neck cancer tissue was assured over 
eight days of culture with the tissue subsequently treated with commonly used 
chemotherapy drugs with the analysis of biomarkers, which have been identified 
in clinical studies. Head and neck cancer has a low survival rate and while there 
have been advances in clinical treatment regimes, translation of these 
improvements into decreases in the mortality rate have not been achieved. 
Developments in in vitro pre-clinical models to assess the effectiveness of 
established and novel chemotherapy drugs in patients before treatment 
commences, would allow a more informed decision by both the clinical team 
and the patient. Both the scientific and medical fields have acknowledged that
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the measurement of biomarkers would be an effective tool in clarifying whether 
the cancer treatment has been successful. To this end, many studies in cancer 
biomarkers have been completed, utilizing cell lines and patients themselves. 
These studies have been productive in providing invaluable information 
nonetheless; they all have their limitations. Models that use cell lines lack the 
complexity of the in vivo microenvironment. Patient studies have been the most 
informative, but there have been questions about the exact nature of the results 
and what is actually being demonstrated. Tissue-based microfluidic systems 
are able to replicate the in vivo microenvironment of the tumour, while also 
containing multiple cell types and maintaining the native tissue architecture. It 
has been shown that the viability of the tumour biopsy remained intact and by 
implementing current chemotherapy regimens, a response has been observed 
in several clinically relevant biomarkers. This work provides an important first 
step into the development of a pre-clinical model, which can be used to provide 
further intelligence into the progression and treatment of cancer.
The challenge of the microfluidic community, in respect to tissue and 
organ biology, is to move beyond the need to replicate conventional cell-based 
methodologies within microfluidic systems and appreciate the gaps in biological 
knowledge that microfluidic technology can fill. This thesis has examined the 
ability to investigate and alter the microenvironment of an ex vivo tissue sample 
has the potential to open new avenues in cell signaling, molecular biology, 
systematics, and developmental biology that with current methods and 
techniques is impossible.
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7. Future Work
'Imagination is more important than knowledge. Knowledge is limited. 
Imagination encircles the world.'
Albert Einstein 1879-1955
It is usual at the end of a thesis for the author to suggest future 
opportunities that their research has afforded. In the case of this thesis, a more 
apt statement would be, 'what can't be done'. The vast majority of studies into 
cell biology have used cell-based models that many biologists agree only give a 
fraction of the whole picture and that snapshot is sometimes so distorted that it 
bears no relation to the original image. The tissue-based microfluidic model 
demonstrated within this thesis is 'one small step' to a future 'giant leap' in 
bringing into focus the complexity of in vivo dynamics. In the first chapter, many 
of the current avenues of research in cell biology using microfluidic technology 
were acknowledged. Many of these studies could be transferred to tissue- 
based methodologies with little or no difficulty, allowing a greater understanding 
of cell kinetics within the context of a tissue environment.
Continuation of the current studies described in this thesis would be the 
addition of downstream modules to the microfluidic system to allow the culture 
and analysis of tissue all on the same platform. Interrogation and then 
subsequent disaggregation of the tissue to the single cell, could allow the ability 
to replicate the 3D in vivo microenvironment followed by the rapid analysis of 
single cells to substantiate individual effects on different cells, cell products and
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ECM. This would be achieved by the coupling the tissue chamber to a 
separation chamber and holding areas as illustrated in Figure 65, which were 
designed by the author, and Jane Woods.
50mm
Inlet 3
Inlet 1
Inlet 2
cell capture areas
Tissue chamber Separation chamber ° Access ports a - j
Figure 65. Schematic of microfluidic device for the maintenance of tissue, disaggregation and 
separation of cells, cell products and ECM.
Further refinements of the system would be to add different analysis 
modules at the end of each 'arm', as shown in Figure 66. These modules could 
include a polymerase chain reaction (PCR) component, for the analysis of DMA 
from lysed cells or extracellular fragments, a microarray, for the analysis of 
individual intracellular and extracellular proteins, and the final module could be 
a flow cell section for the analysis of enzyme function.
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DMA Analysis
Tissue Stage
Cell Capture Microarray
Flow Cell Analysis 
Figure 66. Schematic of envisioned 'lab on a chip' for the analysis of tissue culture.
These components coupled on the same system would allow the analysis 
of a single or indeed many different important cellular pathways from small 
samples, giving access to large amount of information which is not currently 
possible using conventional methodology. This would be definitely classed as a 
'lab on a chip'.
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